The development of a SARS-CoV-2 pseudoparticle assay for the detection of neutralizing antibodies in sera from COVID-19

patients



Submitted in fulfilment of the requirements for the degree Master of Science in the Department of Medical Biosciences, Faculty of Natural Sciences at the University of the

Western Cape

Ame-Leigh Daniels

Supervisor: Prof. Megan L. Shaw

Department of Medical Biosciences, University of the Western Cape

List of abbreviations

%	percentage
°c	degree Celsius
μg	microgram(s)
μl	microlitre(s)
aa	amino acid(s)
Ab	antibody
ACE-2	Angiotensin-converting enzyme- 2
Ag	antigen
APS	ammonium persulphate
bp	base pair
BSA	bovine serum albumin
CO_2	carbon dioxide
cDNA	complementary deoxyribonucleic acid
CoV	coronavirus
CPE	cytopathic effect
C-terminal	carboxy-terminus
DAPI	4",6-diamidino-2-phenylindole, dihydrochloride
dH20	distilled water
DMEM	Dulbecco's modified Eagles Medium
DNA	deoxyribonucleic acid
DTT	dithiothreitol

E. coli	Escherichia coli
EDTA	ethylenediaminetetraacetic- acid
ER	endoplasmic reticulum
FBS	foetal bovine serum
g	gram
GFP	green fluorescent protein
HCoV	human coronavirus
HEK	human embryonic kidney
KB	kilobases
mAb	monoclonal antibody
MERS-CoV	Middle East respiratory syndrome coronavirus
mins	minutes
mL	millilitre
MOI	multiplicity of infection
nAb	neutralizing antibody
ng	nanogram
N-terminal	amino-terminus
ORF	open reading frame
PBS	phosphate buffered saline
PCR	polymerase chain reaction
mg	microgram(s)
рр	pseudoparticles
RBD	receptor binding domain

RDM	receptor binding motif
RNA	ribonucleic acid
RT	reverse transcription
RT-PCR	reverse transcription polymerase chain reaction
S	spike
S protein	spike protein
S1	subunit 1
S2	subunit 2
SARS-CoV	severe acute respiratory syndrome coronavirus
SARS-CoV-2	severe acute respiratory syndrome coronavirus-2
SDS-PAGE	sodium dodecyl sulphate polyacrylamide gel electrophoresis
VSV	vesicular stomatitis virus
VSV-G	vesicular stomatitis virus glycoprotein
RPM	rotations per minute A P E

UNIVERSITY of the WESTERN CAPE

Abstract

The COVID-19 pandemic has caused devastating effects on the global socio-economic landscape. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the causative agent of COVID-19, and infections have led to approximately 7 million fatalities worldwide. Previous findings have confirmed that neutralizing antibodies are a highly predictive measure of immune protection. Thus, measuring SARS-CoV-2 neutralizing responses after infection or vaccination remains a priority, especially in the event of newly emerging SARS-CoV-2 variants.

Due to the limitations of working with live virus in a BSL3 facility, pseudoparticles are an alternative tool used to study viral surface proteins. This research aims to develop a SARS-CoV-2 pseudoparticle system to detect neutralizing antibodies in sera from previously infected or vaccinated individuals. The use of vesicular stomatitis virus (VSV) as a vector for the pseudoparticle system, provides several advantages over the lentivirus system including faster assay time, and lack of interference from antiretroviral drugs present in sera from HIV-positive patients on antiretroviral therapy (ART). The latter is particularly relevant in South Africa where there are more than 7.8 million HIV people living with HIV.

After generating VSV pseudoparticles bearing the SARS-CoV-2 spike from the Wuhan/D614G, Beta, Delta and Omicron variants, a neutralizing assay was optimized using characterized human monoclonal antibodies. The assay was then applied to a sample set of patient sera and the ID₅₀ values were compared to those obtained using a lentivirus-based SARS-CoV-2 neutralization assay. The comparison highlighted a strong concordance between the VSV and lentivirus neutralization assays particularly for the Wuhan/D614G and Omicron variants. The findings indicate that the development of a VSV-based neutralization assay is a valuable contribution to our ongoing efforts to characterize protective immune responses arising from SARS-CoV-2 infection or vaccination.

Declaration

I, Ame-Leigh Daniels, declare that this thesis, *The development of a SARS-CoV-2* pseudoparticle assay for the detection of neutralizing antibodies in sera from COVID-19 patients and vaccinees hereby submitted to the University of the Western Cape for the degree of Magister Scientiae (MSc) has not previously been tendered by

me for a degree at any other university or institution, that it is my own work in design and in execution, and that all materials contained herein have been duly acknowledged.

Ame-Leigh Daniels

10/11/23



UNIVERSITY of the WESTERN CAPE

Acknowledgments

I would like to express my sincere gratitude to Professor Megan L Shaw, for her guidance as my Masters' supervisor and for the opportunity to do my project in her laboratory.

Thank you to the National Research Foundation (NRF) and Poliomyelitis Research Foundation (PRF) for funding my project.

I would like to offer my special thanks to Dr Kim Lategan her assistance and mentorship through these 3 years.

My sincere appreciation to the Shaw Lab, with special recognition to Dr Bianca Gordan and Jihaan Adonis for all your guidance and patience with me through this journey.

Then to my mother Noleen, I would like to express my deepest gratitude for the unwavering support throughout my studies and for all the prayers. To my immediate family Benjiman, Tamara and my nephews and niece thank you for all the love and support.

To my extended family the Lategan's, thank you for playing such a pivotal role in my life these last few years. My close friends Demi-Che, Michealla and Kathryn thank you for being by my side through it all.

I would like to express my deepest appreciation to the late Kevin John Lategan^{*}, I am grateful for the impact you had on my life, for all the lessons and memories. I wish you could have seen this journey from beginning to end. May your soul forever rest in peace.

Lastly I would like to thank God for all He did and continues to do.

UNIVERSITY of the WESTERN CAPE

List of Figures

Figure 1. 1. Possible host range of SARS-CoV-2
Figure 1. 2 SARS-CoV-2 genome4
Figure 1. 3 The SARS-CoV-2 spike genome and 3D structure model6
Figure 1. 4 Amino acid mutations and deletions present in the spike protein of SARS-
CoV-27
Figure 1. 5 Timeline of pandemic waves in the South African population9
Figure 1. 6 Different neutralizing antibodies that bind to various domains in the SARS-
CoV-2 spike protein10
Figure 1. 7 Receptor binding domain specific neutralizing antibodies10
Figure 1. 8 Workflow of Neutralization assay using vesicular stomatitis virus
pseudoparticles11
Figure 1. 9 Ideal sigmoidal/curve of best fit/dose response curve12
Figure 1. 10 Structure and genome organization of vesicular stomatitis virus13
Figure 1. 11 Schematic diagram of the generation of VSV pseudoparticles14

Figure 2.1 Overview of cloning strategy for SARS-CoV-2 spike clones	16
Figure 2. 2 Schematic of preparing reagents for transfection of HEK-293 cells	25

UNIVERSITY of the

Figure 3. 1 PCR of amplicons for the construction of SARS-CoV-2-spike ORF32
Figure 3. 2 Confirmation of SARS-CoV-2 spike WT and Beta clones by restriction enzyme
digest using enzymes Xho I and Sac I
Figure 3. 3 Alignment of the reference sequence for SARS-CoV-2 isolate Wuhan-Hu-1
(NC_045512.2) with the contigs generated from pCAGGS-Spike ^{WT} clone34
Figure 3.4 Alignment of the reference sequence for SARS-CoV-2 isolate Wuhan-Hu-1
(NC_045512.2) with the contigs generated from pCAGGS-spike Beta clone
Figure 3.5 Expression and localisation of SARS-CoV-2 spike-FLAG protein using FLAG
antibody
Figure 3.6 Expression and localisation of SARS-CoV-2 spike-FLAG protein using SARS-
CoV-2 antibody
Figure 3.7 Confirmation of the presence of the SARS-CoV-2 spike gene in the plasmids
obtained from NICD41
Figure 3.8 Detection and localization of SARS-CoV-2 protein

Figure 3.9 Confirmation of SARS-CoV-2 spike expression by Western blot analysis43
Figure 3.10 Titration of VSVpp-spike pseudoparticles in HEK293T-ACE-2 cells44
Figure 3.11 Optimization of neutralization of VSVpp-spike ^{WT} and VSVpp-VSV-G45
Figure 3. 12 Neutralization of SARS-CoV-2 spike pseudoparticles by CA-1 antibody. The
neutralizing effect of CA-146
Figure 3. 13 Neutralization of SARS-CoV-2 spike pseudoparticles by CB-6 antibody. The
neutralising effect of CB-647
Figure 3. 14 The neutralization activity of 084-7D48
Figure 3. 15 Neutralisation of SARS-CoV-2 spike pseudoparticles by Bebtelovimab antibody
Figure 3.16 Neutralisation of VSVpp-spike ^{WT} by serum samples 1-9. The percent
neutralization relative to the dilution of serum is shown as a best fit curve for each sample.
Figure 3. 17 Neutralisation of VSVpp-spike ^{Beta} by serum samples 1-9. The percent
neutralization relative to the dilution of serum is shown as a best fit curve for each sample.
Figure 3. 18 Neutralisation of VSVpp-spike ^{Delta} by serum samples 1-9. The percent
neutralization relative to the dilution of serum is shown as a best fit curve for each sample.
TICE PROSPLE
Figure 3. 19 Neutralisation of VSVpp-spike ^{Omicron} by serum samples 1-9. The percent
neutralization relative to the dilution of serum is shown as a best fit curve for each sample.
Figure 3. 20 Dot plot of the ID50s of each serum sample tested against the WT, Beta, Delta,
and Omicron variants of VSVpp-spike56
Figure 3. 21 Comparison of VSV- or lentivirus-based SARS-CoV-2 neutralisation data.

List of Table

Table 2. 1 Primers for the amplification of the SARS-CoV-2 spike gene	17
Table 2. 2 Reaction preparation for the synthesis of cDNA from RNA	
Table 2. 3 Thermocycler conditions for the synthesis of cDNA from RNA	
Table 2. 4 Q5® High-Fidelity PCR amplification reaction mixtures	
Table 2. 5 Q5® High-Fidelity PCR amplification reaction thermocycler condition	s19
Table 2. 6 Ligation mixture preparation reaction	21

Table 3.1 Table of listed mutation detected in the clone of pCAGGS-spike ^{Beta}	
Table 3.2 The SARS-CoV-2 spike expression constructs received from NICD	40
Table 3. 3 Summary of IC ₅₀ of VSVpp ^{VARIANTS} against human monoclonal antib	ody in
ng/mL	50
Table 3. 4. Table showing the sera samples and the corresponding NICD sera sam	ole 51



UNIVERSITY of the WESTERN CAPE

List of Appendices	
Appendix A: List of Materials	64
Appendix B:Alignment of pCAGGS-spike ^{WT} with reference sequen	ce isolate Wuhan-Hu-
1 (NC_045512.2)	68
Appendix C : Alignment of pCAGGS-spike ^{BETA} with reference sequ	uence isolate Wuhan-
Hu-1(NC_045512.2)	74



UNIVERSITY of the WESTERN CAPE

Table of Content	
List of abbreviations	ii
Abstract	v
Declaration	vi
Acknowledgments	vii
List of Figures	viii
List of Table	X
List of Appendices	xi
Chapter 1. Introduction	1
1.1. Host species of coronaviruses	1
1.2 SARS-CoV-2 pathogenicity	2
1.3. Genome organisation of SARS-CoV-2 and its expressed proteins	4
1.4. The role of SARS -CoV-2 spike protein in virus entry	5
1.5. SARS-CoV-2 mutations and variants of concern (VOC)	7
1.6. COVID-19 waves in the South African population	8
1.7. Role of neutralizing antibodies	9
1.8. Neutralization assay	11
1.9 Pseudoparticles	12
1.10. Vesicular stomatitis virus pseudoparticles	13
Aim and objectives	15
Chapter 2. Methodology	16
2.1 Amplification and cloning of SARS-CoV-2 spike genes into mammalian ex	xpression .16
vectors	16
2.1.2. Synthesis of cDNA from RNA	17
2.1.3. PCR amplification of SARS-CoV-2 spike genes	
2.1.4 Single restriction enzyme digest	19
2.1.5 Agarose gel electrophoresis	20
2.1.7 Ligation of SARS-CoV-2 spike into pCAGGS vector	20
2.2. Preparation of plasmid DNA	22
2.2.1 Transformation of DHα competent <i>E.coli</i>	22
2.2.2. Transformation of JM109 competent <i>E.coli</i>	22
2.2.3. Small scale generation of plasmid DNA (miniprep)	22
2.2.4 Double restriction enzyme digest of plasmid DNA	23
2.2.5 Large scale generation of plasmid DNA (maxiprep)	23
2.2.6 Ethanol precipitation of DNA	23

2.2.7. Quantification of plasmid DNA	24
2.2.8 Sanger Sequencing	24
2.3. Maintenance of mammalian cell lines	24
2.4 Transfection of mammalian cells	24
2.5. Western Blots	25
2.6. Immunofluorescence	26
2.6. Generation of pseudoviruses using a VSV-based system	26
2.6.1 Propagation of VSV* ΔG (FLuc) trans complemented with VSV-G	26
2.6.2. Titration of VSV*ΔG(FLUc) +(VSV-G) stock	27
2.6.3. Generation of VSV*ΔG(FLUc) +(SARS-CoV-2 spike) pseudoparticles	28
2.6.4 Titration of VSV*ΔG(FLUc) +(SARS-CoV-2 spike) pseudoparticles	28
2.7. SARS-CoV-2 neutralization assay	29
2.7.1. SARS-CoV-2 neutralizing antibodies and human sera	29
2.7.2. Optimisation of assay conditions using SARS-CoV-2 spike neutralizing antiboo	dies 29
2.7.3 Validation of the assay using human SARS-CoV-2 sera	30
Chapter 3: Results	
3.1. Amplification of SARS-CoV-2 spike genes from viral cDNA	31
3.2. Cloning of Flag-tagged SARS-CoV-2 spike genes into pCAGGS	33
3.3. Sequence confirmation of pCAGGS spike-Flag clones	34
3.4. Expression and localisation of pCAGGS-spike ^{WT} -FLAG and pCAGGS-spike ^{Beta} FLAG	38
3.5. Validation of SARS-CoV-2 spike protein expression from the plasmids obtained fr	om
NICD	40
3.6. Generation of VSV pseudoparticles bearing the SARS-CoV-2 spike protein	43
3.7. Optimisation of neutralization conditions using SARS-CoV-2 neutralizing human monoclonal antibodies	44
3.8. Neutralization of SARS-CoV-2 spike pseudoparticles using CA-1 antibody	45
3.9. Neutralization of SARS-CoV-2 spike pseudoparticles using CB-6 antibody	46
3.10. Neutralization of SARS-CoV-2 spike pseudoparticles using the 084-7D antibody .	48
3.11. Neutralization of SARS-CoV-2 spike pseudoparticles using Bebtelovimab antibod	ly 48
3.12 Validation of the SARS-CoV-2 neutralization assay with sera from COVID-19 patients	50
3.13 Comparison of neutralization activities obtained using the VSV or lentivirus SARS CoV-2 neutralization assays	3 56
Chapter 4: Discussion	

Limitations of the study62
Conclusion62
Appendix A: List of Materials64
Table 1: Bacterial strains
Table 2: Cell lines 64
Table 3: Plasmids 64
Table 4: Viruses 65
Table 5: Molecular Reagents
Table 6: Cell culture reagents
Table 7: Antibodies 66
Table 8: Software 66
Table 9:Buffers and solutions 67
Appendix B
Appendix B:Alignment of pCAGGS-spike ^{WT} with reference sequence isolate Wuhan-Hu-1 (NC_045512.2)
Appendix C74
Appendix C :Alignment of pCAGGS-spikeBETA with reference sequence isolate Wuhan- Hu-1(NC_045512.2)
References

UNIVERSITY of the WESTERN CAPE

SPICE PROSPICE

VERSITY of the

Chapter 1. Introduction

SARS-CoV-2 has caused the greatest pandemic of the 21st century so far, infecting approximately 772 million people and causing the deaths of nearly 7 million worldwide. COVID-19 is the disease caused by the coronavirus severe acute respiratory syndrome coronavirus 2(SARS-CoV-2). Coronaviruses cause mild to severe respiratory disease in humans and are the largest of all RNA viruses. They are sub divided into four genera; Alpha, Beta Gamma and Delta with SARS-CoV-2 belonging to the Beta genus, which also includes SARS-CoV-1 (causes severe acute respiratory syndrome or SARS) and MERS-CoV (causes middle east respiratory syndrome or MERS) (Shereen et al. 2020) SARS-CoV-1 and MERS-CoV caused epidemics in 2003 and 2012, respectively.

Coronaviruses were first identified in humans in the 1960's isolating HCoV-229E strain, B814 as the cause of the common cold in humans (Kendall, et al. 1962, Fani, et al. 2020). Since then, more knowledge of human coronaviruses was acquired through the considerable research of isolates HCoV-229E and HCoV-OC43 (Ye, et al. 2020). Studies later identified HCoV-NL63 which demonstrated that coronaviruses have been circulating in the human population for a vast amount of time (Van Der Hoek, et al. 2006). Zoonotic coronavirus infections came under the spotlight in 2003 after the outbreak of SARS-CoV-1 prompted scientists to intensively investigate coronaviruses isolated from domesticated and wild animals (Wertheim et al. 2013).

1.1. Host species of coronaviruses

A broad variety of coronaviruses are harboured in bat populations (Menachery, et al. 2017) and this correlates with evidence presented from Zhang and Holmes who state that both SARS-CoV-1 and MERS-CoV have bats as primary hosts (Zhang and Holmes 2020). Bat-CoV-RaTG13, from the bat species *Rhinolophus affinis*, shares 96% nucleotide homology with SARS-CoV-2, suggesting that SARS-CoV-2 may have originated in bats. Another SARS-like coronavirus isolated from Chinese horseshoe bats (*Rhinolophus sinicus*) shares 79% nucleotide homology with SARS-CoV-2. This is similar to the percent nucleotide homology shared between SARS-

CoV-1 and SARS-CoV-2 (Mackenzie and Smith 2020). However, there is still much speculation and investigation of which animal/animals acted as an intermediate amplification host causing the transmission of SARS-CoV-2 from animal to human.

Studies from Liu, et al and Lam, et al. have both suggested that Malayan Pangolins could be an intermediatory host due to coronaviruses isolated from these animals showing 85.5–92.4% genomic identity with SARS-CoV-2(Liu, et al., Lam, et al. 2020). There is also evidence that six key amino acid residues in the S1 region of the receptor binding site present in the spike protein of coronaviruses isolated from Pangolins are similar to those found in SARS-CoV-2 spike protein (Andersen, et al. 2020). This is an important feature as the spike protein's primary function is to mediate attachment of the virus to target cells.

However, viruses transmitted from an intermediary host to humans should share higher nucleotide similarity than that of the virus transmitted directly from the primary host (Yuan, et al. 2020). This contradicts the theory that Malayan Pangolins could be intermediary host as the nucleotide similarity for RaTG13 coronavirus isolated from the *Rhinolophus affinis* bat is higher than that of coronaviruses isolated from pangolins. However, it is hypothesized that pangolins may have been involved in a recombination event leading to transmission of SARS-CoV-2 to humans (Polatoğlu, et al. 2023).

A variety of animal species are susceptible to SARS-CoV-2 infection, either naturally or experimentally (Figure 1.1). Further studies are needed to positively identify both primary and intermediary hosts and fully understand the transmission chain that led to the initial human infection.

1.2 SARS-CoV-2 pathogenicity

Similar to other coronaviruses, the primary route of transmission of SARS-CoV-2 is via respiratory droplets, with infection occurring by direct or indirect contact with nasal, conjunctival, or oral secretions (Hui, et al. 2020). SARS-CoV-2 targets cells that express the receptor, ACE-2, and due to the variability in distribution of ACE-2 in different organs (Scialo, et al. 2020) this may lead to a broad spectrum of infection sites and patient symptoms. Patients infected with SARS-CoV-2 can have symptoms ranging from mild upper respiratory tract infection to life-threatening sepsis.

In severe cases of COVID-19, it is hypothesized that the course of infection goes through the following stages: Viral invasion and replication, dysregulated immune response, multiple organ damage and recovery. First the virus enters susceptible cells, replicates, and is released before

going on to infect other cells. This causes direct damage and deterioration of parenchymal cells such as alveolar epithelial cells. Simultaneously a large number of pathogen associated molecular pattern (PAMP) and damage associated molecular pattern (DAMP) molecules are produced, which upregulate the innate immune response, leading to inflammatory cell infiltration, excretion of large quantities of cytokines, chemokines, proteases and free radicals (Li, et al. 2021). High levels of these immune responses can lead to the development of



Figure 1. 1. Possible host range of SARS-CoV-2.(Hossain, et al. 2021)

diseases such as acute respiratory distress syndrome (ARDS) (Wang, et al. 2021) and multiple organ dysfunction syndrome (MODS) (Robba, et al. 2020), which cause excess pathological damage to respiratory structures in the lungs (von der Thüsen and van der Eerden 2020). Following the initial critical stage there is a decrease in immune hyperactivity and recovery of some of the damaged organs. However, repercussions of this infection can leave chronic illnesses such as fibrosis, constant inflammation, immunosuppression persistent inflammation, immunosuppression and catabolism syndrome (PICS) and the recently defined sequalae referred to as "long COVID" (Li,et al. 2023).

1.3. Genome organisation of SARS-CoV-2 and its expressed proteins

The SARS-CoV-2 genome is a non-segmented large positive-sense stranded RNA with a length of about 30 kB. The first two thirds of the SARS-CoV-2 genome encodes for two polyproteins, ORF1a and ORF1ab that are proteolytically cleaved into a total of 16 non-structural proteins (nsp) (Figure 1.2). These nsp have various functions in viral replication, viral assembly, and viral pathogenesis (Naqvi, et al. 2020).



Figure 1. 2 SARS-CoV-2 genome. Starting from the 5' cap to the 3' poly A tail. the genome starts with open reading frame (ORF) 1a and 1ab encode for 16 non-structural proteins. Subsequently followed by ORFs encoding the structural proteins; spike(S), envelope(E), membrane (M) and nucleocapsid (N) along with several accessory proteins. (Redondo, et al. 2021)

SARS-CoV-2 expresses four structural proteins; spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins. These proteins share high amino acid similarity with the corresponding proteins from SARS-CoV-1 and MERS-CoV. Located on the outside of the virion, the structural glycoprotein spike is responsible for the attachment of the virus to human cells and thereby initiates infection. It is composed of 1273 amino acid residues and is divided into two subunits, namely S1 and S2. The first subunit, S1, mediates attachment of virions to the receptor on the host cell. That subsequently primes the activation of S2 which possesses fusion activity (Wong and Saier Jr 2021) and causes fusion of the viral membrane with the

mammalian cell membrane, effectively allowing release of the viral genome into the cell (Naqvi, et al. 2020).

The M protein, is the most abundant viral protein and recruits other structural proteins to the endoplasmic reticulum (ER)–Golgi intermediate compartment (ERGIC), where virus assembly and budding of takes place (Zhang, et al. 2022). The M protein also aids in morphogenesis via packaging of the genomic RNA into viral particles (Neuman, et al.

2011)

E protein is the smallest of the structural proteins, and it is an integral membrane protein consisting of three subdomains. This protein forms viroporins which are essential for the assembly and release of the virus particles (Cao, et al. 2021). By interacting with M protein it also helps to maintain viral structure (Wong and Saier Jr 2021).

N protein is best known for its ability to bind to genomic RNA to form a ribonucleoprotein complex that is essential for genome replication and translation (Arya, et al. 2021). It also interacts with the structural membrane (M) protein to promote membrane envelope folding and virion assembly (Wong and Saier Jr 2021). The N protein has been described to have various functions that manipulate the cellular machinery e.g. dysregulating the host cell cycle, stimulating the production of proinflammatory markers, suppressing the production of interferon, and inducing apoptosis. (V'kovski, et al. 2021)

Nestled between the structural genes are ORFs encoding the eleven accessory proteins. Four are wedged between the S and E genes (ORFs 3a, b,c,d), four between the M and N genes (6, 7a, 7b, 8) and two found within the N gene (9b,9c). The final accessory protein is encoded is ORF10. Accessory proteins have been shown to participate in viral-host interactions, and regulate apoptosis and immune functions (Zandi, et al. 2022). Furthermore, mutations in accessory proteins such as ORF3a,ORF6, ORF7a, ORF8 and ORF10 have been detected in currently circulating variants of concern (VOC) so they could potentially contribute to the increasing pathogenesis and transmissibility in these SARS-CoV-2 strains (Redondo, et al. 2021).

1.4. The role of SARS -CoV-2 spike protein in virus entry

SARS CoV-2 spike protein(S) is a homotrimer, class I fusion glycoprotein and it contains two functional subunits, S1 and S2 (Figure 1.3). S1 contains the N terminal domain (NTD) and the receptor binding motif (RBM) or receptor binding domain (RBD) and C-terminal domain(CTD). The RBM is the region that mediates binding to the ACE-2 receptor (Lan, et al. 2020). The NTD is not well characterized but it has an important role in maintaining the

structural conformation of spike (Magazine, et al. 2022). Mutations in the NTD are also associated with immune escape, indicating that the NTD is an antibody target (Harvey, et al. 2021). SARS-CoV-2 spike C-Terminal domain (CTD) has a larger binding interface and binding surface area with the ACE-2 receptor than RBD thus making this region a great target site for antibody neutralization (Huang, et al. 2020). Nonetheless, the SARS-RBD still has a higher interaction and affinity for ACE-2 receptor than SARS-CTD

Made up of eight subdomains, S2 has a fusion peptide (FP), fusion peptide proximal domain (FPPR), two heptad repeat subdomains (HR 1 and HR 2), a central helix (CH1), connector domain (CD) a transmembrane subdomain (TM) and the C terminal tail (CT). In the solved 3D structure of SARS-CoV-2 spike protein, the S2 portion forms a trimeric stalk, on top of which is the head-like structure of S1 with the RBD exposed for engagement with the receptor.



Figure 1. 3 The SARS-CoV-2 spike genome and 3D structure model (A) is the genome for the spike glycoprotein protein(B) is the protein in a pre-fusion state (C) is the protein in postfusion state. Adaptation from (Pedenko, et al. 2023)

Once the spike protein binds to ACE-2 receptors, the interaction causes a conformational change in the spike structure that exposes the S2 fusion peptide which gets inserted into the host cell membrane. While the TM anchors S in the viral membrane, the HR1 and HR2 subdomains are pulled towards each other and form what is known as a six helical bundle (Huang, et al. 2020). The energy involved pulls the viral and host membranes into close proximity, and this then leads to fusion of the two membranes (Weissenhorn, et al. 2007).

http://etd.uwc.ac.za

1.5. SARS-CoV-2 mutations and variants of concern (VOC)

The SARS-CoV-2 spike gene is very susceptible to mutation with the most vulnerable regions being the RBD and NTD within the S1 subunit of the spike protein. Mutations occurring in the RBD can modify both the biological and immunological characteristics of the virus by interfering with ACE-2 spike binding affinity, increasing virus transmissibility and allowing the virus to escape immune responses) (Scovino, et al. 2022).

There have been approximately 20 000 mutations detected in the SARS-CoV-2 genome between 2020-2022 (Wang, et al. 2023), with the majority being synonymous amino acid changes (Harvey, et al. 2021). This was evident early in the early stages during the emergence of SARS-CoV-2, when the amino acid change D614G was detected in the spike protein. The frequency of this mutation quickly gained 100% prevalence in circulating viruses by June of 2020 (Wang, et al. 2023). The mutation changed the conformation of the spike protein which resulted in increased virus infectivity and transmissibility, thus reducing vaccine efficacy (Yurkovetskiy, et al. 2020). Any mutation able to increases transmissibility, cause an elevation severity of illness and to escape vaccines or other medicinal treatment are known as variants of concern (VOC) (Young, et al. 2022). The classification of these variants is determined by World Health Organization (WHO) and the Centres of Disease





Figure 1. 4 Amino acid mutations and deletions present in the spike protein of SARS-CoV-2 variants of concern (Yoon, et al. 2022)

Other spike amino acid mutations (Figure 1.4), N501Y emerged firstly in the Alpha variant in September 2020 and was also present in the Beta and Gamma variants. This mutation lies in the RBD, and variants carrying N501Y showed increased binding affinity for ACE2 and the ability to evade immune responses (Chakraborty 2022). The Beta and Gamma variants, which emerged in December 2020 and January 2021 respectively, carried an E484K mutation that led to the decrease in neutralization potency of some human sera by 10-fold (Greaney, et al. 2021). The Delta variant, that emerged in May 2021 introduced two additional significant mutations; L452R and T478K. The L452R mutation resulted in enhanced spike stability, increased viral infectivity, and immune evasion. (Motozono, et al. 2021) Whilst T478K caused enhanced viral entry into ACE-2-expressing cells but it had negligible effect on antibody neutralization efficiencies compared to that of the WT (D614G) strain (Wang, et al. 2022). The Omicron VOC was originally detected in South Africa in December 2021 and contained more than 30 mutations in the spike protein, 15 of them in the RBD region and 8 of them causing impairment in antibody neuralization.

1.6. COVID-19 waves in the South African population

There were four waves of COVID-19 experienced in South Africa from March 2020 until January 2022, with each wave defined as a period in which there was a significant increase in the number of COVID-19 cases (Figure 1.5). During these waves the weekly incidence increased above 30 cases per 100 000 individuals (Jassat, et al. 2021). Each wave also saw the emergence and dominance of a new VOC. Wave 1 was dominated by the D614G variant, Wave 2 by the Beta variant, Wave 3 by the Delta variant, and Wave 4 by the Omicron variant (Yang and Shaman 2022).



Figure 1.5. Timeline of pandemic waves in the South African population between March 2020 and January 2022 (Jassat, et al. 2022)

1.7. Role of neutralizing antibodies

When the body encounters pathogens such as viruses it triggers various immunological pathways as a mechanism of defence and protection. This involves the activation of B-lymphocytes which produce antibodies specific for the invading pathogen. Some of these antibodies have the ability to bind to the virus and prevent it from infecting a cell. Such antibodies are known as neutralizing antibodies (nAbs), and their presence usually correlates with protection from subsequent infection with the same virus (Abebe and Dejenie 2023). Neutralizing antibodies are produced in both infected individuals, and in those who have been vaccinated against the pathogen (Morales-Núñez, et al. 2021). However, the quality and quantity of the neutralizing antibody response differs from person to person (Gupta and Jaiswal 2022).

SARS-CoV-2 infection elicits virus specific antibodies against several different virus proteins, however only those directed against the S protein have neutralization activity (Figure1.6) (Galipeau et al. 2020, Perkmann, et al. 2021). Although neutralizing antibodies have been described to target both S1 and S2 regions of the spike protein, those that are directed specifically at the RBD appear to have a stronger neutralizing activity (Jackson, et al. 2022,Gattinger, et al. 2022).



Figure 1.6. Different neutralizing antibodies that bind to various domains in the SARS-

CoV-2 spike protein (Chen, et al. 2022)



Figure 1. 7 Receptor binding domain specific neutralizing antibodies classified into four classes based on the epitopes they target in the spike protein (Chen, et al. 2022)

These neutralizing antibodies inhibit virus infectivity by blocking binding of the RBD to ACE2 receptors, or by disrupting the viral fusion process (Stephens and McElrath 2020), both of which prevent virus entry.

Analysis of the SARS-CoV-2 neutralizing antibody response can provide critical information on the longevity and stability of the protective immune response, both in response to infection and vaccination (Lau, et al. 2021). Furthermore, such studies can provide accurate predictions of whether existing antibodies will afford cross-neutralizing activity against a newly emerged virus variant (Khoury, et al. 2021).

Various antibodies have the ability to neutralize more than one variant due to it binding to more conserved areas in the spike protein shared by the different variants. Thus, there is a need to discover neutralizing antibodies that are able to bind to various unmutated regions of the spike domain (Seydoux, et al. 2020).

1.8. Neutralization assay

Neutralization assays are a vital tool to detect and quantify the presence of functional antibodies in sera samples of infected patients and vaccinees. The classical method used for a neutralizing assay is to incubate live virus with serial dilutions of sera, and measure the extent of virus infectivity in permissive cells (e.g. by viral plaque assay or cytopathic effect) (Matusali, et al. 2021). However, an alternative method has been developed that is particularly useful when dealing with highly pathogenic viruses that can only be handled in biosafety level (BSL) 3 or 4 laboratories. Instead of using live virus, an engineered viral pseudoparticle is used that carries the surface glycoprotein of the pathogenic virus, but is otherwise harmless. As well as allowing the assay to be handled in a BSL-2 setting, these pseudoparticles carry a reporter gene so viral entry can be measured using either fluorescence or luminescence. (Figure 1.8)



Figure 1. 8 Workflow of neutralization assay using vesicular stomatitis virus pseudoparticles. (A) Sera is serially diluted, (B) a set amount of virus is added to the

sera and incubated for 1hr. Cells are then added (C) to the sera/virus and incubated for 24 hours. After incubation, cells are lysed and luciferase activity quantified using a luminometer (D), providing readings in relative light units (RLU).

Data is usually processed with statistical analysis programmes to determine dose response curves; Figure 1.9 is an ideal shape of a dose response curve to determine inhibitory dilution 50(ID₅₀).



Figure 1. 9 Ideal sigmoidal/curve of best fit/dose response curve. Used to determine inhibitory dilution (ID₅₀) values (Vogt 2008).

The ID₅₀ is defined as the reciprocal of the inhibitory dilution that causes 50% inhibition of the sera. The lower the IC₅₀ the less neutralizing activity the sera have and the higher the IC₅₀ the higher the neutralizing ability (Sarzotti-Kelsoe, et al. 2014).

1.9 Pseudoparticles

Pathogens are classified into four biosafety levels for the purpose of reducing the risk of exposure to a potentially infectious microbe and limiting contamination of the work environment and, ultimately, the community (Burnett, et al. 2009). There are four levels of biosafety with biosafety level (BSL) 1, being for the lowest risk associated organisms and level 4 having the highest risk associated organisms. SARS-CoV-2 is classified as a BSL-3 organism. However, most developing countries across the globe lack the highly trained personnel and infrastructure for BSL-3 facilities, especially in African countries.

One way of overcoming this hurdle and allowing us to study BSL-3 organisms in a BSL-2 setting is by developing pseudotyped viruses. A pseudoparticle is a recombinant virus particle that has the backbone of a less pathogenic virus but expresses the proteins/glycoproteins of more pathogenic viruses on its surface (Li, et al. 2018). The genome of the vector is genetically

modified to not produce its own surface protein, but through transfection or stable cell induction the surface protein of the pathogenic virus can be supplied *in trans* (Travieso, et al. 2022). It is also engineered to carry a reporter gene (fluorescence protein or luciferase) which serves to measure virus entry into cells, and aids in the process of obtaining quantitative data. There are three main pseudovirus packaging systems described that use either lentivirus (LV), vesicular stomatitis virus (VSV) and Murine leukaemia virus (MLV). For the purpose of the project, the focus will be on the VSV system.

1.10. Vesicular stomatitis virus pseudoparticles

Vesicular stomatitis virus (VSV) belongs to the Rhabdovirus family (Figure 1.9), and is found in insect vectors such as flies and midges which predominately targets farm animals (Letchworth, et al. 1999). The is virus considered to be harmless in humans, and any infections are mostly asymptomatic, or cause acute illness with symptoms that may include fever, muscle aches, headache and malaise (Peck, et al. 2020).



Figure 1. 10 Structure and genome organization of vesicular stomatitis virus. The genome encodes five proteins, N, P, M, G, and L. The glycoprotein (G) is found on the surface of the virus and aids in attachment to target cells (Liu, et al. 2021)

Laboratory strains of VSV have been engineered to replace the endogenous glycoprotein with two reporter genes, firefly luciferase gene (FLUc) and green fluorescence protein (GFP), creating a virus known as VSV* Δ G (FLUc)+VSV-G. To propagate this virus, the G protein must be supplied *in trans*, either by transient transfection or by stable expression. In order to generate a pseudovirus that carries the glycoprotein of another virus, e.g., SARS-CoV-2, cells are transfected with a SARS-CoV-2 spike expression plasmid, and then infected with VSV* Δ G (FLuc)+ VSV-G. The VSV pseudoparticle will acquire the spike glycoprotein during budding (Whitt 2010). (Figure 1.10)



Figure 1. 11 Schematic diagram of the generation of VSV pseudoparticles. (a) Cells are first transfected with the plasmid encoding the desired protein (SARS-CoV-2 spike gene). (b) Cells are infected with the packaging virus VSV* $\Delta G(FLUc)$ +VSV-G. (c) Cells release pseudoparticles VSV* $\Delta G(FLUc)(GFP)$ +(SARS-CoV-2 spike) = VSVpp^{spike variant} into the cell supernatant. *- denotes the open reading frame of enhanced green fluorescent protein The VSV-based pseudoparticle system has some desirable advantages over the lentivirus-based system. The first one being that the generation of VSV pseudoparticles is less time consuming. It takes a total of 48 hours to generate VSV pseudoparticles whereas it takes up to 72 hours to generate lentivirus pseudoparticles (Fukushi, et al. 2008).

The second advantage relates to the prevalence of HIV infection in the population. A recently published article from De La Torre-Tarazona, González-Robles et al. reported that SARS-CoV-2 neutralizing titres in HIV patients on antiretroviral treatment (ART) are artificially elevated if using lentivirus-based pseudoparticles (De La Torre-Tarazona, et al. 2023). This is because antiretroviral drugs in the serum can inhibit the lentivirus polymerase, leading to decreased expression of the reporter gene, and hence a false positive neutralizing titre. The authors recommended that a VSV backbone be used instead, particularly if quantifying SARS-CoV-2 neutralization activity in HIV patients on ART. This precaution was further supported by Garcia-Beltran, Lam et al. who demonstrated that sera from patients on ART generated a large proportion of false positive results (Garcia-Beltran, et al. 2021).

It is estimated that there are more than 7.7 million HIV positive people in South Africa, of which 4.6 million currently receive ART (Burger, et al. 2022). Thus, the VSV pseudoparticle system is more suitable for conducting studies on SARS-CoV-2 neutralization titres in a dense HIV positive population such as South Africa.

Aim and objectives

<u>Aim</u>: To develop a VSV based pseudoparticle system to detect SARS-CoV-2 neutralizing antibodies in human sera.

Objective 1: Clone the spike gene and express the spike protein from SARS-CoV-2 Wild type and variants (Beta, Alpha, Delta, Omicron)

- Clone SARS-CoV-2 wild type and variant spike genes into the mammalian expression vector pCAGGS.
- Verify expression of the cloned spike proteins by performing both western blots and immunofluorescence assays.

Objective 2: Develop a pseudoparticle entry assay for SARS-CoV-2 wild type and variants

- Generation of VSV pseudoparticles bearing the SARS-CoV-2 spike protein of wild type and Beta, Alpha, Delta, and Omicron variants.
- Establish infection conditions for the pseudoparticles and use reporter gene expression to provide quantitative data on spike-mediated entry.

Objective 3: Establish an assay to detect SARS-CoV-2 neutralizing antibodies in patient <u>serum samples</u>.

- Optimize conditions for assessing neutralization by using a control neutralizing antibodies to inhibit entry of SARS-CoV-2 spike pseudoparticles.
- Use the established neutralization assay to quantify the presence of SARS-CoV-2 neutralizing antibodies present in the sera of COVID-19 patients.

Chapter 2. Methodology

2.1 Amplification and cloning of SARS-CoV-2 spike genes into mammalian expression

vectors

2.1.1. Primer design for SARS-CoV-2 spike gene amplification

Oligonucleotide primers were designed to target the SARS-CoV-2 spike open reading frame (ORF) based on the NCBI Reference Sequence: NC_045512.2 (on 18th of July 2020). For the amplification of the spike ORF from subsequent variants, the primer sequences were aligned with the published sequences of the variant spike genes. No mismatches were observed.

Due to the large size of the SARS-CoV-2 spike gene, the ORF was amplified in three overlapping fragments sized between 1210-1355 base pairs. Each fragment was flanked with 15-30 base pair overlapping ends as indicated in Figure 2.1 and Table 2.1. During ligation of the three fragments, endonuclease creates a single stranded 3' overhang that allows for the ligation of these complementary ends (overlapping regions). Thus, the forward primer for Fragment 1 and the reverse primer for Fragment 3 included overlapping sequence corresponding to the cut sites of the pCAGGS vector after *KpnI* digestion.



Figure 2.1 Overview of the cloning strategy for the generation of plasmids expressing SARS-CoV-2 spike. Taken from the instructional manual (Biolabs 2022)

	Forward	Reverse
	MLS-1	MLS-2
Fragment 1 <i>1210bp</i>	5'-attcgagetcatcgatgcatggtacACCATG	5'-attagtaaagcaGAGATCATTTAATTT
	TTTGTTTTTTTTTGTTTTATTG-3'	AGTAGGAGAC-3'
	MLS-3	MLS-4
Fragment 2 1355bn	5'-attaaatgatctcTGCTTTACTAATGT	5'-catattgtttgaTGAAGCCAGCATCTGC
Ĩ	CTATGCAGATTCATTTG-3'	AAGTG-3'
	MLS-5	MLS-6
Fragment 3 1327bp	5'-catattgtttgaTGAAGCCAGCATCTG	5'-catattgtttgaTGAAGCCAGCATCTGC
	CAAGTG-3'	AAGTG-3'

Table 2. 1 Primers for the amplification of the SARS-CoV-2 spike gene.

2.1.2. Synthesis of cDNA from RNA

SARS-CoV-2 RNA was isolated from amplified virus stocks of WT, Beta, Alpha and Delta variants (kindly provided by Dr Tasnim Suliman). To generate amplicons for downstream PCR reactions, the RNA was converted to cDNA using New England Biotech LunaScript reverse transcriptase as illustrated below.

UNIVERSITY of the

WESTERN CAPE

Table 2. 2Reaction preparation for the synthesis of cDNA from RNA

	Test	No RT	No template
	sample	control	control
LunaScriptRT	4 1		<i>A</i> µ1
SuperMix (5X)	+μI	-	+ μ1
Viral RNA	4 µl	4 µl	-
No RT control mix	-	4 µl	-
Nuclease free water	12 µl	12 µl	16 µl
Total		20 µl	

Table 2. 3 Thermocycler conditions for the synthesis of cDNA from RNA

Cycle step	Temperature	Time	Cycles
Primer Annealing	25°C	2 minutes	
cDNA Synthesis	55°C	10 minutes	1
Heat Inactivation	95°C	1 minute	7 . 6 .7
UI	AIVER	(311)	x of the

cDNA was stored at -20°C.

2.1.3. PCR amplification of SARS-CoV-2 spike genes

Three separate reactions were performed to generate the three fragments of the SARSCoV-2 spike gene. Reactions were prepared as per manufactures instructions (New England Biolab) using the Q5® High-Fidelity PCR Kit.

CAPE

Reagent	Volume
Q5 High Fidelity Master Mix(2X)	12.5µl
Forward primer (10 µM)	0.5µl
Reverse primer (10 µM)	0.5µl
Nuclease Free water	9.5µl
Template DNA	2 µl
Total volume	25µl

Table 2. 4 Q5® High-Fidelity PCR amplification reaction mixtures

Reactions were placed in the thermocycler under the following conditions:

 Table 2. 5 Q5® High-Fidelity PCR amplification reaction thermocycler conditions

Step(s)	Temperature(°C)	Time	Number of cycles
Initial denaturation	98	30s	1
Denaturation	98	10s	17.
Annealing	58	30s	35
Extension	72	45s	PE
Final extension	72	2 mins	1

2.1.4 Single restriction enzyme digest

In order to ligate the expression vector and the three PCR fragments, the plasmid vector had to be linearized at the KpnI cut site. Using New England BioLab manufacturer's instructions $pCAGGS(1\mu g)$ was mixed with $1\mu l$ of KpnI-HF (see Appendix 1 Table 5), $3\mu l$ of CutSmart buffer and $21\mu l$ of nuclease free water. The mixture was then incubated at $37^{\circ}C$ for 1hour.

2.1.5 Agarose gel electrophoresis

PCR and digest products were run on a 1% (w/v) agarose gel. This was prepared by combining 1g of agarose powder in 100 ml of TAE buffer and then heated in a microwave until the solutes were dissolved. After allowing the solution to cool down slightly, 1μ (10mg/mL) of ethidium bromide (see Appendix 1, Table 5) was added. The agarose was poured into a casting tray with appropriate combs depending on the specifications of the experiment. The solution was left to solidify for approximately an hour. An equal ratio of DNA: 6X loading dye was loaded into each well. A 1kB ladder (NEB Biolabs) was also loaded, and the gel was then electrophoresed for 60 mins at 100V in TAE buffer. DNA was visualized via UV light and images were captured. 2.1.6 DNA extraction from agarose gels

After samples were run on the agarose gel, DNA was extracted as per manufactures instructions (NucleoSpin Gel and PCR clean up). DNA fragments were visualized on a UV lightbox, excised from the agarose gel, and transferred to an Eppendorf tube. For each 100mg of agarose gel, 200µl of Buffer NTI was added, and the samples were incubated for 10 mins at 50°C with vertexing in intervals of 2 mins. Once the agar was completely dissolved a NucleoSpin Gel Clean up column was placed in a 2mL Eppendorf tube and up to 700µl of sample was loaded. The collection tube and column were centrifuged for 30s at 11,000 x g. Flow through was discarded and the column membrane was washed with Buffer NT3 before centrifuging the column twice at 11,000 x g for 1 minute each to allow the membrane to dry completely. The column was then placed in a new 1.5ml tube and 30µl of elution buffer was added at room temperature, before finally centrifuging for 1 minute at 11,000 x g.

2.1.7 Ligation of SARS-CoV-2 spike into pCAGGS vector

The 3 PCR fragments of the SARS-CoV-2 spike gene were ligated into the pCAGGS mammalian expression vector using NEBuilder HiFi DNA Assembly Reaction kit from New England BioLabs.

Table 2. 6 Ligation mixture preparation reaction

	Spike gene	Positive	Negative
pCAGGS(100ng/µl) (linearised with KpnI)	1µ1	-	1μl
Fragment 1(pmol/µl)	3.3µ1	-	-
Fragment 2(pmol/µl)	3.7µ1	-	-
Fragment 3(pmol/µl)	1.8µl	-	-
NEBuilder HiFi Assembly reaction master mix	10µ1	10µ1	10µ1
Nuclease Free water	0.2µ1		9µ1
Positive control	-	10µ1	-
Total	20µl	20µl	20µl

The samples were incubated for 15 minutes at 50 C, and then stored at -20°C for subsequent transformation.



UNIVERSITY of the WESTERN CAPE

2.2. Preparation of plasmid DNA

2.2.1 Transformation of DHα competent E.coli

A 50µl vial of high efficiency DHα cells (Appendix 1, Table 1), provided with the NEBuilder HiFi DNA Assembly kit, was briefly thawed on ice, and 2µl of the PCR ligation reaction was added and gently mixed by pipetting and placed on ice for 30 minutes Cells were heat shocked at 42°C for 30 seconds before immediately placing the tubes back on ice for 2 minutes. S.O.C media was added to the tube and incubated at 37°C for 1 hour on a shaker with vigorous agitation (225 rpm). 100µl of the mixture was plated onto pre-warmed LB-Ampicillin agar plates which were inverted and incubated at 37°C overnight.

2.2.2. Transformation of JM109 competent E.coli

A 50µl vial of Promega JM109 (Appendix 1, Table 1) competent *E.coli* was thawed on ice before adding 1µl of plasmid DNA at a concentration of 10ng/µl. The vial was incubated on ice for 30 minutes and then briefly incubated at 42°C for 30 secs before being transferred back onto ice. 250µl of prewarmed Invitrogen S.O.C media was added to the vial before incubation on a shaking rotator for 1 hour at 225 rpm. 10µl of each transformation reaction was plated onto LB- Ampicillin agar plates, which were inverted and incubated at 37°C overnight.

2.2.3. Small scale generation of plasmid DNA (miniprep)

The extraction of plasmid DNA from transformed *E.coli* was done according to the manufacturer's instructions of the NucleoSpin Plasmid kit from Macherey-Nagel. One isolated colony from an LB-agar plate was inoculated into 3ml of LB broth (Appendix 1, Table 9) containing 50μ g/ml of ampicillin antibiotic (Appendix 1,Table 5), and the culture was incubated overnight at 37° C on a shaking rotator. Thereafter, the cultures were transferred into 1.5 mL Eppendorf tubes and centrifuged at 11 000 x g for 30 secs. The supernatant was then discarded and the remaining pellet thoroughly resuspended in resuspension buffer. Cell lysis buffer was then added, and the tube gently inverted. Neutralization buffer was then added to the mixture and the tube inverted until the solution became colourless. Insoluble material was pelleted at 11 000 x g for 10 minutes, and the supernatant was transferred to a NucleoSpin column and centrifuged at 11 000 x g for 1 minute. The silica column was then washed with wash buffer and centrifuged at 11 000 x g for 2 mins. DNA was then eluted from the membrane by addition of elution buffer and centrifuging at 11 000 x g for 1 minute. The plasmid DNA was stored at -20°C for further downstream use.
2.2.4 Double restriction enzyme digest of plasmid DNA

Restriction enzyme digest was done as per manufacturer's instructions (New England BioLabs). Briefly, 1µg of miniprep plasmid DNA was mixed with 1.2µl of CutSmart buffer and 0.3µl of each restriction enzyme. The reaction was incubated overnight at 37°C. The digested plasmid DNA was then analysed on a 1% agarose gel by gel electrophoresis.

2.2.5 Large scale generation of plasmid DNA (maxiprep)

Large quantities of plasmid DNA were prepared using the NucleoBond Xtra Plasmid Purification kit from Macherey-Nagel. Bacterial cultures containing 300ml of LB-broth and 50µg/ml of Ampicillin antibiotic were inoculated with 300µl of starter culture broth, and were incubated overnight at 37°C on a shaking rotator. Cells were pelleted via centrifugation at 4 000 x g for 30 minutes at 4°C, the supernatant was discarded, and the pellets resuspended in resuspension buffer until the mixture became homogenous. Cell lysis buffer was added and the container gently inverted before being incubated for 5 minutes at room temperature. Thereafter, neutralization buffer was added and mixed until a transparent colour with white flocculants appeared. This mixture was then centrifuged at 4 000 x g for 10 minutes to allow for separation of the flocculant and supernatant. The column and filter were equilibrated with equilibration buffer prior to the addition of the supernatant which was allowed to flow through via gravitational flow. The filter was then washed with equilibrium buffer before discarding the column filter and a second wash step was done with wash buffer directly onto the column. The DNA was eluted from the column by the addition of elution buffer heated to 50°C and set aside for elution via gravity flow. The DNA was then mixed with iso-propanol and precipitated via centrifugation at 13 000 x g for 30 minutes at 4°C. DNA pellets were washed with 70% ethanol and centrifuged at 13 000 x g for 5 minutes at room temperature. Pellets were left to dry before resuspending the pellet in TE Buffer. The plasmid DNA was stored at -20°C for further WESTERN CAPE downstream use.

2.2.6 Ethanol precipitation of DNA

Ethanol precipitation was used to purify and concentrate DNA. The DNA was mixed with 1/10th the DNA volume of 3M of sodium acetate and 3 times the DNA volume of 100% ethanol. The solution was then left to precipitate overnight at -20°C, and the next day the solution was centrifuged at 14 000 RPM at 4°C for 30 minutes to pellet the DNA. The pellets were then washed twice with 70% ethanol and centrifuged at 14 000 RPM for 10 minutes. Thereafter, the pellets were spun for 30 secs to allow for removal of any excess ethanol. Finally,

the pellets were left to dry at room temperature, and resuspended in nuclease-free water. The DNA were stored at -20°C.

2.2.7. Quantification of plasmid DNA

Plasmid DNA concentrations were determined using the ThermoFisher Nanodrop 3300. Absorbance readings at 260nm and 280nm (A260/A280) were determined, where a ratio of 1.8 and above indicated that the preparation was relatively free of contaminants.

2.2.8 Sanger Sequencing

In order to verify the correct sequence of the cloned SARS-CoV-2 spike genes. Plasmid DNA clones were sequenced using forward and reverse vector plasmid primers (CAGGS-3 and CGGS-5), in addition to internal forward and reverse primers that bind within the spike ORF (MLS-2, MLS-3, MLS-4, and MLS-5). Samples were sent to Inqaba BioTech labs for Sanger sequencing. Results in the form of chromatograms were analysed using Ape, A plasmid editor and Snapgene. The DNA contigs were aligned against the SARS-CoV-2 spike reference sequence (NC_045512.2) using the BLAST tool in order to check for any mismatches and mutations in the cloned sequences.

2.3. Maintenance of mammalian cell lines

Human embryonic kidney cells (HEK-293T) and African green monkey kidney cells (Vero E6) cells (see Appendix 1, Table 2) were maintained in Dulbecco's Modified Eagles Medium (DMEM) supplemented with 10% foetal bovine serum (FBS) and 1% Amphotericin B/PenStrep (Penicillin-Streptomycin) (Appendix 1, Table 6) and cultured in a T75 tissue culture flask at 5% CO₂ and 37°C.

HEK-293T cells that stably express human angiotensin converting enzyme 2 (HEK293T/ACE-2) were kindly provided by Prof Penny Moore (NICD). This cell line was maintained in DMEM supplemented with 10% FBS, 1% Amphotericin B/PenStrep, and $3\mu g/uL$ Puromycin (see Appendix 1, Table 6).

2.4 Transfection of mammalian cells

HEK-293T cells at a density of 8×10^5 cells per well were transfected in suspension with ThermoFisher Lipofectamine 3000 reagent as per manufacturer's instructions. A 1:3 ratio of DNA to Lipofectamine is used during all transfections and are done according to manufacturer's instructions. As per Figure 2.2, two aliquots of Gibco OptiPRO serum free media were dispensed into individual Eppendorf tubes. Lipofectamine 3000 reagent was added to tube 1 and plasmid DNA $(1\mu g/\mu l)$ and 5 μl of P3000 reagent were mixed together in tube 2. The DNA/P3000 was then mixed with the diluted Lipofectamine 3000, and incubated at room temperature for 15 minutes. The transfection solution was added to cells in a dropwise manner and the cells were incubated at 37°C for 24 hours.



2.5. Western Blots

Media was removed from cells and was washed twice with 2 X DPBS before the addition of 200µl RIPA buffer to each well. Cells were incubated on ice and gently agitated for 30 minutes. Thereafter cells were manually dislodged from each well and transferred to Eppendorf tubes before centrifuging at 13 000 rpm for 10 mins at 4°C. Pellets were discarded, and supernatants were stored at -20°C.

An equal amount of lysate was mixed with an equal amount of 1X SDS-PAGE sample buffer (see Appendix 1, Table 9), the suspension was boiled at 95°C for 15 minutes, and then loaded into individual wells of the SDS-PAGE gel along with a protein marker. Electrophoresis was performed at 0.02 constant amps for 2 hours. Total proteins were then transferred from the gel to nitrocellulose membrane using Bio-Rad semi- dry transfer system at constant voltage of 25V for 2 hours. The membrane was blocked in 5% non-fat milk (see Appendix 1, Table 9) for 2

hours at room temperature with slight agitation. The primary antibody, mouse monoclonal SARS-CoV-2 spike S1 subunit (R&D systems

MAB105403), was diluted 1/10 000 dilution (0.5mg/mL) in block solution and incubated overnight at 4°C with slight agitation. The membrane was then washed with PBS-Tween 20 (PBS-T) three times for 10 minutes each.

Subsequently, secondary antibody Goat anti Mouse IgG (H+L) HRP conjugated (Invitrogen, # 31430) was diluted 1/5 000 (0.8mg/mL) in block solution, and added to the membrane which was incubated for 1 hour at room temperature. The membrane was washed in PBS-T three times for 20 minutes each, then 1-2 mL of TMB Membrane Peroxidase Substrate (see Appendix 1, Table 9) (pre-warm to 37°C) was added to the membrane for 5-10 minutes to allow the substrate to react with the HRP enzyme (resulting in a blue precipitate). To stop the reaction, the membrane was covered with distilled water and then viewed.

2.6. Immunofluorescence

The transfected cells were fixed and permeabilized with 100% methanol at – 20°C for 30 minutes, and then washed twice with PBS. Blocking solution (5% bovine serum albumin (BSA) in PBS) was added to each well and incubated for 30 minutes at room temperature. Thereafter primary antibody (SARS-CoV-2 Spike S1 Subunit Antibody (R&D systems MAB105403)) at a 1:1000 dilution(0.5mg/mL) or mouse monoclonal ANTI-FLAG® M2 antibody (Sigma Alrich, F3165) at a 1:1000 dilution (1mg/mL) was added to coverslips and incubated at 1 hour at room temperature. Coverslips were washed 3 times with PBS-T before adding secondary antibody Goat anti-mouse IgG(H+L) highly cross absorbed Alexa Fluor Plus 488 (Invitrogen, #A32723) diluted 1:1000 (2mg/mL) and DAPI for 45 minutes at room temperature in the dark. Coverslips were then washed again 3X with PBS-T and 1X with distilled water before being briefly dabbed on tissue paper to remove excess liquid. Coverslips were then inverted i.e., cell side down, and mounted in Invitrogen ProLong Gold antifade mounting media on a microscope slide. Slides were stored in the dark at 4°C.

2.6. Generation of pseudoviruses using a VSV-based system

2.6.1 Propagation of VSV*ΔG(FLUc) trans complemented with VSV-G

Vesicular stomatitis virus (VSV) engineered to express firefly luciferase (FLUc) and green fluorescent protein (GFP) in place of the viral glycoprotein (G), was kindly provided by Dr Gert Zimmer at the Institute for Virology, Mittelhäusern, Switzerland. The propagation of VSV* Δ G(FLUc) trans complemented with VSV-G was performed in a 6 well plate that was

pre-treated with poly-L-lysine for 20 minutes and left to dry in a laminar flow hood. HEK-293T cells (8x10⁵/well) were transfected with an expression plasmid for VSV-G (pCG-1-VSV-G) using Lipofectamine 3000.

After 24 hours the cells were infected with VSV* $\Delta G(FLUc)+(VSV-G)$ (see Appendix 1, Table 2) at an MOI of 3 for 1 hour at room temperature with gentle agitation every 15 minutes. The virus was removed from cells before gently washing the cells 6 times with PBS and adding 2% post infection media (1X DMEM supplemented with 2% FBS and %1 Pen/Strep). Cells were incubated for 24 hours at 33°C before harvesting the supernatant which was then centrifuged at 2000 RPM for 5 minutes and aliquoted into cryovials and frozen at -80°C.

2.6.2. Titration of VSV*ΔG(FLUc) +(VSV-G) stock

The VSV* $\Delta G(FLUc)$ +(VSV-G) stock was titrated using a TCID-50 assay in HEK-293T cells. A 10-fold dilution series of the virus stock was made in a 96-well plate from columns 3-12, to which a suspension of cells at a density of 4×10⁵ cells/well was added. The infected cells were incubated for 24 hours at 37°C. The luciferase activity in the infected cells was quantified using Bright-GloTM Luciferase Assay System (Promega). Briefly, supernatant was removed, and the cells were lysed in 30 µl 1X passive lysis buffer for 10mins, before adding 100µl of BrightGlo substrate. The contents of each well were then transferred to a 96-well white plate and the luminescence was read using the SpectraMax ID3 with an integration time of 1 sec. Relative light units (RLU) were recorded.

The Reed Muench method was used to calculate the TCID 50/mL of the virus stock as follows: 1. A positive (+) sign was assigned to all RLU values >1000, and a negative (-) for all values < than 1000.

2. A percentage for each dilution ranging from 10^{-1} - 10^{-10} was calculated by dividing the number of positive signs of each dilution by the number of replicates (8 replicates for a full 96 well plate) x100%

3. LogID50 = Log (dilution with >50% RLU) + [difference of logs or PD x (-Log of dilution factor)] is the equation used to determine TCID 50

4. The proportional distance (PD) or difference in logs value is calculated as follows:

5. The proportional distance (PD) or difference in logs value is calculated as follows:

(% RLU at the viral dilution that shows > 50%) – 50%

 $\begin{array}{l} (\% \ RLU \ at \ the \ viral \ dilution \ that \ shows > 50\% \) - (\% \ RLU \ at \ the \ viral \ dilution \ that \ shows < 50\% \) \\ 6. \qquad \mbox{LogID50} \qquad \longrightarrow \quad \mbox{ID50} = 10^{\mbox{LogID50}} \end{array}$

7. TCID50/mL = $\frac{\frac{1}{ID \ 50}}{volume \ of \ virus \ inoculum(mL)}$

2.6.3. Generation of VSV*ΔG(FLUc) +(SARS-CoV-2 spike) pseudoparticles

To generate SARS-CoV-2 spike expressing VSV pseudoparticles, HEK-293T cells were transfected with pcDNA expression plasmids expressing SARS-CoV-2 spike from the wild-type (WT)/D614G, Beta, Delta, and Omicron (BA1) variants of SARS-CoV2, which were kindly provided by Prof Penny Moore (NICD).

After transfection the media was aspirated and the cells washed twice with DPBS. Transfected cells were then infected with VSV* $\Delta G(FLUc)$ +VSV-G at an MOI of 3 for 1 hour at room temperature with gentle agitation every 15 minutes. The virus was removed from cells before gently washing cells 6 times and adding 2% Post infection media. Cells were incubated for 24 hours before harvesting supernatant which were then centrifuged at 2000 RPM for 5 minutes and aliquoted in cryovials and frozen at -80°C.

2.6.4 Titration of VSV*ΔG(FLUc) +(SARS-CoV-2 spike) pseudoparticles

A 2-fold serial dilution of the VSVpp-Spike pseudoparticle preparation was made in a 96 well cell culture plate, before adding 100µl of HEK-293T/ACE-2 cells at a density of 8×10^5 cells per well. The infected cells were incubated for 24 hours at 37°C. Luciferase activity was measured using the Bright-GloTM Luciferase Assay System (Promega). The media was aspirated off the cells, briefly and 30µl of 1X passive lysis buffer was added to each well and incubated for 10 minutes before adding 100µl of BrightGlo substrate. The contents of each well were then transferred to a 96 well white plate, and luminescence was measured using the SpectraMax ID3 with an integration time of 1 second. Relative light units (RLU) were recorded and plotted on the Y-axis vs. dilution factor on the X-axis. Dilutions that resulted in approximately 100 000 RLUs were used for neutralization assays.

 \mathbf{PE}

2.7. SARS-CoV-2 neutralization assay

2.7.1. SARS-CoV-2 neutralizing antibodies and human sera

Human monoclonal antibodies (CA1, CB6, 084-7D) targeting the spike protein that have been described to neutralize SARS-CoV-2 were kindly provided by Prof Penny Moore (NICD). The neutralizing antibody, Bebtelovimab (Eli Lilly), was kindly provided by Dr Craig Fenwick (Lausanne University Hospital, Lausanne, Switzerland).

Human sera from COVID-19 patients were obtained from two different cohorts, one from the University of Pretoria, the other the University of Cape Town.

Ethics statement: The use of human antibodies and human sera for research purposes was approved by the Biomedical Science Research Ethics Committee of the University of the Western Cape. Ref No. BM21/9/19.

2.7.2. Optimisation of assay conditions using SARS-CoV-2 spike neutralizing antibodies A 3-fold serial dilution of the neutralizing antibodies CA-1 (10 µg/mL starting concentration), CB-6 (5µg/mL), 087-4D (50µg/mL), and Bebtelovimab (1µg/mL) was performed in a 96 well culture plate. VSVpp-spike pseudoparticles (variants WT, Beta, Delta and Omicron) were diluted to obtain approximately 100 000 RLU of virus (based on the titration described in 2.6.4) and 50µl was added per well. The antibody and pseudoparticle were mixed and the suspension were incubated for 1 hour at 37°C. HEK293-T/ACE-2 cells were added to the antibody/pseudoparticle mixture at a density 8×10^5 cells per well, and incubated for 24 hours at 37° C, 5% CO₂.

Thereafter, the media was aspirated off the cells, and 30μ l of 1X passive lysis buffer was added and incubated for 10 minutes before adding 100μ l of BrightGlo substrate. The contents of each well were then transferred to a 96 well white plate and luminescent signal was quantified using the SpectraMax ID3 with an integration time of 1 sec.

RLU values were recorded in Excel before plotting the normalized values vs. the antibody concentration, and applying a line of best fit in GraphPad. The statistical programme also generated IC50 values (50% inhibitory concentration).

2.7.3 Validation of the assay using human SARS-CoV-2 sera

A batch of blinded human serum samples was sent by Prof Penny Moore (NICD) to test the validity of VSV-based SARS-CoV-2 neutralization assay. The nine samples were initially centrifuged at 14 000 rpm for 1 minutes before being heat inactivated at 55°C for 30 minutes to destroy the naturally occurring complement factors. Samples were aliquoted and stored at - 80°C.

All serum samples were initially diluted 1:20 before performing a serial 3-fold dilution. A set amount of VSVpp-spike (~100 000 RLU) was added to the plate before incubating for 1 hour at 37° C. A suspension of HEK-293T/ACE-2 cells was prepared and added at a final density of $2X10^{4}$ cells/well. Cells were incubated at 37° C at 5% CO₂.

After incubating for 24 hours, the media was aspirated off the cells and 30µl of 1X passive lysis buffer was added and incubated for 10 mins before adding 100µl of BrightGlo substrate. The contents of each well were transferred to a 96 well white plate and luciferase activity was measured.

The data generated by SoftMax Pro relative light units (RLU) reading was then processed in Excel to standardize values $\frac{RLU value}{RLU virus only value} \times 100\%$ to give us a percentage of neuralization of each sample. The percentage of neutralization was then plotted against the corresponding serum dilution using GraphPad.

To further determine accuracy of ID_{50} values the data was processed using a Macro programme provided to us from the NICD.

WESTERN CAPE

http://etd.uwc.ac.za

Chapter 3: Results

3.1. Amplification of SARS-CoV-2 spike genes from viral cDNA

Viral SARS-CoV-2 RNA was isolated from amplified virus stocks of wild type/D614G (WT), alpha beta, and delta variants. The RNA was converted to cDNA using random hexamer and poly dT primers. The Q5® High-Fidelity PCR Kit was then used to amplify three overlapping fragments using specific primer pairs (Table 2.1)

Due to the lack of availability of commercial SARS-CoV-2 spike antibodies at the time of this experiment, a FLAG tag was added to the C-terminus of the ORF for downstream protein detection. Another modification at the C-terminus of the ORF was the deletion of the last 19 amino acids to eliminate the ER-retention motif. Research has shown that the deletion of the 19 amino acid retention sequence increases the presence of spike protein at the cell surface (Johnson, et al. 2020, Chen, et al. 2021, Wang, et al. 2021, Zhang, et al. 2023). These modifications were incorporated into the reverse primer for Fragment 3 (Table 2.1) The forward primer of fragment 1 and the reverse primer of fragment 3 also contained KpnI sites which would allow for recombination with the vector once it had been linearized at the *KpnI* site present in the multiple cloning sites. Images of the DNA gels showing successful amplification of the three fragments (approximately 1210bps,1355 bps, and 1327 bps) for each SARS-CoV-2 variant are shown in Figure 3.1 A-D.

UNIVERSITY of the WESTERN CAPE

UNIVERSITY of the





A 1 % agarose gel showing the three amplicons (SARS-2-S-1, SARS-2-S-2 and SARS-2-S-3) which together comprise the full-length spike gene of the SARS-CoV-2 WT (panel

A), alpha (panel B), beta (panel C), and delta (panel D) variants, respectively. Lane 1 contains a 1kB ladder. Negative controls: Neg.1 = no reverse transcriptase (RT), Neg.2 = a no template control, Blank= empty wells

3.2. Cloning of Flag-tagged SARS-CoV-2 spike genes into pCAGGS

Once the SARS-CoV-2 spike fragments were amplified, they were purified and combined with the expression vector, pCAGGS, that had been linearised with *KpnI*. The four DNA fragments were ligated by means of recombination using NEBuilder HiFi DNA Assembly Reaction kit. To confirm the presence of the entire SARS-CoV-2 spike gene in the resultant clones, a double digest using enzymes *Xho I* and *Sac I* was performed, which should remove the SARS-CoV-2 spike gene from the pCAGGS vector. The presence of bands at approximately 3.9 kB and 4.7Kb, which represent SARS-CoV-2 spike and pCAGGS, respectively, was used to identify positive clones (Figure 3.2).



Figure 3. 2 Confirmation of SARS-CoV-2 spike WT and Beta clones by restriction enzyme digest using enzymes *Xho I* and *Sac I*. Lanes 1-9 (wild type) and lanes 1-12 (beta) contain the digest products of different plasmid clones electrophoresed on a 1% agarose gel. The positions of the pCAGGS vector at 4.7kB, the SARS-CoV-2 S gene at 3.9kB, and undigested plasmid are indicated.

3.3. Sequence confirmation of pCAGGS spike-Flag clones

Once positive clones were identified, and purified plasmid DNA was generated, it was sent for sequence confirmation. The plasmid was subjected to Sanger sequencing using the forward and reverse primers that generated each of the three PCR fragments of SARS-CoV-2 spike. In addition, forward and reverse pCAGGS primers that bind either side of the multiple cloning sites were utilized. This allowed for the generation of multiple overlapping sequences that were then aligned to reconstruct the cloned spike gene. The aligned sequences were compared to the SARS-CoV-2 Wuhan-Hu-1 reference sequence (Figures 3.3 and 3.4). For the WT spike clone, one missense mutation was detected at position 614 of the amino acid sequence which changed an aspartic acid to glycine (Figure 3.3). The results were expected because it is known that the virus acquired this mutation in the spike gene very soon after it began circulating in humans in early 2020. The viral RNA that was used as a template for the amplification of the WT spike gene was from a virus isolated in the first wave of COVID-19 in South Africa (April 2020), corresponding to the presence of the D614G mutation in spike.



Figure 3. 3 Alignment of the reference sequence for SARS-CoV-2 isolate Wuhan-Hu-1 (NC_045512.2) with the contigs generated from pCAGGS-Spike^{WT} clone.

For the pCAGGS-spike^{Beta} clone, 8 missense mutations resulting in the change of amino acids were detected, namely: L18F, D80A, D215G, K417N, E484K, N501Y D614G and A701V (Fig 3.4 and Table 3.1). In addition, a deletion of amino acids 242-244 was observed. A synonymous mutation occurred at position 1532 of the genome sequence but still encoded for the amino acid value. These mutations correspond to the report from Tegally *et al.* (Tegally, et al. 2020) who first detected the emergence of the Beta variant in South Africa.







UNIVERSITY of the WESTERN CAPE



Figure 3.4 Alignment of the reference sequence for SARS-CoV-2 isolate Wuhan-Hu-1 (NC_045512.2) with the contigs generated from pCAGGS-spike ^{Beta} clone.

Mutation	Genome	Genome	Amino acid	Amino acid conversion
	position	sequence	position	
L18F	52	CTT-TTT	18	Leucine – Phenylalanine
D80A	239	GAT - GCT	80	Aspartic acid- Alanine
D215G	644	GAT - G G T	215	Aspartic acid - Glycine
K417N	1242	AAG - AAT	417	Lysine - Asparagine
E484K	1441	GAA - AAA	484	Glutamic acid - Lysine
N501Y	1492	TTA - TAT	501	Asparagine - Tyrosine
D614G	1833	GAT - G G T	614	Aspartic acid to Glycine
A701V	2193	GCA - GTA	701	Alanine to Valine
Ę				10 C
		ESPICE PROSPICE		
4	UNI WES	VERSITY of t TERN CAP	he E	-
Sector Se				

Table 3.1 Table of listed mutation detected in the clone of pCAGGS-spike ^{Beta}.

UNIVERSITY of the WESTERN CAPE

3.4. Expression and localisation of pCAGGS-spike ^{WT}-FLAG and pCAGGS-spike ^{Beta}FLAG

After cloning the SARS-CoV-2 spike gene into the mammalian vector pCAGGS, successful expression and localisation of the spike protein from pCAGGS-Spike ^{WT}-FLAG and pCAGGS-Spike ^{Beta} had to be confirmed. HEK-293T cells were transfected with plasmid DNA of pCAGGS-spike^{WT}-FLAG and pCAGGS-spike^{Beta} -FLAG. Cells were then fixed and permeabilised before adding mouse monoclonal ANTI-FLAG® M2 antibody to detect the FLAG epitope that was engineered onto the spike protein. Secondary antibody Goat anti-mouse Alexa Fluor Plus 488 (Thermo-Fisher Scientific, Catalogue No. A-10680) and DAPI were added before viewing the cells on a fluorescence microscope. As seen in Figure 3.5 no detection of the spike protein can be seen in cells transfected with pCAGGS-spike^{WT}-FLAG and pCAGGS-spike^{Beta} -FLAG. However, the positive control pCAGGS-KPNA4-FLAG showed positive staining, with KPNA-4 visible in the nucleus and perinuclear region.



Figure 3.5 Expression and localisation of SARS-CoV-2 spike-protein using FLAG antibody. HEK293T cells were transfected with of pCAGGS-spike^{WT}-FLAG and pCAGGS-spike^{Beta} -FLAG or pCAGGS-KPNA4-FLAG. The expression of spike and KPNA4 proteins were detected with an anti-FLAG antibody and an Alexa Fluor 488 secondary antibody (green signal). Nuclei were visualised with DAPI staining (blue signal). Representative images captured by fluorescent microscopy are shown. Scale bars are indicated.

One potential explanation for why the spike protein was not being detected is that the FLAG epitope was hidden in the context of the folded protein, and therefore not accessible to the antiFLAG antibody. Thus, in a repeat experiment the transfected cells were probed with a SARSCoV-2 spike-specific antibody (Fig 3.6), but unfortunately no spike-specific signal was observed. A thorough investigation of the plasmid sequences could not provide a logical explanation for why no protein expression could be observed, as the spike ORF was intact and the FLAG sequence was in-frame. We reached out to Prof Penny Moore at NICD for assistance, and she kindly provided us with pcDNA3.1 plasmids encoding the SARS-CoV-2 spike gene from several variants.



Figure 3.6 Expression and localisation of SARS-CoV-2 spike protein using SARS-CoV-2 spike antibody. HEK293T cells were transfected with, pCAGGS-spike^{WT}-FLAG and pCAGGS-spike^{Beta} -FLAG or empty pCAGGS. The expression of spike protein was detected with a SARS-CoV-2 spike S1 Subunit Antibody followed by probing with an Alexa Fluor 488 secondary antibody (green). Nuclei were stained with DAPI (blue). Representative images captured by fluorescent microscopy are shown. Scale bars are indicated

3.5. Validation of SARS-CoV-2 spike protein expression from the plasmids obtained from NICD

The NICD gifted us with pcDNA3.1 constructs encoding the spike genes of five variants – WT/D614G, Alpha, Beta, Delta, and Omicron (Table 3.2). A mutant form of the Omicron spike in which the C-terminal 18 residues had been deleted, were also received.

Table 3.2	The SARS-CoV-2	2 spike expression	constructs received	from NICD
14010 012		- spine expression	constructs received	nomined

Name of variant and sub-linage	Abbreviated names	
Wild type-D614G	WT	
B.1.1.7 Alpha	ALPHA	
B.1.351 Beta	BETA	
B.1.617.2 Delta	DELTA	
B.1.1.529 Omicron	OMI-1	
B.1.1.529 Omicron-d18	OMI-Δ18	
36.	NY I I I I I I I I I I I I I I I I I I I	

All sub lineages of the variants are denoted in the table. Omi-d18 contains a deletion of the Cterminal 18 amino acid ER retention sequence for enhanced expression of SARS-CoV-2 spike protein on the cell surface.

To confirm that the SARS-CoV-2 spike ORF was cloned into the pcDNA 3.1 vector, a double restriction enzyme digest was performed using restriction enzymes *HindIII* and *ApaI* (Fig 3.7). The presence of bands at 5.4Kb and 3.4 Kb respectively indicated the vector and spike gene, respectively.

WESTERN CAPE



Figure 3.7 Confirmation of the presence of the SARS-CoV-2 spike gene in the plasmids obtained from NICD. Plasmid DNA was subjected to restriction enzyme digest with *HindIII* and *ApaI*. The bands representing the pcDNA 3.1 vector (5.4. Kb) and the SARS-CoV-2 spike gene (3.9Kb) are indicated.

To validate that the plasmid constructs were expressing the various spike proteins, HEK-293T cells were transfected with spike plasmids for WT and each variant (beta, alpha, delta and omicron). Cells were then fixed and probed with a specific SARS-CoV-2 S1 subunit monoclonal antibody and Alexa Fluor 488 secondary antibody. A green signal can be seen in the cytoplasm for all spike variants (Figure 3.8) with a pattern that likely represents the.ER/Golgi



UNIVERSITY of the WESTERN CAPE



Figure 3.8 Detection and localization of SARS-CoV-2 protein. HEK293T cells were transfected with SARS-CoV-2 plasmids probed with a SARS-CoV-2 S monoclonal antibody specific to the S1 subunit and Alexa Fluor 488 secondary antibody(green). DAPI was used as a counterstain(blue). Scale bar 10µm

In order to verify the correct size of the spike protein, transfected cell lysates were run on an SDS-page gel before transferring proteins to a nitrocellulose membrane for immunostaining. An antibody raised against the S1 subunit of SARS-CoV-2 spike was able to detect the presence of the full-length spike protein (~180kDa) for all variants as indicated by the presence of a clear purple band (Fig 3.9).



Figure 3.9 Confirmation of SARS-CoV-2 spike expression by Western blot analysis. HEK293T cells were transfection with plasmids expressing SARS-CoV-2 spike protein from the indicated variants, and cell lysates were subjected to SDS-PAGE. The positive control is lysates from VeroE6 cells infected with SARS-CoV-2. The blot was probed with SARS-CoV-2 spike S1 Subunit antibody and an HRP secondary antibody. Visualization was done via colourimetric reaction. Protein ladders are shown on both sides of the gel.

3.6. Generation of VSV pseudoparticles bearing the SARS-CoV-2 spike protein

To produce SARS-CoV-2 spike-expressing pseudoparticles, the VSV packaging system was used. This system allows us to express the SARS-CoV-2 spike protein on the surface of the VSV particle. This VSV pseudoparticle system has been engineered so that it lacks expression of its own glycoprotein, G, and instead expresses a green fluorescence protein

(GFP) and firefly luciferase (FLUc), which allow for downstream quantitative analysis

SARS-CoV-2 spike proteins of WT and variants (beta, alpha, delta and omicron) were generated by transfecting HEK293T cells with the SARS-CoV-2 spike of interest, and then infecting the cells 24 hours later with the parent virus, VSV* $\Delta G(FLUc)(GFP) + (VSV-G)$. The pseudoparticles were harvested 24 hours later. To titrate the pseudoparticle (VSV-pp) stocks, each VSV-pp was serially diluted before adding HEK293T-ACE-2 cells. Infected cells were

incubated for 24 hours before measuring the luciferase activity (relative luciferase units) in the lysates (Fig 3.10). VSVpp-spike ^{ALPHA} generated the highest titre of 4.8x10⁵ RLU, followed by VSVpp-spike ^{WT} at 3.1x10⁵ RLU, VSVpp-spike ^{OMICRON} at 1.7x10⁵ RLU, with with the lowest values of 1.2x10⁵ RLU and with the lowest values of 1.2x10⁵ RLU and 7.8X10⁴ RLU respectively.



Figure 3.10 Titration of VSVpp-spike pseudoparticles in HEK293T-ACE-2 cells. Pseudoparticles were serially diluted (1:2) and incubated with HEK293T-ACE-2 cells for 24 hours. Luciferase activity was measured in cell lysates and expressed as relative luciferase units (RLU).

INIVERSITY of the

3.7. Optimisation of neutralization conditions using SARS-CoV-2 neutralizing human monoclonal antibodies

In the first step of optimising the neutralization assay, VSVpp-spike^{WT} was tested against a characterised SARS-CoV-2 neutralizing human monoclonal antibody, CA-1. This antibody has been shown to neutralize the SARS-CoV-2 wild type/D614G variant(Wibmer, et al. 2021). The CA-1 antibody was also titrated against VSVpp-VSV-G to control for specificity to the spike protein. A set amount of VSVpp-spike^{WT} or VSVpp-VSV-G was mixed with decreasing concentrations of CA-1, before adding HEK293T-ACE-2 cells and measuring luciferase activity 24 hours later. A clear dose-responsive neutralizing effect was observed for CA-1 vs. VSVpp-spike^{WT} with an IC₅₀ of 600 ng/mL, but there was no activity observed for CA-1 vs. VSVpp-VSV-G (Fig 3.11). To ensure specificity, VSVpp-spike^{WT} was also tested against an unrelated antibody, HT103, which is specific for the influenza A virus nucleoprotein. No activity was observed for HT103 vs. VSVpp-spike^{WT} (Fig 3.11).



Figure 3.11 Neutralization of VSVpp-spike^{WT} and VSVpp-VSV-G by increasing concentrations of SARS-CoV-2 neutralizing monoclonal antibody, CA-1, or HT-103 antibody (anti-influenza A, nucleoprotein). The average percent neutralization (from 3 replicates) is shown +/- StdDev.

3.8. Neutralization of SARS-CoV-2 spike pseudoparticles using CA-1 antibody

Neutralization of VSVpp were tested against the human monoclonal antibody CA-1. CA-1 was discovered early in 2020 by researchers who isolated human monoclonal antibodies from a COVID-19 patient's convalescent plasma (Shi, et al. 2020). The antibody was tested against WT, Delta and Omicron pseudoparticles (Fig 3.12). In this experiment,

reproducibility both within an assay, and between assays performed on separate days was also assessed. However, the CA-1 antibody was only able to neutralize the WT variant, with an







3.9. Neutralization of SARS-CoV-2 spike pseudoparticles using CB-6 antibody

Thereafter, the neutralization effect of human monoclonal antibody CB-6 was assessed against pseudoparticles bearing the spike proteins of WT, Delta, and Omicron variants. CB-6 is a human monoclonal antibody isolated from a COVID -19 patient's convalescent plasma and it has been reported to neutralize SARS-CoV-2 *in vivo* and *in vitro* (Shi, et al. 2020). It is characterised as a class 1 RBD-targeting antibody and is able to prevent the interaction of ACE-2 receptors with the spike protein. The results show that CB-6 is able to neutralize both VSVpp-spike^{WT} and VSVpp-spike^{DELTA} generating IC₅₀ values of 55.89 ng/mL and 19.33 ng/mL, respectively (Fig 3.13). The strongest neutralizing effect of CB-6 is seen against the Delta variant, being able to neutralize the virus at a third of the concentration needed for WT. No neutralizing effect was seen against VSVpp-spike^{OMI}.



Figure 3. 13 Neutralization of SARS-CoV-2 spike pseudoparticles by CB-6 antibody. The neutralizing effect of CB-6 on (A) VSVpp-spike^{WT}, (B) VSVpp-spike^{DELTA}(C) VSVpp-spike^{OMI} expressed as percentage (%) neutralization. The assay was performed with 3 replicates, and on 3 separate days as indicated. Error bars represent StdDev, and the average IC₅₀ value is shown.

3.10. Neutralization of SARS-CoV-2 spike pseudoparticles using the 084-7D antibody

Neither CA-1 nor CB-6 showed activity against the Beta variant (data not shown). So, to validate VSVpp-spike ^{BETA} in the neutralization assay, the human antibody 084-7D was used. This antibody was isolated from a patient infected with the beta variant of SARS-CoV-2 which possesses the amino acid mutation K417N. 084-7D targets the N417 mutation and has shown neutralization potency similar to the convalescent plasma (Moyo-Gwete, et al. 2022). Reproducible neutralization of VSVpp-spike ^{BETA} by 084-7D was observed, with an IC₅₀ of 71 ng/mL (Fig 3.14), whereas the study conducted by Moyo-Gwete et al. (Moyo-Gwete, et al. 2022) observed an IC₅₀ of 100 ng/mL.





3.11. Neutralization of SARS-CoV-2 spike pseudoparticles using Bebtelovimab antibody

As the CA-1, CB-6, and 084-74 antibodies did not display neutralization activity against the Omicron variant, a fourth antibody was required to validate VSVpp-spike^{OMI} in the neutralization assay. Bebtelovimab (LY-CoV1404) is a human monoclonal antibody first detected in a B-cell high throughput screening assay. LY-CoV1404 is another RBD-specific binding antibody but according to research, the antibody binds to epitopes in domains that are less susceptible to mutation (Greaney, Loes et al. 2021). Wild type, Beta, Delta, and Omicron pseudoparticles, were all neutralized by Bebtelovimab (Fig 3.15). Comparable IC₅₀ values of around 4 ng/mL were obtained for WT, Beta, and Omicron variants, while the IC₅₀ for the Delta variant was slightly higher at 10.62 ng/mL.



Figure 3. 15 Neutralization of SARS-CoV-2 spike pseudoparticles by Bebtelovimab antibody. The neutralizing effect of Bebtelovimab on (A) VSVpp-Spike^{WT}, (B) VSVpp-spike^{DELTA}, (C) VSVpp-spike^{OMI}, and (D) VSVpp-spike^{BETA} expressed as percentage (%) neutralization. The assay was performed with 3 replicates, and on 3 separate days as indicated. Error bars represent StdDev, and the average IC50 value is shown.

Table 3. 3 Summary of IC₅₀ of VSVpp^{VARIANTS} against human monoclonal antibody in ng/mL



UNIVERSITY of the

3.12 Validation of the SARS-CoV-2 neutralization assay with sera from COVID-19 patients

To validate the VSV-based SARS-CoV-2 neutralization assay with human serum, I tested 9 serum samples collected from COVID-19 patients during the different (most prevalent variants of concerns) waves of infection experienced in South Africa. These same sera had been tested by Prof Penny Moore's lab at NICD in their lentivirus-based SARS-CoV-2 neutralization assay, but they were blinded so I did not have any information on them besides their code name and the wave in which the sera were collected. For ease of use, I numbered them 1-9 (Table 3.4).

Sera sample number	NICD sera sample code	Wave of infection sera collected in
Sample 1	COV-186	4
Sample 2	COV-140	4
Sample 3	COV-158	4
Sample 4	COV-109-V1	3
Sample 5	SA-01-0079	2
Sample 6	COV-004	1
Sample 7	COV-183	4
Sample 8	COV-111-V1	3
Sample 9	COV-189	4

 Table 3. 4 Table showing the sera samples and the corresponding NICD sera sample codes.

Before use, the serum samples were heat inactivated to destroy the complement factors. Each sample was then serially diluted before adding the respective pseudoparticles (WT, Beta, Delta, Omicron) for each experiment. HEK-293T-ACE-2 cells were added to the pseudoparticle-sera mixture and incubated for one hour before reading luciferase activity using a luminometer. This was done in replicates for each sera sample. Statistical analysis was done and normalised data were plotted to a sigmoidal dose response curve using GraphPad Prism. To interpret the neutralizing activity of the sera the inhibitory dose 50 (ID₅₀) was determined. The ID₅₀ is the reciprocal of the serum dilution that causes 50% inhibition of the virus, and a high ID₅₀ indicates a high level of neutralizing antibody activity in the sera. The baseline ID₅₀ is 20, which is indicative of no neutralization occurring.

The data obtained with VSVpp-spike^{WT} (Fig 3.16), VSVpp-spike^{Beta} (Fig 3.17), VSVppspike^{Delta} (Fig 3.18), and VSVpp-spike^{Omicron} (Fig 3.19) are shown. With VSVpp-spike^{WT} samples 7 and 2 produced the highest ID values of 448 and 116, respectively. Samples 1 and 6 also produced ID₅₀ above the threshold of detection at 40 and 41, respectively, whereas, samples 3,4,5,8 and 9 produce no neutralization (Fig 3.16)



Figure 3.16 Neutralization of VSVpp-spike^{WT} by serum samples 1-9. The percent neutralization relative to the dilution of serum is shown as a best fit curve for each sample. Data points represent the average of duplicates. The ID₅₀ for each sample is indicated

ESTER

The sera were also tested against VSVpp-spike^{BETA} and samples 7, 8, and 9 showed the highest levels of neutralization with ID_{50} values of 389, 5073, and 417, respectively (Fig 3.17). Low neutralization activity was observed for samples 1 and 3 with ID_{50} values of 82 and 33, respectively. No neutralizing antibodies were detected in samples 2, 3, 4, and 6.



Figure 3. 17 Neutralization of VSVpp-spike^{Beta} by serum samples 1-9. The percent neutralization relative to the dilution of serum is shown as a best fit curve for each sample. Data points represent the average of duplicates. The ID₅₀ for each sample is indicated

For VSVpp-spike^{Delta} samples 7 and 2 showed the highest neutralization activity with ID_{50} values of 18603 and 87, respectively (Fig 3.18). Sample 8 displayed low activity with an ID_{50} of 29, whereas samples 1, 2, 4, and 9 showed no neutralization.



UNIVERSITY of the

Figure 3.18 Neutralization of VSVpp-spike^{Delta} by serum samples 1-9. The percent neutralization relative to the dilution of serum is shown as a best fit curve for each sample. Data points represent the average duplicates. The ID₅₀ for each sample is indicated

Finally, the sera were tested against VSVpp-spike^{Omicron} (Fig 3.19). Serum samples 1, 2, 3, 7, and 9 displayed high ID₅₀ values of 1030, 2431, 5850, 13727, and 836, respectively. Sample 5 showed low neutralization activity with a ID₅₀ of 52, while no neutralization activity was seen in samples 4, 6, and 8.



Figure 3.19 Neutralization of VSVpp-spike^{Omicron} by serum samples 1-9. The percent neutralization relative to the dilution of serum is shown as a best fit curve for each sample. Data points represent the average of duplicates. The ID₅₀ for each sample is indicated

To compare the data generated above in Figure 3.16 to 3.19, a dot plot of the ID50 values was generated (Fig 3.20) allowing visualisation of the relative neutralization activities of the sera against each SARS-CoV-2 variant.



Figure 3.20 Dot plot of the ID50s of each serum sample tested against the WT, Beta, Delta, and Omicron variants of VSVpp-spike.

Each shape represents an individual patient serum tested against the VSV-pp^{SPIKE} variants. Any values below 20 were assigned an arbitrary value of 20 as a baseline value.

3.13 Comparison of neutralization activities obtained using the VSV or lentivirus SARS CoV-2 neutralization assays

The neutralization titres obtained for the 9 sera using the VSV-based assay were then compared to the data obtained for the same sera using the lentivirus-based assay (these data were supplied by Prof Penny Moore, NICD). The purpose of comparing the ID₅₀ values is to determine if there is concordance between the two pseudoparticle systems used for the neutralization assays. Neutralization titres obtained with the VSV system (UWC) are shown in blue, and those for the lentivirus system (NICD) are shown in orange (Fig 3.21).





Figure 3.21 Comparison of VSV- or lentivirus-based SARS-CoV-2 neutralization data. ID50 data for n=9 sera tested with either the VSV (blue) or the lentivirus (orange) SARS-CoV-2 neutralization assays are shown for each variant. (A) WT, (B) Beta, (C) Delta, and (D). The dotted line represents the minimum ID₅₀ value of 20.



UNIVERSITY of the WESTERN CAPE

Chapter 4: Discussion

The sudden emergence of SARS-CoV-2 highlights the significance of zoonotic viral infections and their ability to cause devastating effects, not only on local public health, but on a global scale (Morens and Fauci 2020). Reports suggest that SARS-CoV-2 highly likely originated in the bat species *Rhinolophus* but there is still much speculation over which animal served as an intermediary host and was able to transmit the virus to the human population. Identifying the intermediatory host is important as this may help curb the transmission of the virus and also help scientists investigate the mechanism of cross species transmission (Nova 2021).

After early investigation showed that SARS-CoV-2 spike protein had a high affinity for ACE2 expressing cells (Huang, et al. 2020), researchers started studying the virus entry mechanisms into host cells and exploiting this as an avenue for vaccine development and potential therapeutic treatment. A rapid accumulation of mutations in the spike glycoprotein has seen an influx of variants of concern (VOC) from all across the world. As more SARS-

CoV-2 spike variants emerged, this put more pressure on scientists to create vaccines and antiviral treatments that would effectively target all variants.

Due to the pathogenicity, all studies of SARS-CoV-2 that use live virus are limited to BSL-3 facilities which are scarce and require skilled personnel. To circumvent this obstacle, the pseudoparticle system has been developed as a means to study viral entry mechanisms while mitigating the risk of infection. In this study I generated SARS-CoV-2 spike expressing pseudoparticles using the VSV packaging system, and successfully produced pseudoparticles expressing the spike proteins of SARS-CoV-2 Wild Type/D614G and Beta, Delta and Omicron VOCs. Furthermore, I quantified the neutralizing effect of human monoclonal antibodies against the abovementioned pseudoparticles, and these was used as a standard for the establishment of a neutralizing assay to test the potency of convalescent patient sera against VSV-spike pseudoparticles.

Cloning and expression of the SARS-CoV-2 spike proteins were an essential first step towards generating the VSV-spike pseudoparticles. However, even though clones of pCAGGS-spike^{WT} and pCAGGS-spike^{Beta} were verified through double restriction enzyme digest, and through Sanger sequencing, no expression of spike^{WT} or spike^{Beta} could be observed from these constructs. One explanation for this could be due to conformational folding of the protein masking the FLAG epitope that was added to the C-terminus. Perhaps inserting a 3xFLAG tag or repositioning of the FLAG tag to the N-terminus might increase the likelihood of detection. However, this hypothesis might not be valid as expression was also tested using a SARS-CoV2 anti-spike antibody, and there was still no protein detected. It is possible that there was
something wrong with the promoter region in the pCAGGS plasmid vector, so another alternative could be to clone the spike ORF into an alternative expression vector such as pcDNA3.1. In the interest, of time, I obtained SARS-CoV-2 spike plasmids from Prof Penny Moore at the National Institute for Communicable Disease (NICD) and I used these to successfully generate spike-expressing VSV pseudoparticles. Prof Moore and Dr Craig Fenwick (Lausanne University Hospital, Lausanne, Switzerland) also kindly provided human monoclonal antibodies that are known to have SARS-CoV-2 neutralizing activity which I was able to use as positive controls. This not only validated that my pseudoparticles were in fact expressing spike proteins on the surface but also provided us with information regarding the neutralizing potency of the antibodies against the respective spike variants.

CA-1 and CB-6 antibodies were some of the first neutralizing antibodies found in human plasma in early 2020, with CA-1 displaying weaker potency than CB-6 (Shi, et al. 2020). I demonstrated that CA-1 antibody was only able to neutralize the wild type variant at an IC₅₀ value of $2\mu g/mL$, whereas CB-6 was able to neutralize the wild type variant at an IC₅₀ 40 times lower than CA-1 (shown in Fig 3.12 A and Fig 3.13B). This corresponds with data published by (Zhou, et al. 2022) using SARS-CoV-2 spike lentivirus pseudoparticles to test neutralization potency of human monoclonal antibodies against VOC. Even though the assay used to measure neutralization was different, the IC₅₀ values are similar to the values from my study (Zhou, Wang et al. 2022). CB-6 was able to neutralize the wild type variant with an IC₅₀ of 50.5 ng/mL in their study compared to an IC₅₀ of 55.89 ng/mL in my study. CB6 is also able to neutralize the delta variant with an IC₅₀ of 19.33 ng/mL which is very similar to the IC₅₀ of 14.8 ng/mL obtained by Zhou et al. The epitope that is bound by CB-6 is highly mutated in the Beta and Omicron variants (Cao, et al. 2023), which explains the lack of neutralization activity against the Beta and Omicron spike pseudoparticles. Cheng et al. (Cheng, et al. 2022) suggests this might be due to one key residue mutation, K417N, decreasing the binding affinity of CB-6. The antibody, 084-7D, was the control used to neutralize Beta pseudoparticles, and produced an IC₅₀ of 71ng/mL which is similar to the IC₅₀ value of 100 ng/mL reported by Moyo-Gwete et al. (Moyo-Gwete, et al. 2022). Data on this neutralizing antibody are very limited due to the short-lived dominance of the Beta variant in countries other than South Africa and France. Bebtelovimab was the antibody with the most potent and broadest neutralizing effect. It was able to neutralize all WT, Beta, Delta, and Omicron pseudoparticles with IC₅₀ values ranging from 4-10ng/mL. This correlates with a number of studies such as Westendorf et al. (Westendorf, et al. 2022) who also reported IC₅₀ values for Bebtelovimab against the abovementioned variants ranging from 2-5 ng/mL in a VSV-pseudoparticle system. Syed et al. (Syed, et al. 2022) conducted a similar experiment but used virus-like particles (VLP) and generated IC₅₀ for Bebtelovimab of <10ng/mL for both Delta and Omicron. Similar results were also found by Zhou et al. (Zhou, et al. 2022) using lentivirus pseudoparticles for Wild Type, Beta, Delta, and Omicron with IC₅₀ values ranging from 3-5 ng/mL. Together these results support the significant efficacy and potency of Bebtelovimab and also the validate the spikpseudoparticles that I produced. In a phase 2 clinical trial (Gottlieb, et al. 2021), patients with mild-to-moderate COVID-19 were treated with Bebtelovimab on its own or in combination of Bebtelovimab, Bamlanivimab and Etesevimab (CB-6) which were delivered via slow intravenous push (Dougan, et al. 2022). The results showed significant viral clearance and reduction in symptom resolution. But despite this success, on the 10th of November 2022, the FDA ended its emergency authorization of Bebtelovimab due to resistance observed with a number of omicron subvariants (BQ.1, BQ1.1, BJ.1, XBB, BR.1, CH.1.1 and BA.4.6.3) circulating in the USA (Cao, et al. 2023). And since the BQ.1 and BQ1.1 variants accounted for >50% of COVID-19 cases (Ma 2023), the usefulness of Bebtelovimab was limited. This highlights the struggle of antiviral therapy development in the face of constant evolution of viruses that may render the drug or antibody useless if resistance develops. (Strasfeld and Chou 2010)

As we have observed, the development of a successful vaccine is crucial for being able to control a pandemic. As part of this process, the ability to detect neutralizing antibodies is an extremely useful tool in vaccine development (Pang, et al. 2021). It is important to gather data on the levels of protective neutralizing antibodies that are elicited upon vaccination, and for how long these levels are sustained. The ability to detect neutralizing antibodies in convalescent sera is also important for seroprevalence studies (Khoury, et al. 2021). In South Africa there is a high incidence of comorbidities such as HIV and TB which increases the risk of COVID-19 disease severity and fatalities (Tolossa, et al. 2021). Therefore, seroprevalence studies in populations like South Africa is important to identify vulnerable people and prioritize them for vaccination if their neutralizing antibodies are below the protective threshold.

Choosing an appropriate pseudoparticle packaging system is also of utmost importance, with the most popular systems being VSV, MLV and lentivirus. It has also been reported that sera from HIV patients on antiretroviral therapy (ART) may also cause false positives. This could be due to the inhibitory effect of the compounds found in ART on the replication machinery of the HIV-based pseudovirus (Garcia-Beltran, et al. 2021, Huang, et al. 2021, De La Torre-Tarazona, et al. 2023) Consequently, this could can bias the results as it may cause an overestimation in neutralization titres. This is particularly concerning for Africa as the WHO

reported more than 68% of individuals living with HIV from the African continent and 7.52 million of those people reside in South Africa. Interference with the readouts of neutralization activity impede the accuracy and efficacy of data which may form the basis for major public health decisions.

Additionally, the generation of VSV pseudoparticles is also less time consuming. The VSV system requires the spike expressing plasmid to be transfected into permissive cells in suspension on day 1, followed by infection with the carrier virus VSV* $\Delta G(FLUc)(GFP)$ on day 2, and then collection of the pseudoparticles in the supernatant on day three, so taking a total of three days to generate. In contrast, the generation of lentivirus pseudoparticles requires cells to be seeded in a monolayer before co-transfecting the cells with multiple plasmids for 24 hours. Thereafter, cells incubate for a further 48-72 hours before collection of the pseudoparticles. From start to finish this requires 5-6 days to generate.

To validate my VSV-based neutralization assay for SARS-CoV-2, I received a set of 9 blinded sera from Prof Penny Moore's lab that had previously been assayed with their lentivirus-based SARS-CoV-2 neutralization assay. The sera were from COVID-19 patients that had experienced an infection in either wave 1 (WT/D614G), wave 2 (beta), wave 3 (delta) or wave 4 (omicron) of the pandemic in South Africa. I observed strong concordance between the neutralizing titres (ID₅₀ values) from the lentivirus vs the VSV system for the WT and omicron variants. However, there were discrepancies observed for the beta and delta variants between the lentivirus, and the VSV system. The reasons for this are not exactly clear. We could theorize that sample 4 (COV-109-V10 and sample 8 (COV-111-V1), which showed high neutralizing titres against Delta in the lentivirus assay, but low in the VSV assay, could possibly have come from HIV positive patients on ART. Thus, the ID₅₀ values might be elevated in the lentivirus assay due to non-specific antibody neutralization occurring. This could be a similar explanation for sample 5 which showed a neutralization titre 10 times higher with the delta lentivirus pseudoparticles than the delta VSV pseudoparticles. The problem with this theory is that if this was the case, the titres obtained with the sera should have been elevated across all variants, not just Delta.

Sample 7 (COV-183), which was collected during the Omicron wave, generated positive activity across all variants in the VSV system. After much speculation an article by Richardson *et al.* (Richardson, et al. 2022) may have provided a possible explanation. The study showed that vaccinated individuals who subsequently become infected with the Omicron variant have elevated levels of cross-neutralization, thus increasing the overall neutralizing titres observed with the Wild type, Beta, and Delta variants. Furthermore Khan *et al.* (Khan, et al. 2022) stated

that vaccinated individuals infected with Omicron can show increase neutralization activity against the Delta variant. This corresponds with the variability and elevation of neutralization titres for sample 7(COV-183) that I observed, however the same was not seen with the lentivirus system. One can make an inference that the sera collected from the patient was most likely a vaccinee who contracted the omicron variant of SARS-CoV-2. This could suggest that the VSV packaging system might more sensitive and specific to neutralization than a lentivirus system. In fact, Steeds et al. (Steeds et al. 2020), who tested pseudotyped particles expressing the Ebola virus glycoprotein, reported that the VSV system was more sensitive for detecting Ebola virus neutralizing activity than a lentivirus system.

Another explanation for the increase in ID₅₀ values for sample 7 could be that the patient developed anti-VSV antibodies, as the virus is most commonly found in farm animals. Occupational interaction with farm animals such as a veterinarian or farm worker who contracted the VSV and then later contracted the omicron-variant of SARS-CoV-2. This could be an explanation for the elevated neutralization titres. However, the likelihood for this occurrence is low as VSV is endemic to the western hemisphere (Rozo-Lopez, et al. 2018). Which indicates the patient would have needed to travel countries in South and North America and have contracted a VSV infection before travelling back to South Africa and contracting SARS-CoV-2 omicron variant.

Limitations of the study

This study had certain limitations that need to be considered when interpreting the findings. One of the limitations include the availability of only a small sample size of sera from patients. The NICD provided only one sera sample for the wild type and beta variant and two samples for the delta variant, for testing purposes. If the sample size is too small, one may include a disproportionate number of sera, which are outliers and anomalies. This skews the results which might not be a fair picture of the whole population.

Further limitations include inter and intra experimental variation when testing concordance between the Lentivirus vs VSV neutralization assay. Lentivirus sera was tested in a different laboratory (NICD) at different time periods to that of my study which was conducted at UWC.

Conclusion

Virus pseudoparticles are a safe and versatile tool that can be used for a number of applications such as developing neutralizing assays. Prior to this study, the only SARS-CoV-2 neutralization assays in use by the South African virology community were a live-virus assay (requiring a

BSL3) and the lentivirus-based pseudoparticle assay. Both of these methods have limitations as were discussed earlier in the thesis (e.g. need for enhanced biosafety, or issues with false positives when conducting studies on sera from HIV-positive patients on ARVs). Therefore, it was necessary to investigate alternative approaches.

The establishment of a VSV-based neutralization assay for SARS-CoV2 is thus an important and significant contribution, and it can now be applied to studies assessing SARS-CoV-2 vaccine immunogenicity, sero-surveillance studies, etc.

Recent research has also shown various advantages of the VSV system including favouring its use when testing patient sera from HIV-positive individuals on ART. This is a significant discovery as South Africa and the African continent account for more than 68% of the global HIV population. The wider use of the VSV system will allow for more accurate and precise results when conducting studies on virus neutralizing activity in the South African and African population.



UNIVERSITY of the WESTERN CAPE

Appendix A: List of Materials

Table 1: Bacterial strains

Table Bacterial strains		
Strain	Source	Identifier
JM109 Competent E. coli cells	Promega	Catalogue No.PR-L1001
NEB 5 alpha Competent E. coli cells	New England BioLabs	Catalogue No.C2987H

Table 2: Cell lines

Table Cell lines		
Cell Lines	Source	Identifier
Hek-293 T cells	Prof Penny Moore	
Hek-293T-ACE-2 cells	Prof Penny Moore	
Vero E6	Cellonex	CVER-FL (flask)
	A construction of the second s	

Table 3: Plasmids

Table Plasmids	
Plasmid names	Source
pCAGGS WESTERN CAPE	Shaw Lab
pCAGGS-KPNA-FLAG	Shaw Lab
pCAGGS-spike Beta-FLAG	Shaw Lab
pCAGGS-spike WT-FLAG	Shaw Lab
pcDNA 3.1 B.1.1.529 Omicron d18	NICD
pcDNA3.1 B.1.1.7 Alpha	NICD
pcDNA3.1 B.1.1529 Omicron	NICD
pcDNA3.1 B.1.351 Beta	NICD
pcDNA3.1 B.1.617.2 Delta	NICD
pcDNA3.1 WTD614G	NICD

Table 4: Viruses

Table of viruses	
Virus	Source
VSV*∆G(FLUc)+VSV-G	Dr Gert Zimmer

Table 5: Molecular Reagents

Table of Molecular Reagents		
Name	Source	Identifier
10x Phosphate buffered salt	d salt Thermo-Fisher Scientific Catalogue No.	
Agarose powder (Molecular grade)	Invitrogen	Catalogue No.17850
Ampicillin sodium salt	Sigma-Aldrich	Catalogue No. A9518
Bovine albumin serum powder	Sigma-Aldrich	Catalogue No. A2153
DTT	Roche	Catalogue No.3483-12-3
EDTA	Sigma-Aldrich	Catalogue No. E9884
Ethidium bromide	Sigma-Aldrich	Catalogue No. E7637
HindIII	New England Biolabs	Catalogue No. R0104S
Kpnl	New England Biolabs	Catalogue No. R3142S
Non-fat dried milk	Sigma-Aldrich	Catalogue No.M7409
S.O.C media	New England Biolabs	Catalogue No.15544034
Sacl	New England Biolabs	Catalogue No. R3156S
TEMED	Sigma-Aldrich	Catalogue No. 1.10732
TRIS	Bio-Rad	Catalogue No.1610719

Table 6: Cell culture reagents

Table of cell culture reagents		
Name	Source	Identifier
1 X Dulbecco's Modified Eagles media	Gibco	Catalogue No.41966052
1 X PBS	Gibco	Catalogue No.10010023
1 X Trypsin	Gibco	Catalogue No.25200056
Fetal Bovine Serum	Gibco	Catalogue No.16000044
Lipofectamine 3000	Thermo-Fisher Scientific	Catalogue No. L3000015

OptiPro Serum free media	Gibco	Catalogue No.12309050
Penicillin/Streptomycin/Amphotericin B	Pan Biotech	Catalogue No. P0607350
Poly-L-lysine	Sigma-Alrich	Catalogue No. P8920
Puromycin	Gibco	Catalogue No. A1113803

Table 7:Antibodies

Table of antibodies		
Name	Source	Identifier
Anti-Influenza A, Nucleoprotein [HT103] Antibody	Sigma-Alrich	Catalogue No. MABF2164
Goat anti-Mouse IgG (H+L) Secondary Antibody, HRP	Thermo-Fisher Scientific	Catalogue No. 31430
Goat anti-Mouse IgG, IgM (H+L) Secondary Antibody, Alexa Fluor™ 488	Thermo-Fisher Scientific	Catalogue No. A-10680
Monoclonal ANTI-FLAG [®] M2 antibody produced in mouse	Sigma-Aldrich	Catalogue No. F3165
SARS-CoV-2 spike S1 subunit antibody	R&D	Catalogue No. MAB105407

Table 8: Software

UNIVERSITY of the

WESTERN CAPE

Table of software	
Table of Software	Name of Version
ApE_win_current	2.0.49.0
GraphPad Prism	9
ImageJ	N/A
Snapgene	IN GARE
SoftmaxPro	7
Windows Excel	Microsoft 360

Table 9:Buffers and solutions

Table of Buffers and Solution	ons	
Name	Recipe	Identifier
0.1% Wash Buffer	Dilute 200µl of Tween 20 in 2L of 1xPBS	
0.5 M Tris pH (6.8)	6.06g of Tris base in 100mL of distilled water	
10% APS	10% (w/v) of APS into 10mL of distilled water	
10% SDS	Dissolve 10 g of SDS in 100 mL of distilled water	
10X Transfer buffer	5,76g of Tris base,2,95g of glycine,3, 75mL of 10% SDS,200mL methanol,800 mL of distilled water	
10X TRIS-Glycine SDS Running buffer	30g of Tris base,144g pf glycine,10g of SDS and 100 mL of distilled water	
10XPBS	From manufacturer-Gibco	Catalogue No.70011044
1M DTT	Mix 1.54g of DTT powder to 10mL of distilled water	P
1M Tris pH (7.8)	12.11g of Tris base in 100mL of distilled water	
20% SDS	Dissolve 20 g of SDS in 100 mL of distilled water	
2X Sample buffer	UNIVERSITY of the	
30% Bis-acrylamide solution	From manufacturer-Sigma-Alrich	Catalogue No. A3699
5% Blocking buffer	Dissolve 1g of Non-fat dried milk powder in 20mL of 5% Blocking buffer	a'
KPL TMB Peroxidase Substrate	From manufacturer-SeraCare	Catalogue No. 4200025
Luria Bertani (Miller's	Add 25 g of pre-mixed powder containing	Condalabs
broth) solution	Tryptone, NaCl and Yeast Extract to 950 mL of Milli-Q H2O	Catalogue No.1551
S.O.C media	From manufacturer- Invitrogen	Catalogue No.15544034

Appendix B

Appendix B:Alignment of pCAGGS-spike ^{WT} with reference sequence isolate Wuhan-Hu-1 (NC_045512.2)

	10 20 30 40 50 60 70 80 90
5 /	ATGTTTGTTTTCTTGTTTTATTGCCACTAGTCTCTAGTCAGTGTGTTAATCTTACAACCAGAACTCAATTACCCCCTGCATACACTAATTCTTT
s	tart codon
2 🔸	ATGTTTGTTTTCTTGTTTTATTGCCACTAGTCTCTAGTCAGTGTGTTAATCTTACAACCAGAACTCAATTACCCCCTGCATACACTAATTCTTT ATGTTTGTTTTCTTGTTTTATTGCCACTAGTCTCTAGTCAGTGTGTTAATCTTACAACCAGAACTCAATTACCCCCTGCATACACTAATTCTTT
	100 110 120 130 140 150 160 170 180 190
	CACACGTGGTGTTATTACCCTGACAAAGTTTTCAGATCCTCAGTTTTACATTCAACTCAGGACTTGTTCTTACCTTTCTTT
	CACACGTGGTGTTTATTACCCTGACAAAGTTTTCAGATCCTCAGTTTTACATTCAACTCAGGACTTGTTCTTACCTTTCCTATGTACTT
2	CACACGTGGTGTTTATTACCCTGACAAAGTTTTCAGATCCTCAGTTTTACATTCAACTCAGGACTTGTTCTTACCTTTCCTAATGTTACTT
	CASBACITETTCCCAATGTACT
	200 210 220 230 240 250 260 270 280
	GGTTCCATGCTATACATGTCTCTGGGACCAATGGTACTAAGAGGTTTGATAACCCTGTCCTACCATTTAATGATGGTGTTTATTTTGCTTCCACT
	GGTTCCATGCTATACATGTCTCTGGGACCAATGGTACTAAGAGGTTTGATAACCCTGTCCTACCATTTAATGATGGTGTTTATTTTGCTTCCACT
3	BGTTCCATGCTATACATGTCTCTGGGACCAATGGTACTAAGAGGTTTGATAACCCTGTCCTACCATTTAATGATGGTGTTTATTTTGCTTCCACT
	290 300 310 320 330 340 350 360 370 380
	GAGAAGTCTAACATAATAAGAGGCTGGATTTTTGGTACTACTTTAGATTCGAAGACCCAGTCCCTACTTATTGTTAATAACGCTACTAATGTTGT
	GAGAAGTCTAACATAATAAGABGCT6GATTTTTGGTACTACTTTAGATTCGAAGACCCAGTCCCTACTTATTGTTAATAACGCTACTAATGTTGT
3 +	GAGAAGTCTAACATAATAAGAGGCTGGATTTTTGGTACTACTTTAGATTCGAAGACCCAGTCCCTACTTATTGTTAATAACGCTACTAATGTTGT GAGAAGTCTAACATAATAAGAGGCTGGATTTTTGGTACTACTTTAGATTCGAAGACCCCAGTCCCTACTTATTGTTAATAACGCTACTAATGTTGT
	<u>390</u> 400 410 420 430 440 450 460 470
	TATTAAAGTCTGTGAATTTCGAATTTTGTAATGATCCATTTTTGGGTGTTTATTACCACAAAAACAACAACAAAGTTGGATGGA
2 📥	TATTAAAGTCTGTGAATTTCGAATTTTGTAATGATCCATTTTTGGGTGTTTATTACCACAAAAAACAACAACAACAACAACAACAACA
3 🔶	TATTAAAGTCTGTGAATTTCAATTTTGTAATGATCCATTTTTGGGTGTTTATTACCACAAAAACAACAACAAAGTTGGATGGA
	480 490 500 510 520 530 540 550 560 570
	TTTATTCTAGTGCGAATAATTGCACTTTTGAATATGTCTCTCAGCCTTTTCTTATGGACCTTGAAGGAAAACAGGGTAATTTCAAAAATCTTAGG
	TTTATTCTAGTGCGAATAATTGCACTTTTGAATATGTCTCTCAGCCTTTTCTTATGGACGTAAAGGAAAACAGGGTAATTTCAAAAAATCTTAGG
2 🔶	TTTATTCTAGTGCGAATAATTGCACTTTTGAATATGTCTCTCAGCCTTTTCTTATGGACCTTGAAGGAAAACAGGGTAATTTCAAAAAATCTTAGG
3 📥	TTTATTCTAGTGCGAATAATTGCACTTTTGAATATGTCTCTCAGCCTTTTCTTATGGACCTTGAAGGAAAACAGGGTAATTTCAAAAAATCTTAGG
	<u> </u>
	GAATTTGTGTTTAAGAATATTGATGGTTATTTTAAAATATATTCTAAGCACACGCCTATTAATTTAGTGCGTGATCTCCCTCAGGGTTTTTCGGC
2 📥	GAATTTGTGTTTAAGAATATTGATGGTTATTTTAAAATATATTCTAAGCACACGCCTATTAATTTAGTGCGTGATCTCCCTCAGGGTTTTTCGGC
3 📥	GAATTTGTGTTTTAAGAATATTGATGGTTATTTTAAAATATATTCTAAGCACACGCCTATTAATTTAGTGCGTGATCTCCCTCAGGGTTTTTCGGC
	620 600 700 700 700 700 700 700 700 700 70
	TTTAGAACCATTGGTAGATTTGCCAATAGGTATTAACATCACTAGGTTTCAAACTTTACTTGCTTTACATAGAAGTTATTTGACTCCTGGTGATT
2 📥	TTTAGAACCATTGGTAGATTTGCCAATAGGTATTAACATCACTAGGTTTCAAACTTTACTTGCTTTACATAGAAGTTATTTGACTCCTGGTGATT

		770 780 790 800 810 820 830 840 850
		CTTCTTCA86TT66ACA6CT66T6CT6CA6CTTATTAT6T6666TTATCTTCAACCTA66ACTTTTCTATTAAAATATAAT6AAAAT66AAACAT6
		CTTCTTCA86TT66ACA6CT66T6CT6CA6CTTATTAT6T666GTTATCTTCAACCTA66ACTTTTCTATTAAAATATAAT6AAAAT66AACCATT
2	1	CTTCTTCAGGTTGGACAGCTGGTGCTGCAGCTTATTATGTGGGTTATCTTCAACCTAGGACTTTTCTATTAAA@TATAATGAAAATGGAACCATT
3	-	
		860 870 880 890 900 910 920 930 940 950
		ACAGATGCTGTAGACTGTGCACTTGACCCTCTCCAGAAACAAAGTGTACGTTGAAATCCTTCACTGTAGAAAAAGGAATCTATCAAACTTCTAA
		······
		ACAGATGCTGTAGACTGTGCACTTGACCCTCTCTCAGAAACAAAGTGTACGTTGAAATCCTTCACTGTAGAAAAAGGAATCTATCAAACTTCTAA
2	I	ACAGATGCTGTAGACTGTGCACTTGACCCCTCTCTCAGAAACAAAGTGTACGTTGAAATCCTTCACTGTAGAAAAAGGAATCTATCAAACTTCTAA
-		
		960 970 980 990 1000 1010 1020 1030 1040
		CTTTAGAGTCCAACCAACAGAATCTATTGTTAGATTTCCTAATATTACAAACTTGTGCCCTTTTGGTGAAGTTTTTAACGCCACCAGATTTGCAT
		CTTTAGAGTCCAACCAACAGAATCTATTGTTAGATTTCCTAATATTACAAACTTGTGCCCTTTTGGTGAAGTTTTTAACGCCACCAGATTTGCAT
2	+	CTTTAGAGTCCAACCAACAGAATCTATTGTTAGATT
3	+	CTTTAGAGTCCAACCAACAGAATCTATTGTTAGATTTCCTAATATTACAAACTTGTGCCCTTTTGGTGAAGTTTTTAACGCCACCAGATTTGCAT
		1050 1060 1070 1080 1090 1100 1110 1120 1130 1140
		CTGTTTATGCTTGGAACAGGAAGAGAATCAGCAACTGTGTTGCTGATTATTCTGTCCTATATAATTCCGCATCATTTTCCACTTTTAAGTGTTAT
з	+	CTGTTTATGCTTGGAACAGGAACAGGAATCAGCAACTGTGTTGGTGATTATTCTGTCCTATATAATTCCGCATCATTTTCCACTTT
7	+	AACTGTGTTGCTGATTATTCTGTCCTATATAATTCCGCATCATTTTCCACTTTTAAGTGTTAT
		1150 1160 1170 1180 1190 1200 1210 1220 1230
		66A6T6TCTCCTACTAAATTAAAT6ATCTCT6CTTTACTAAT6TCTAT6CA6ATTCATTT6TAATTA6A66T6AT6AA6TCA6ACAAATC6CTCC
		learnelearnelearnelearnelearnelearnelearnelearnelearnelearnelearnelearnelearnelearnel
		66A6T6TCTCCTACTAAATTAAAT6ATCTCT6CTTTACTAAT6TCTAT6CA6ATTCATTT6TAATTA6A66T6AT6AA6TCA6ACAAATC6CTCC
4	1	
-		
		1340 1350 1350 1350 1350 1350 1350 1350 135
		AGGGCAAACTGGAAAGATTGCTGATTATAAATTATAAATTACCAGATGATTTTACAGGCTGCGTTATAGCTTGGAATTCTAACAATCTTGATTCTA
4	+	AGGGCAAACTGGAAAGATTGCTGATTATAAATTATAAATTACCAGATGATTTTACAGGCTGCGTTATAGCTTGGAATTCTAACAATCTTGATTCTA
7	+	AGGGCAAACTGGAAAGATTGCTGATTATAAATTATAAATTACCAGATGATTTTACAGGCTGCGTTATAGCTTGGAATTCTAACAATCTTGATTCTA
		WESTERN CAPE
		1340 1350 1360 1370 1380 1390 1400 1410 1420
		AGGTTGGTGGTAATTATAATTACCTGTATAGATTGTTTAGGAAGTCTAATCTCAAACCTTTTGAGAGAGA
4	+	AGGTTGGTGGTAATTATAATTACCTGTATAGATTGTTTAGGAAGTCTAATCTCAAACCTTTTGAGAGAGA
7	+	AGGTTGGTGGTAATTATAATTACCTGTATAGATTGTTTAGGAAGTCTAATCTCAAACCTTTTGAGAGAGA
		1430 1440 1450 1460 1470 1480 1490 1500 1510 1520
		GGTAGCACACCTTGTAATGGTGTTGAAGGTTTTAATTGTTACTTTCCTTTACAATCATATGGTTTCCAACCCACTAATGGTGTTGGTTACCAACC
		GGTAGCACACCTTGTAATGGT6TTGAAG6TTTTAATTGTTACTTTCCTTTACAATCATATGGTTTCCAACCCACTAAT66TGTT66TTACCAACC
4	1	GGTAGCACACCTTGTAATGGTGTTGAAGGTTTTAATTGTTACTTTCCTTTACAATCATATGGTTTCCAACCCACTAATGGTGTTGGTTACCAACC
7	-	GO TAGUAULUT TO TAATOO TO TO TAATOO TO TO AAGO TI TTAATTO TTACTI TUUTITACAATUATA (GO TAUCAACUUAU TAATOO TO TO AAGO TAATOO

		1530 1540 1550 1560 1570 1580 1590 1600 1610
		ATACAGAGTAGTAGTACTTTCTTTTGAACTTCTACATGCACCAGCAACTGTTTGTGGACCTAAAAAGTCTACTAATTTGGTTAAAAAACAAATGTG
		ATACAGAGTAGTAGTACTTTCTTTTGAACTTCTACATGCACCAGCAACTGTTTGTGGACCTAAAAAGTCTACTAATTTGGTTAAAAAACAAATGTG
	4 🔶	ATACAGAGTAGTAGTACTTTCTTTTGAACTTCTACATGCACCAGCAACTGTTTGTGGACCTAAAAAGTCTACTAATTTGGTTAAAAAACAAATGTG
	5	ATACAGAGTAGTAGTACTTTCTTTTGAACTTCTACATGCACCAGCAACTGTTTGTGGACCTAAAAAGTCTACTAATTTGGTTAAAAAAAA
		1620 1630 1640 1650 1660 1670 1680 1690 1700 1710
		TCAATTTCAACTTCAATGGTTTAACAGGCACAGGTGTTCTTACTGAGTCTAACAAAAAGTTTCTGCCTTTCCAACAATTTGGCAGAGACATTGCT
		······································
		TCAATTTCAACTTCAATGGTTTAACAGGCACAGGTGTTCTTACTGAGTCTAACAAAAAGTTTCTGCCTTTCCAACAATTTGGCAGAGACATTGCT
	-	TCAATTTCAACTTCAATGGTTTAACAGGCACAGGTGTTCTTACTGAGTCTAACAAAAAGTTTCTGCCTTTCCAACAATTTGGCAGAGACATTGCT
	7 +	TCAATTTCAACTTCAATGGTTTAACAGGCACAGGTGTTCTTACTGAGTCTAACAAAAAGTTTCTGCCTTTCCAACAATTTGGCAGAGACATTGCT
		1720 1730 1740 1750 1760 1770 1780 1790 1800
		GACACTACTGATGCTGTCCGTGATCCACAGACACTTGAGATTCTTGACATTACACCATGTTCTTTGGTGGTGTCAGTGTTATAACACCAGGAAC
		GACACTACTGATGCTGTCCGTGATCCACAGACACTTGAGATTCTTGACATTACACCATGTTCTTTGGTGGTGTCAGTGTTATAACACCAGGAAC
	-	GACACTACTGATGCTGTCCGTGATCCACAGACACTTGAGATTCTTGACATTACACCCATGTTCTTTGGTGGTGTCAGTGTTATAACACCCAGGAAC
	7 📥	GACACTACTGATGCTGTCCGTGATCCACAGACACTTGAGATTCTTGACATTACACCATGTTCTTTTGGTGGTGTCAGTGTTATAACACCAGGAAC
1		
		1010 1020 1020 1020 1020 1020 1020 1020
		D614G
		AAATACTTCTAACCA66TT6CT6TTCTTTATCA66AT6TTAACT6CACA6AA6TCCCT6TT6CTATTCAT6CA6ATCAACTTACTCCTACTT66C
	7 -	AAATACTTCTAACCAGGTTGCTGTTCTTTATCAGGGTGTTAACTGCACAGAAGTCCCTGTTGCTATTCATGCAGATCAACTTACTCCTACTTGGC
1		
		1 1910 1 1920 1 1930 1 1940 1 1950 1 1960 1 1970 1 1980 1 1990
		GTGTTTATTCTACAGGTTCTAATGTTTTTCAAACACGTGCAGGCTGTTTAATAGGGGCCTGAACATGTCAACAACTCATATGAGTGTGAGCATACCC
	4 📥	GTGTTTATTCTACAGGTTCTAATGTTTTTCAAACACGTGCAGGCTGTTTAATAGGGGGTGAACATGTCAACAACTCATATGAGTGTGACATACCC
	5 🔶	GTGTTTATTCTACAGGTTCTAATGTTTTTCAAACACGTGCAGGCTGTTTAATAGGGGCTGAACATGTCAACAACTCATATGAGTGTGACATACCC
	7 🔶	GTGTTTATTCTACAGGTTCTAATGTTTTTCAAACACGTGCAGGCTGTTTAATAGGGGGCTGAACATGTCAACAACTCATATGAGTGTGACATACCC
		2000 2010 2020 2030 2040 2050 2060 2070 2080 2090
		ATT66T8CA66TATAT6C6CTA6TTATCA6ACTCA6ACTAATTCTCCTC66C666CAC6TA6T6TA6CTA6TCAATCCATCAT6CCTACACTAT
		ATTGGTGCAGGTATATGCGCTAGTTATCAGACTCAGACTAATTCTCCTCGGCGGGCACGTAGTGTAGCTAGTCAATCCATCATTGCCTACACTAT
	4 🔶	ATTEGTECAGETATATECECTAETTATCAEACTCAEACTAATTCTCCTCEECEEECACETAETEAECTAECT
	5 🔶	ATTGGTGCAGGTATATGCGCTAGTTATCAGACTCAGACTAATTCTCCTCGGCGGGCACGTAGTGTAGCTAGTCAATCCATCATTGCCTACACTAT
	7 🔶	ATTEGTECAGETATATECECTAETTATCAEACTCAEACTCATTCTCCTCEECEEECACETAETEAECTAETCAATCCATCATTECCTACACTAT
		2100 2110 2120 2130 2140 2150 2160 2170 2180
		GTCACTT66T6CA6AAAATTCA6TT6CTTACTCTAATAACTCTATT6CCATACCCACAAATTTTACTATTA6T6TTACCACA6AAATTCTACCA6
		GTCACTT66T6CA6AAAATTCA6TT6CTTACTCTAATAACTCTATT6CCATACCCACAAATTTTACTATTA6T6TTACCACA6AAATTCTACCA6
	4 -	GTCACTTGGTGCAGAAAATTCAGTTGCTTACTCTAATAACTCTATTGCCATACCCACAAATTTTACTATTAGTGTTACCACAGAAATTCTACCAG
	7 +	BICACTIBUIUCAUAAAATTCAUTTUCTTACTCTAATAACTCTATTGCCATACCCACAAATTTTACTATTAGTGTTACCACAGAAATTCTACCAG
	-	

		2190 2200 2210 2220 2230 2240 2250 2260 2270 2270 2280
		TGTCTATGACCAAGACATCAGTAGATTGTACAATGTACATTTGTGGTGATTCAACTGAATGCAGCAATCTTTTGTTGCAATATGGCAGTTTTTGT
		TGTCTATGACCAAGACATCAGTAGATTGTACAATGTACATTTGTGGTGATTCAACTGAATGCAGCAATCTTTTGTTGCAATATGGCAGTTTTTGT
	4 🔶	TGTCTATGAC
	5 🔶	TGTCTATGACCAAGACATCAGTAGATTGTACAATGTACATTTGTGGTGATTCAACTGAATGCAGCAATCTTTTGTTGCAATATGGCAGTTTTTGT
		2290 2300 2310 2320 2330 2340 2350 2360 2370
i.		AP AP A ATTA A APP OT OPTITA APT COA AT A OPTITICA AP A A CAP A A A AP APP C CAA CAA CTTTTTC CAP A A CTCAA APT A A A APT A A A AP A A APT A CAA CA
	5 📥	
	8 🔸	AAAAAACACC
1		
		2380 2390 2400 2410 2420 2430 2440 2450 2460 2470
		ACCAATTAAAGATTTTGGTGGTTTTAATTTTTCACAAATATTACCAGATCCATCAAAAACCAAGAGGGTCATTTATTGAAGATCTACTTTTCA
		ACCAATTAAAGATTTTGGTGGTTTTAATTTTTCACAAATATTACCAGATCCATCAAAACCAAGAGGGTCATTTATTGAAGATCTACTTTTCA
	5	ACCAATTAAAGATTTTGGTGGTTTTAATTTTTCACAAATATTACCAGATCCATCAAAACCAAGCAAG
	8 🗭	ACCAATTAAAGATTTTGGTGGTTTTAATTTTTCACAAATATTACCAGATCCATCAAAACCAAGCAAG
		2480 2490 2500 2510 2520 2530 2540 2550 2560
		ACAAAGTGACACTTSCAGATGCTGGCTTCATCAAACAATATG6TGATTGCCTTS6TGATATT6CTGCTAGASACCTCATTTGTSCACAAAAGTTT
		ACAAAGTGACACTTGCAGATGCTGGCTTCATCAAACAATATGGTGATTGCCTTGGTGATATTGCTGCTAGAGACCTCATTTGTGCACAAAAGTTT
	6 🔶	TTGCTGCTAGAGACCTCATTTGTGCACAAAAGTTT
	8 🔶	ACAAAGTGACACTTGCAGATGCTGGCTTCATCAAACAATATGGTGATTGCCTTGGTGATATTGCTGCTAGAGACCTCATTTGTGCACAAAAGTTT
		2570 2580 2590 2600 2610 2620 2630 2640 2650 2660
		AACGGCCTTACTGTTTTGCCACCTTTGCTCACAGATGAAATGATTGCTCAATACACTTCTGCACTGTTAGCGGGTACAATCACTTCTGGTTGGAC
		AACGGCCTTACTGTTTTGCCACCTTTGCTCACAGATGAAATGATTGCTCAATACACTTCTGCACTGTTAGCGGGTACAATCACTTCTGGTTGGAC
	6 🔶	AACGGCCTTACTGTTTTGCCACCTTTGCTCACAGATGAAATGATTGCTCAATACACTTCTGCACTGTTAGCGGGTACAATCACTTCTGGTTGGAC
	8 🔶	AACGGCCTTACTGTTTTGCCACCTTTGCTCACAGATGAAATGATTGCTCAATACACTTCTGCACTGTTAGCGGGTACAATCACTTCTGGTTGGAC
		phillipping and a second statement of the second state
		2670 2680 2690 2700 2710 2720 2730 2740 2750
		CTTINGTACAGGICCTCCTATACAAATACCATTICCTATACCAATCCATTACCACAGAATACTCCACAGAATACTCCCATACAACAACACACAC
ľ		CTTT66T6CA66T6CT6CATTACAAATACCATTT6CTAT6CAAAT66CTTATA66TTTAAT66TATT66A6TTACACA6AAT6TTCTCTAT6A6A
	6 🔶	CTTTGGTGCAGGTGCTGCATTACAAATACCATTTGCTATGCAAATGGCTTATAGGTTTAATGGTATTGGAGTTACACAGAATGTTCTCTATGAGA
	8 🔶	CTTTGGTGCAGGTGCTGCATTACAAATACCATTTGCTATGCAAATGGCTTATAGGTTTAATGGTATTGGAGTTACACAGAATGTTCTCTATGAGA
1		WESTEDNCADE
		2760 2720 2700 2700 2000 2010 2010 2010 201
		200 2010 2010 2010 2010 2010 2010 2010
		ACCAAAAATTGATTGCCAACCAATTTAATAGTGCTATTGGCAAAATTCAAGACTCACTTTCTTCCACAGGCAAGTGCACTTGGAAAACTTCAAGAT
	6 📥	ACCARARATIGATISCCARCCARTIANTAGISCINISSCARAATICARGACICACITICITCACAGGCARGIGCACITSGAAAACTICARGAT
	8 📥	ACCAAAAATTGATTGCCAACCAACTTAATAGTGCTATTGGCAAAATTCAAGACTCACTTTCTTCCACAGGCAAGTGCACTTGGAAAACTTCAAGAT
1		
		2860 2870 2880 2890 2900 2910 2920 2930 2940
		GTGGTCAACCAAAATGCACAAGCTTTAAACACGCTTGTTAAACAACTTAGCTCCAATTTTGGTGCAATTTCAAGTGTTTTAAATGATATCCTTTC

		6T66TCAACCAAAAT6CACAA6CTTTAAACAC6CTT6TTAAACAACTTA6CTCCAATTTT66T6CAATTTCAA6T6TTTTAAAT6ATATCCTTTC
	6	GTGGTCAACCAAAATGCACAAGCTTTAAACACGCTTGTTAAACAACTTAGCTCCAATTTTGGTGCAATTTCAAGTGTTTTAAATGATATCCTTTC
1.1	0	UTUUTCAACCAAAATUCACAAUCTTTAAACACUCTTUTTAAACAACTTAGCTCCAATTTTGGTGCAATTTCAAGTGTTTTAAATGATATCCTTTC

	2950 2960 2970 2980 2990 3000 3010 3020 3030 3040
	ACGTCTTGACAAAGTTGAGGCTGAAGTGCAAATTGATAGGTTGATCACAGGCAGACTTCAAAGTTTGCAGACATATGTGACTCAAACAATTAATT
	ACGTCTTGACAAAGTTGAGGCTGAAGTGCAAATTGATAGGTTGATCACAGGCAGACTTCAAAGTTTGCAGACATATGTGACTCAACAATTAATT
6 🔶	ACGTCTTGACAAAGTTGAGGCTGAAGTGCAAATTGATAGGTTGATCACAGGCAGACTTCAAAGTTTGCAGACATATGTGACTCAAACAATTAATT
8 🔶	ACGTCTTGACAAAGTTGAGGCTGAAGTGCAAATTGATAGGTTGATCACAGGCAGACTTCAAAGTTTGCAGACATATGTGACTCAAACAATTAATT
	3050 3060 3070 3080 3090 3100 3110 3120 3130
	64671674644417464671771671447716716716714714444167674646767474716647447744446467164717176766446
1 🔶	TGGAAAG
6 🔶	GAGCTGCAGAAATCAGAGCTTCTGCTACTTGCTGCTACTAAAATGTCAGAGTGTGTACTTGGACAATCAAAAAGAGTTGATTTTTGTGGAAAA
8 🔶	GAGCTGCAGAAATCAGAGCTTCTGCTAATCTTGCTGCTACTAAAATGTCAGAGTGTGTACTTGGACAATCAAAAAGAGTTGATTTTTGTGGAAAG
	3140 3150 3160 3170 3180 3190 3200 3210 3220 3220
	GGCTATCATCTTATGTCCTTCCCTCAGTCAGCACCTCATGGTGTAGTCTTCTTGCATGTGACTTATGTCCCTGCACAAGAAAAGAACTTCACAAC
	GGCTATCATCTTATGTCCTTCCCTCAGTCAGCACCTCATGGTGTAGTCTTCTTGCATGTGACTTATGTCCCTGCACAAGAAAAGAACTTCACAAC
1 🔶	GGCTATCATCTTATGTCCTTCCCTCAGTCAGCACCTCATGGTGTAGTCTTCTTGCATGTGACTTATGTCCCTGCACAAGAAAAGAACTTCACAAC
6 🔶	GGCTATCATCTTATGTCCTTCCCTCAGTCAGCACCTCATGGT6TAGTCTTCTTGCATGTGACTTATGTCCCTGCACAAGAAAAGAACTTCACAAC
8 🔶	GGCTATCATCTTATGTCCTTCCCTCAGTCAGCACCTCATGGTGTAGTCTTCTTGCATGTGACTTATGTCCCTGCACAAGAAAAGAACTTCACAAC
	3240 3250 3260 3270 3280 3290 3300 3310 3320
	TECTCCTECCATTECTCATEATEEAAAAECACACTTTCCTCETEAAEETETCTTETTTCAAATEECACACACCEETTTETAACACAAAEGAATT
	and the second s
	TECTCCTECCATTESTCATESTAAAAGCACACTTTCCTCETEAAGETETCTTETTTCAAATESCACACACTESTTTETAACACAAAGGAATT
1 🔶	TGCTCCTGCCATTTGTCATGATGGAAAAGCACACTTTCCTCGTGAAGGTGTCTTTGTTTCAAATGGCACACACTGGTTTGTAACACAAAGGAATT
1 + 6 +	Tectccteccatttetcatgategaaaagcacactttcctcgtgaaggtetctttetttcaaategcacacactgetttetaacacaaaggaatt Tectcctgccatttetcatgategaaaagcacactttcctcgtgaaggtetctttettcaaategcacacactegtttetaacacaaaggaatt Tectccteccatttetcatgategaaaagcacactttcctcgtgaaggtetctttettcaaategcacacacactegtttetaacacaaaggaatt
1 + 6 + 8 +	Tectccteccatttetcateateeaaaegcacactttcctceteaaegtetctttetttcaaategcacacteetttetaacacaaaegaaatt Tectccteccatttetcateateeaaaegcacactttcctceteaaegetetctteettcaaategcacacacteettetaacacaaaegaatt Tectccteccatttetcateategaaaaegcacactttcctceteeteeaegtetttettcaaategcacacacteettetaacacaaaegaatt Tectccteccatttetcateategaaaaegcacactttcctceteeteeteeteeteeteeteeteeteeteet
1 + 6 + 8 +	TECTCCTECCATTTETCATEATEEAAAAGCACACTTTCCTCETEAAEETETCTTETTTCAAATEECACACACTEETTTETAACACAAAEEAAATT TECTCCTECCATTETCATEATEEAAAEEACACACTTTCCTCETEAAEETETTTCAAATEECACACACA
1 + 6 + 8 +	Tectccteccatttetcateateeaaaeecacactttcctceteaaeetetttett
	Tectccteccatttetcateateeaaaeecacactttcctceteaaeetetttett
	T6CTCCT6CCATTT6TCATGAT6GAAAAGCACACTTTCCTCGT6AAG6TGTCTTT6TTTCAAAT6GCACACACTGGTTT6TAACACAAA6GAATT T6CTCCT6CCATTT6TCATGAT6GAAAAGCACACTTTCCTCGT6AAG6TGTCTTT6TTTCAAAT6GCACACACTGGTTT6TAACACAAA6GAATT T6CTCCT6CCATTT6TCATGAT6GAAAAGCACACTTTCCTCGT6AAG6TGTCTTT6TTTCAAAT6GCACACACACG6TTT6TAACACAAA6GAATT T6CTCCT6CCATTT6TCATGAT6GAAAA6CACACTTTCCTCGT6AA6GTGTCTTT6TTTCAAAT6GCACACACACG6TTT6TAACACAAA6GAATT T6CTCCT6CCATTT6TCATGAT6GAAAA6CACACTTTCCTC6T6AA6GTGTCTTT6TTTCAAAT6GCACACACT6GTTT6TAACACAAA6GAATT T6CTCCT6CCATTT6TCATGAT6GAAAA6CACACTTTCCTC6T6AA6GTGTCTTT6TTTCAAAT6GCACACACACT6GTTT6TAACACAAA6GAATT *3330 *3340 *3360 *3370 *3380 *3400 *3410 *3420 *TTTAT6AACCACAAATCATTACTACAGAACACACTTT6T6TCT66GTAACT6T6GTAT6TAATA66GAATT6TCAACAACAACACACACACACACTTACTACAACAACACACACTTACTAC
	T6CTCCT6CCATTT6TCATGAT6GAAAAGCACACTTTCCTCGTGAAGGTGTCTTT6TTTCAAAT6GCACACACTGGTTTGTAACACAAA6GAATT T6CTCCT6CCATTT6TCATGAT6GAAAAGCACACTTTCCTCGTGAAGGTGTCTTT6TTTCAAAT6GCACACACAGGTTTGTAACACAAA6GAATT T6CTCCT6CCATTT6TCATGAT6GAAAAGCACACTTTCCTCGTGAAGGTGTCTTTGTTTCAAAT6GCACACACACGGTTTGTAACACAAA6GAATT T6CTCCT6CCATTT6TCATGAT6GAAAA6CACACTTTCCTCGTGAAGGTGTCTTTGTTTCAAAT6GCACACACACT6GTTT6TAACACAAA6GAATT T6CTCCT6CCATTT6TCATGAT6GAAAA6CACACTTTCCTCGTGAA6GTGTCTTTGTTTCAAAT66CACACACACGGTTT6TAACACAAA6GAATT T6CTCCT6CCATTT6TCATGAT6GAAAA6CACACTTTCCTCGTGAA6GTGTCTTTGTTTCAAAT66CACACACACGGTTT6TAACACAAA6GAATT 3330 3340 3350 3360 3390 3400 3410 3420 TTTAT6AACCACAAATCATTACTACAGGACAACACATTT6T6TCT6GTAACT6TGAT6TGTAATAGGAATT6TCAACAACACACACACATTAT6ATCCT T 1 1 1 1
	T6CTCCT6CCATTT6TCATGAT6GAAAAGCACACTTTCCTCGTGAAGGTGTCTTTGTTTCAAATGGCACACACTGGTTTGTAACACAAAGGAATT T6CTCCTGCCATTT6TCATGAT6GAAAAGCACACTTTCCTCGTGAAGGTGTCTTTGTTTCAAATGGCACACACTGGTTTGTAACACAAAGGAATT T6CTCCTGCCATTT6TCATGAT6GAAAAGCACACTTTCCTCGTGAAGGTGTCTTTGTTTCAAATGGCACACACA
	T6CTCCT6CCATTT6TCAT6AT66AAAA6CACACTTTCCTC6T6AA66T6TCTTT6TTTCAAAT66CACACACT66TTT6TAACACAAA66AATT T6CTCCT6CCATTT6TCAT6AT66AAAA6CACACTTTCCTC6T6AA66T6TCTTT6TTTCAAAT66CACACACT66TTT6TAACACAAA66AATT T6CTCCT6CCATTT6TCAT6AT66AAAA6CACACTTTCCTC6T6AA66T6TCTTT6TTTCAAAT66CACACACT66TTT6TAACACAAA66AATT T6CTCCT6CCATTT6TCAT6AT66AAAA6CACACTTTCCTC6T6AA66T6TCTTT6TTTCAAAT66CACACACT66TTT6TAACACAAA66GAATT T6CTCCT6CCATTT6TCAT6AT66AAAA6CACACTTTCCTC6T6AA66T6TCTTT6TTTCAAAT66CACACACT66TTT6TAACACAAA66AATT T6CTCCT6CCATTT6TCAT6AT66AAAA6CACACTTTCCTC6T6AA66T6TCTTT6TTTCAAAT66CACACACT66TTT6TAACACAAA66AATT *3330 *3340 *3350 *3370 *3380 *3390 *3400 *3410 *3420 ************************************
	T6CTCCT6CCATTT6TCATGAT6GAAAAGCACACTTTCCTCGTGAAGGTGTCTTT6TTTCAAAT6GCACACACGGTTTGTAACACAAAGGAATT T6CTCCT6CCATTT6TCATGAT6GAAAAGCACACTTTCCTCGTGAAGGTGTCTTT6TTTCAAAT6GCACACACACGGTTTGTAACACAAAGGAATT T6CTCCT6CCATTT6TCATGAT6GAAAAGCACACTTTCCTCGTGAAGGTGTCTTTGTTTCAAAT6GCACACACACGGTTTGTAACACAAAGGAATT T6CTCCT6CCATTT6TCATGAT6GAAAAGCACACTTTCCTCGTGAAGGTGTCTTTGTTTCAAAT6GCACACACT6GTTTGTAACACAAAAGGAATT T6CTCCT6CCATTT6TCATGAT6GAAAAGCACACTTTCCTCGTGAAGGTGTCTTTGTTTCAAAT6GCACACACT6GTTTGTAACACAAAGGAATT T6CTCCT6CCATTT6TCATGAT6GAAAA6CACACTTTCCTCGTGAAGGTGTCTTTGTTTCAAAT6GCACACACACGGTTTGTAACACAAAGGAATT T6CTCCT6CCATTT6TCATGATGCACACACACTTTCCTCGTGAAGGTGTCTTTGTTCAAAT6GCACACACCACGGTTTGTAACAACAAAGGAATT T6CTCCT6CCATTT6TCATGATCACAAAGCACACTTTCCTCGTGAAGGTGTCTTTGTTCAAAT6GCACACACACGGTTTGTAACAACAAAGGAATT T6CTCCT6CCATTT6TCATGAACGACACACTTTGTGTCTGGTAACTGTGAACTGTGAATGGCACACACCACTGGTTTGTAACAACAACACACGGTTTATGATCCT T73340 3350 3360 3390 3400 3410 3420 T74ATGAACCACAAATCATTACTACAGGACAACACATTTGTGTCTGGTAACTGTGAACTGTGAACTGTGAACAACACACAC
	T6CTCCT6CCATTT6TCATGAT6GAAAAGCACACTTTCCTCGTGAAGGTGTCTTTGTTTCAAAT6GCACACACTGGTTTGTAACACAAAGGAATT T6CTCCTGCCATTTGTCATGAT6GAAAAGCACACTTTCCTCGTGAAGGTGTCTTTGTTTCAAAT6GCACACACTGGTTTGTAACACAAAGGAATT T6CTCCTGCCATTTGTCATGAT6GAAAAGCACACTTTCCTCGTGAAGGTGTCTTTGTTTCAAAT6GCACACACTGGTTTGTAACACAAAGGAATT T6CTCCTGCCATTTGTCATGAT6GAAAAGCACACTTTCCTCGTGAAGGTGTCTTTGTTTCAAAT6GCACACACTGGTTTGTAACACAAAGGAATT T6CTCCTGCCATTTGTCATGAT6GAAAAGCACACTTTCCTCGTGAAGGTGTCTTTGTTCAAAT6GCACACACTGGTTTGTAACACAAAGGAATT T6CTCCTGCCATTTGTCATGAT6GAAAAGCACACTTTCCTCGTGAAGGTGTCTTTGTTCAAAT6GCACACACTGGGTTTGTAACACAAAGGAATT T6CTCCTGCCATTTGTCATGATGGAAAAGCACACTTTCCTCGTGAAGGTGTCTTTGTTCAAAT6GCACACACTGGGTTTGTAACAACAAAGGAATT T6CTCCTGCCATTTGTCATGAACACACACTTTGTGTCTGGTAACTGTGAATGGCACACACA
	T6CTCCT6CCATTT6TCATGAT6GAAAAGCACACTTTCCTCGTGAAGGTGTCTTTGTTTCAAAT6GCACACACTGGTTTGTAACACAAAGGAATT T6CTCCTGCCATTT6TCATGAT6GAAAAGCACACTTTCCTCGTGAAGGTGTCTTTGTTTCAAAT6GCACACACTGGTTTGTAACACAAAGGAATT T6CTCCTGCCATTT6TCATGAT6GAAAAGCACACTTTCCTCGTGAAGGTGTCTTTGTTTCAAAT6GCACACACTGGTTTGTAACACAAAGGAATT T6CTCCTGCCATTT6TCATGAT6GAAAAGCACACTTTCCTCGTGAAGGTGTCTTTGTTTCAAAT6GCACACACTGGTTTGTAACACAAAGGAATT T6CTCCTGCCATTT6TCATGAT6GAAAAGCACACTTTCCTCGTGAAGGTGTCTTTGTTTCAAAT6GCACACACACGGTTTGTAACACAAAGGAATT T6CTCCTGCCATTT6TCATGAT6GACAAAGCACACTTTCCTCGTGAAGGTGTCTTTGTTCAAAT6GCACACACACGGTTTGTAACACAAAGGAATT T6CTCCTGCCATTT6TCATGAT6GACAAAGCACACTTTCCTCGTGAAGGTGTCTTTGTTCAAAT6GCACACACACGGTTTGTAACACAAAGGAATT T6CTCCTGCCATTT6TCATGATCACAAAGCACACTTTGTGTGTCGGTAACTGTGATGTGTAAT6GCACACACACGGTTTATGATCCT T7GCTCCTGCCACAAATCATTACTACAGACAACACATTTGTGTCTGGTAACTGTGATGTGTAATAGGAATTGTCAACAACACACGTTTATGATCCT T7TATGAACCACAAATCATTACTACAGACAACACATTTGTGTCTGGTAACTGTGATGTTGTAATAGGAATTGTCAACAACACACGTTTATGATCCT T7TATGAACCACAAATCATTACTACAGACAACACATTTGTGTCTGGTAACTGTGATGTGTAATAGGAATTGTCAACAACACACGTTTATGATCCT T7TATGAACCACAAATCATTACTACAGACAACACATTTGTGTCTGGTAACTGTGATGTTGTAATAGGAATTGTCAACAACACACGTTTATGATCCT
	TBCTCCT 6CCATTT6 TCATGAT 6GAAAA6CACACTTTCCTCGT 6GAA66 TGTCTTT6TTTCAAAT66CACACACT6 GTTT 6TAACACAAA6GAATT T6CTCCT 6CCATTT6 TCATGAT 6GAAAA6CACACTTTCCTCGT 6GAA66 TGTCTTT6TTTCAAAT66CACACACT6 GTTT6TAACACAAA6GAATT T6CTCCT 6CCATTT6 TCATGAT 6GAAAA6CACACTTTCCTCGT 6GAA66 TGTCTT TGTTTCAAAT66CACACACT6 GTTT6TAACACAAA6GAATT T6CTCCT 6CCATTT6 TCATGAT 6GAAAA6CACACTTTCCTCGT 6GAA66 TGTCTT TGTTTCAAAT66CACACACT6 GTT 6TAACACAAA6GAATT T6CTCCT 6CCATTT6 TCATGAT 6GAAAA6CACACTTTCCTCGT 6GAA66 TGTTT TGTTTCAAAT66CACACACT6 GTT 6TAACACAAA6GAATT T6CTCCT 6CCATTT6 TCATGAT 6AA6CAACACTTTCCTCCT 6G TGAA6G TGTTT TGTTCAAAA6GCAACACT6 GTT 6TAACACAAA6GAATT T6CTCCT 6CCATTT6 TCATGAAA6CAACACCACTTTCCTCCT 6G TGAA6G TGTTT 6TATCAACACACACCACT6 GTT 6TAACAACAACACACACACACACAAA6GAATT 3330 3340 3350 3360 3390 3400 3410 3420 3330 3340 3350 3360 3390 3400 3410 3420 TTTAT6AACCACAAATCATTACTACAGACAACACATTT6TGTCT6GGT AACT6TGAAT6TG TAATA6GAATT6TCAACAACACACAGTTTAT6ATCCT TTTATGAACCACAAATCATTACTACAGACAACACATTT6TGTCT6GGTAACT6GTGAACT6TGTAATA6GAATT6TCCAACAACACACAGTTTAT6ATCCT TTTATGAACCACAAATCATTACTACAGACAACACATTT6TGTCT6GTAACT6GTGAACT6TGTAATA6GAATT6TCCAACAACACACAGTTTAT6ATCCT TTTATGAACCACAAATCATTACTACAGACAACACATTT6TGTCT6GTAACT6TGAACT6TGTAATA6GAATT6TCCAACAACACACAGTTTAT6ATCCT TTTAT6AACCACAAATCATTACTACAGACAACACATTT6TGTCT6GTAACT6TGAACT6TGTAATA6GAATT6TCAACAACAACACAGTTTAT6ATCCT TTTAT6AACCACAAATCATTACTACAGACAACACATTT6TGTCT6GTAACT6TGAACT6TGTAA
	TGCTCCTGCCATTTGTCATGATGGAAAAGCACACTTTCCTCGTGAAGGTGTCTTTGTTTCAAATGGCACACACGGTTTGTAACACAAAAGGAATT TGCTCCTGCCATTTGTCATGATGGAAAAGCACACTTTCCTCGTGAAGGTGTCTTTGTTTCAAATGGCACACACTGGTTTGTAACACAAAAGGAATT TGCTCCTGCCATTTGTCATGATGGAAAAGCACACTTTCCTCGTGAAGGTGTCTTTGTTTCAAATGGCACACACTGGTTTGTAACACAAAAGGAATT TGCTCCTGCCATTTGTCATGATGGAAAAGCACACTTTCCTCGTGAAGGTGTCTTTGTTTCAAATGGCACACACTGGTTTGTAACACAAAAGGAATT TGCTCCTGCCATTTGTCATGATGGAAAAGCACACTTTCCTCGTGAAGGTGTCTTTGTTTCAAATGGCACACACTGGTTGTAACACAAAAGGAATT TGCTCCTGCCATTTGTCATGATGGAAAAGCACACTTTCCTCGTGAAGGTGTCTTTGTTTCAAATGGCACACACCTGGTTGTAACACAAAAGGAATT TGCTCCTGCCATTTGTCATGGACAACCACTTTGTGTCTGGTAACGGTGTTGTAATAGGAATTGTCAACAACACAGGTTTATGATCCT TTTATGAACCACAAATCATTACCTACAGGACAACACACTTTGTGTCTGGTAACTGTGAAGGTGTTGTAATAGGAATTGTCAACAACACACGGTTTATGATCCT TTTATGAACCACAAATCATTACTACAGGACAACACACTTTGTGTGTG
	TGCTCCTGCCATTTGTCATGATGGAAAAGCACACTTTCCTCGTGAAGGTGTCTTTGTTTCAAATGGCACACACTGGTTTGTAACACAAAGGAATT TGCTCCTGCCATTTGTCATGATGGAAAAGCACACTTTCCTCGTGAAGGTGTCTTTGTTTCAAATGGCACACACTGGTTTGTAACACAAAAGGAATT TGCTCCTGCCATTTGTCATGATGGAAAAGCACACTTTCCTCGTGAAGGTGTCTTTGTTTCAAATGGCACACACTGGTTTGTAACACAAAAGGAATT TGCTCCTGCCATTTGTCATGATGGAAAAGCACACTTTCCTCGTGAAGGTGTCTTTGTTTCAAATGGCACACACTGGTTTGTAACAACAAAAGGAATT TGCTCCTGCCATTTGTCATGATGGAAAAGCACACACTTTCCTCGTGAAGGTGTCTTTGTTTCAAATGGCACACACA
	TGCTCCTGCCATTTGTCATGATGGAAAAGCACACATTTCCTCGGGAAGGTGTCTTTGTTTCAAATGGCACACACTGGTTTGTAACACAAAGGAATT TGCTCCTGCCATTTGTCATGATGGAAAAGCACACATTTCCTCGTGAAGGTGTCTTTGTTTCAAATGGCACACACTGGTTTGTAACACAAAGGAATT TGCTCCTGCCATTTGTCATGATGGAAAAGCACACATTTCCTCGTGAAGGTGTCTTTGTTTCAAATGGCACACACTGGTTTGTAACACAAAAGGAATT TGCTCCTGCCATTTGTCATGATGGAAAAGCACACATTTCCTCGTGAAGGTGTCTTTGTTTCAAATGGCACACACTGGTTTGTAACACAAAAGGAATT TGCTCCTGCCATTTGTCATGATGGAAAAGCACACACTTTCCTCGTGAAGGTGTCTTTGTTTCAAATGGCACACACTGGTTTGTAACACAAAAGGAATT TGCTCCTGCCATTTGTCATGATGATGAAAAGCACACACTTTCCTCGTGAAGGTGTCTTTGTTTCAAATGGCACACACTGGTTTGTAACAACAAAAGGAATT TGCTCCTGCCATTTGTCATGAAAAGCAACACATTTGCTCGTGAAGGTGTCTTTGTTTCAAATGGCACACACGGTTTGTAACAAAAGGAATT TGCAACCACAAAATCATTACTACAGAACAACATTTGTGTCTGGTAACTGTGAAGGTGTGTTGTAATAGGAATTGTCAACAACAACAGTTTATGATCCT TTTATGAACCACAAAATCATTACTACAGAACAACATTTGTGTCTGGTAACTGTGAACTGTGATGTTGTAATAGGAATTGTCAACAACAACAGTTTATGATCCT TTTATGAACCACAAAATCATTACTACAGAACAACATTTGTGTCTGGTAACTGTGAACTGTGATGTTGTAATAGGAATTGTCAACAACAACAGTTTATGATCCT TTTATGAACCACAAAATCATTACTACAGAACAACATTTGTGTCTGGTAACTGTGATGTGATGTTGTAATAGGAATTGTCAACAACAACAGTTTATGATCCT TTTATGAACCACAAAATCATTACTACAGAACAACATTTGTGTCTGGTAACTGTGATGTGATGTTGAACAACAACAACACGGTTTATGATCCT TTTATGAACCACAAATCATTACTACAGAACAACATTTGTGTCTGGTAACTGTGAACTGTGAACTGTCAACAACAACAACACAGTTTATGATCCT TTTATGAACCACAAATCATTACTACAGACAACACATTTGGTGTGGTGGTGGTTGGATGTGACATTGTCAACAACAACACGGTTTAGTGCCACACACA
	TGCTCCTGCCATTTG TCATGATGGAAAAGCACACTTTCCTCGTGAAGGTGTCTTTGTTTCAAATGGCACACACTGGTTTGTAACACAAAGGAATT TGCTCCTGCCATTTGTCATGATGGAAAAGCACACTTTCCTCGTGAAGGTGTCTTTGTTTCAAATGGCACACACTGGTTTGTAACACAAAAGGAATT TGCTCCTGCCATTTGTCATGATGGAAAAGCACACTTTCCTCGTGAAGGTGTCTTTGTTTCAAATGGCACACACA
	Tectcct6ccattt6ccatta6at6acacacacatttcctc6t6aa66t6tcttt6ttaAta66cacacacac6t60ttt6ttAcacaaA66aAtt TGCtcct6ccattt6tcAtf6t6aAaA6cacacatttcctc6t6aa66t6tcttt6ttAata66cacacact660ttt6ttAacacaAA66aAtt TGCtcct6ccattt6tcAtf6t6aAAA6cacacatttcctc6t6aa66t6tcttt6ttAata66cacacact660ttt6tAacacaAA66aAtt TGCtcct6ccattt6tcAtf6t6aAAA6cacactttcctc6t6aa66t6tcttt6tAat66cacacact6t66ttt6tAaA66aAtt TGCtcct6ccattt6tcAtf6t6aAA6cacacactttcct6t6tt6taa66t6tcttt6tAat66cacacacacacacacacacacacacacacacacaca
	Tectcct6ccattt6ccatta6ata6ata6acacactttcctc6t6aa66t6ctttt6tta4at66cacacact666ttt6tta4ac6acaa66aatt Tectcct6ccattt6ccattt6ct6daaa6cacactttcctc6t6aa66t6cttt16tta4at66cacacact666ttt6tta4ac6acaa66aatt Tectcct6ccattt6ccattt6ct6daaa6cacactttcctc6t6aa66t6tcttt6tta4ac6acacact666ttt6ta4ac6acaa66aatt Tectcct6ccattt6ccattt6ct6ct6tct6tct6tct6tc
	Tectecteccattretecators State Stat
	TOCTCCTGCCATTTG TCATGAT GGAAAAGCACACTTTCCTCGTGAAGGTGCTTTGTTTCAAATGGCACACACTGGTTTGTAACACAAAGGAATT TGCTCCTGCCATTGTCATGATGGAAAAGCACACTTTCCTCGTGAAGGTGCTTTGTTTCAAATGGCACACACTGGTTTGTAACACAAAGGAATT TGCTCCTGCCATTGTCATGATGGAAAAGCACACTTTCCTCGTGAAGGTGCTTTGTTTCAAATGGCACACACTGGTTTGTAACACAAAAGGAATT TGCTCCTGCCATTGTCATGATGGAAAAGCACACTTTCCTCGTGAAGGTGCTTTGTTTCAAATGGCACACACTGGTTTGTAACACAAAAGGAATT TGCTCCTGCCATTGTCATGATGGAAAAGCACACTTTCCTCGTGAAGGTGCTTTGTTTG
	TGCTCCTGCCATTTGTCATGATGGAAAAGCACACTTTCCTCGTGAAAGGTGTCTTTGTTTCAAATGGCACACACTGGTTTGTAACACAAAGGAATT TGCTCCTGCCATTGTCATGATGGAAAAGCACACTTTCCTCGTGAAAGGTGTCTTTGTTTCAAATGGCACACACTGGTTTGTAACACAAAGGAATT TGCTCCTGCCATTGTCATGATGGAAAAGCACACTTTCCTCGTGAAGGTGTCTTTGTTTCAAATGGCACACACTGGTTTGTAACACAAAGGAATT TGCTCCTGCCATTGTCATGATGGAAAAGCACACTTTCCTCGTGAAGGTGTTTTGTTTCAAATGGCACACACTGGGTTTGTAACACAAAGGAATT TGCTCCTGCCATTGTCATGATGGAAAAGCACACTTTCCTCGTGAAGGTGTTTTGTTTCAAATGGCACACACTGGGTTTGTAACACAAAGGAATT TGCTCCTGCCATTAGTCATGATGACGAAAAGCACACTTTGTGTCGGGAAGGTGTTTTGTATTGGAACGACACACTGGGTTGTTGTAATAGGAATTGTCAACACACAC
	TGCTCCTGCCATTTGTCATGATGGAAAAGCACACTTTCCTCGTGAAGGTGTCTTTGTTTCAAATGGCACACACTGGTTTGTAACACAAAGGAATT TGCTCCTGCCATTTGTCATGATGGAAAAGCACACTTTCCTCGTGGAAGGTGTCTTTGTTTCAAATGGCACACACTGGTTTGTAACACAAAGGAATT TGCTCCTGCCATTTGTCATGATGGAAAAGCACACTTTCCTCGTGGAAGGTGTCTTTGTTTCAAATGGCACACACTGGTTTGTAACACAAAGGAATT TGCTCCTGCCATTTGTCATGATGGAAAAGCACACTTTCCTCGTGGAAGGTGTCTTTGTTTCAAATGGCACACACA
	TGCTCCTGCCATTTGTCATGGAAAAGGACACTTTCCTCGTGAAGGTGTCTTTGTTTCAAATGGCACACACTGGTTTGTAACACAAAGGAATT TGCTCCTGCCATTTGTCATGATGGAAAAGGACACTTTCCTCGTGAAGGTGTCTTTGTTTCAAATGGCACACCTGGTTTGTAACACAAAGGAATT TGCTCCTGCCATTTGTCATGATGGAAAAGGACACTTTCCTCGTGAAGGTGTCTTTGTTTCAAATGGCACACCACTGGTTTGTAACACAAAGGAATT TGCTCCTGCCATTTGTCATGATGGAAAAGGACACTTTCCTCGTGAAGGTGTCTTTGTTTCAAATGGCACACCACTGGTTTGTAACACAAAGGAATT TGCTCCTGCCATTTGTCATGATGGAAAAGGACACCTTTCCTCGTGAAGGTGTCTTTGTTTCAAATGGCACACCACTGGTTTGTAACACAAAGGAATT TGCTCCTGCCATTTGTCATGATGAAAAGGAACACCACTTTCCTCGTGAAGGTGTCTTTGTTTCAAATGGCACACCACTGTGTAACAGCAACAAGGAATTG TGCTAGCACAAATCATTAGTACCAGACAACACACTTTGTGTCTGGTAACTGTGATGTTGTAATAGGAATTGTCAACAACACAGGTTTATGATCCT TTTATGGAACCACCAAATCATTAGCAGACAACACACTTTGTGTCTGGTAACTGTGATGTTGTAATAGGAATTGTCAACAACAACACGAGTTATGATCCT TTTATGGAACCACCAAATCATTAGCAGACAACACACTTTGTGTCTGGTAACTGTGATGTTGTAATAGGAATTGTCAACAACACACGTTTATGATCCT TTTATGGAACCACCAAATCATTAGCAGACAACACACTTTGTGTCGTAACTGGGAACTGTGAATGTGTAACTGCAACACACAC





UNIVERSITY of the WESTERN CAPE

Appendix C

Appendix C :Alignment of pCAGGS-spikeBETA with reference sequence isolate Wuhan-Hu-1(NC_045512.2)

	10 20 30 40 50 60 70 80 90
5 1	
3 /	TACAAACAAAAAGAACAAAATAACGGTGATCAGAGATCAGTCACCACAATTAGAATGTTGGTCTTGAGTTAATGGGGGGACGTATGTGATTAAGAAA
s	tart codon L18F
	AT 6 TTT 6 TTTT CTT 6 TTTT ATT 6 C C A CT A 6 T C T A 6 T C T A A TCT T A C A A C C A 6 A A C T C A A TTA C C C C C T 6 C A TA C A C T A A TT C T T
2 🔶	ATGTTTGTTTTCTTGTTTTATTGCCACTAGTCTCTAGTCAGTGTGTTAAT
	100 110 120 130 140 150 160 170 180 190
	CACACGTGGTGTTTATTACCCTGACAAAGTTTTCAGATCCTCAGTTTTACATTCAACTCAGGACTTGTTCTTACCTTTCCTATGTTACTT
	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
2 🔶	CACACGTGGTGTTTATTACCCTGACAAAGTTTTCAGATCCTCAGTTTTACATTCAACTCAGGACTTGTTCTTACCTTTCCTTTTCCAATGTTACTT
	280 220 220 220 220 200 200 200 200 200
	CCARGETACATGETCTCGGGACCCATGETACTAGEGGTTTATTGGTCCCACCATTAATGETGTCTTCCACCATTAATGETGTCTCCCACCATTAATGETGTCTCCCACCATGATGGTGCTCCCACCATGATGGTGCTCCCACCATGATGGTGCTCCCACCATGATGGTGCTCCCACCATGATGGTGCTCCCACCATGATGGTGCTCCCACCATGATGGTGCTCCCACCATGGTGCTGCCACGATGGTGCTGCCACGATGGTGCTGCCACGATGGTGCTGCCACGATGGTGCTGCCACGATGGTGCTGCCACGATGGTGCTGCCACGATGGTGCTGCCACGATGGTGCTGCCACGATGGTGCTGCCACGATGGTGCTGCCACGATGGTGCTGCCACGATGGTGCTGCCACGATGGTGCTGCCACGATGGTGCTGCCACGATGGTGCTGCCACGATGGTGCTGCCACGATGGTGCTGCCACGATGGTGCTGCCACGATGGTGCTGCCACGATGGTGCTGCCACGATGGTGCTGCCACGATGGTGCTGCCACGATGGTGCTGCCACGATGGTGCTGCCACGATGGTGCTGCCACGATGGTGCCACGATGGTGCTGCCACGATGGTGCTGCCACGATGGTGCTGCCACGATGGTGCTGCCACGATGGTGCTGCCACGATGGTGCTGCCACGATGGTGCTGCCACGATGGTGCCACGATGGTGCCACGATGGTGCCACGATGGTGCCACGATGGTGCCACGATGGTGCCACGATGGTGCCACGATGGTGCCACGATGGTGCCACGATGGTGCCACGATGGTGCCACGATGGTGCCACGATGGTGCCACGATGGTGCCACGATGGTGCCACGATGGTGCCACGATGGTGCCACGATGGTGCCACGATGGTGCCACGATGGTGCCACGATGGTGCCACGATGGTGCCACGATGGTGCCACGATGGTGCCACGATGGTGCCACGATGGTGCCACGATGGTGCCACGATGGTGCCACGATGGTGCCACGATGGTGCCACGATGGTGCCACGATGGTGCCACGATGGTGCCACGATGGTGCCACGATGGTGCCACGATGGTGCCACGATGGTGCCACGATGGTGCCACGATGGTGCCACGATGGTGCCACGATGGTGCCACGATGGTGCCACGATGGTGCCACGATGGTGCCACGATGGTGCCACGATGGTGCCACGATGGTGCCACGATGGTGCCACGATGGTGCCACGATGGTGCCACGATGGTGCCACGATGGTGCCACGATGGTGCCACGATGGTGCCACGATGGTGCCACGATGGTGCCACGATGGTGCCACGATGGTGCCACGATGGTGCCACGATGGTGCCACGATGGTGCCACGATGGTGCCACGATGGTGCCACGAGTGGTGCCACGATGGTGCCACGATGGTGCCACGATGGTGCCACGAGGTGGTGCACGATGGTGCCACGAGGTGGTGCACGATGGTGCCACGAGGTGGTGCCACGATGGTGCCACGAGGTGGTGCACGATGGTGCCACGAGGTGGTGCCACGAGGTGGCCACGAGGTGGCCACGAGGTGCCACGAGGTGGCCACGAGGTGGCCACGAGGTGGCCACGAGGTGGCCACGAGGTGGCCACGAGGTGGCCACGAGGTGGCCACGAGGTGGTGCACGAGGTGCGACGGAGGTGGCCACGAGGTGGCCACGAGGTGCGACGAGGTGGCCACGAGGTGGCGAGGTGGCGAGGTGGCACGAGGTGGCGAGGTGGCGAGGTGGCGAGGTGGCGAGGTGGCGAGGTGGCGAGGTGGCGAGGTGGCGAGGTGGGTG
	DB0A
	GGTTCCATGCTATACATGTCTCTGGGACCAATGGTACTAAGAGGTTTGATAACCCTGTCCTACCATTTAATGATGGTGTTTATTTTGCTTCCACT
2	GGTTCCATGCTATACATGTCTCTGGGACCAATGGTACTAAGAGGTTTG <mark>C</mark> TAACCCTGTCCTACCATTTAATGATGGTGTTTATTTTGCTTCCACT
3 -	ATTTGCTTCCACT
	a financial i formani i formani i formani i formani i f
	290 300 300 310 320 330 340 340 350 360 360 370 380
	290       300       310       320       330       340       350       360       370       380         GAGAAGSTCTAACATAACAAGAGGCTGGATTTTTGGTACTACTTTAGATTCGAAGACCCAGTCCCTACTTATTGTTAATAACGCTACTAATGTTGT       GAGAAGSTCTAACAATAATAACGCTACTAAGATCTAAGCTCCGGGTCAGGGATGAATAACAATTATTGCGATGATTACAACA       300       360       370       380
	290         300         310         320         330         340         350         360         370         380           GAGAAGTCTAACATAATAAGAGGCTGGATTTTTGGTACTACTTTAGATTCGAAGACCCAGTCCCTACTTATTGTTAATAACGCTACTAATGTTGT         Internet interne
2 →	290         300         310         320         330         340         350         360         370         380           GAGAAGT CTAACATAATAAGAGG CTGGATTTTTG GTACTACTTTAGATTCGAAGACCCAGTCCCTACTTATTGTTAATAACGCTACTAATGTTGT CTCTTCAGATTGTATTATTCCCCGACCTAAAAACCATGATGAAATCTAAGCTTCTGGGGTCAGGGGATGAATAACAATTATTGCGATGATTACAACA         GAGAAGT CTAACATAATAAGAGGCTGGATTTTGGTACTACTTTAGATTCGAAGACCCAGTCCCTACTTATTGTTAATAACGCTACTAATGTTGT GAGAAGTCTAACATAATAAGAGGCTGGATTTTTGGTACTACTTTAGATTCGAAGACCCAGTCCCTACTTATTGTTAATAACGCTACTAATGTTGT GAGAAGTCTAACATAATAAGAGGCCTGGATTTTTGGTACTACTTTAGATTCGAAGACCCAGTCCCTACTTATTGTTAATAACGCTACTAATGTTGT
2 -	290       300       310       320       330       340       350       360       370       380         GAGAAGTCTAACATAATAAGAGGCTGGATTTTTGGTACTACTTTAGATTCGAAGACCCAGTCCCTACTTATTGTTAATAACGCTACTAATGTTGT       Internet int
2 -	290       300       310       320       330       340       350       360       370       380         GAGAAGTCTAACATAATAAGAGGCTGGATTTTTGGTACTACTTTAGATTCGAAGACCCAGTCCCTACTTATTGTTAATAACGCTACTAATGTTGT CTCTTCAGATTGTATTATTCTCCGACCTAAAAACCATGATGAAATCTAAGCTTCTGGGTCAGGGGTGAATAACAATTATTGCGATGATTACAACA         GAGAAGTCTAACATAATAAGAGGCTGGATTTTTGGTACTACTTTAGATTCGAAGACCCAGTCCCTACTTATTGTTAATAACGCTACTAATGTTGT GAGAAGTCTAACATAATAAGAGGCTGGATTTTTGGTACTACTTTAGATTCGAAGACCCAGTCCCTACTTATTGTTAATAACGCTACTAATGTTGT GAGAAGTCTAACATAATAAGAGGCTGGATTTTTGGTACTACTTTAGATTCGAAGACCCAGTCCCTACTTATTGTTAATAACGCTACTAATGTTGT GAGAAGTCTAACATAATAAGAGGCTGGATTTTTGGTACTACTTTAGATTCGAAGACCCAGTCCCTACTTATTGTTAATAACGCTACTAATGTTGT
2 + 3	290         300         310         320         330         340         350         360         370         380           GAGAAGTCTAACATAATAAGAGGCTGGATTTTTGGTACTACTTTAGATTCGAAGACCCAGTCCCTACTTATTGTTAATAACGCTACTAATGTTGT CTCTTCAGATTGTATTATTGTCGGACCTAAAAACCATGATGAAATCTAAGGCTTCGGGGCCAGGGATGAATAACAATTATTGCGATGATTACAACA         GAGAAGTCTAACATAATAAGAGGCTGGATTTTTGGTACTACTTTAGATTCGAAGACCCAGTCCCTACTTATTGTTAATAACGCTACTAATGTTGT GAGAAGTCTAACATAATAAGAGGCTGGATTTTTGGTACTACTTTAGATTCGAAGACCCAGTCCCTACTTATTGTTAATAACGCTACTAATGTTGT GAGAAGTCTAACATAATAAGAGGCTGGATTTTTGGTACTACTTTAGATTCGAAGACCCAGTCCCTACTTATTGTTAATAACGCTACTAATGTTGT GAGAAGTCTAACATAATAAGAGGCTGGATTTTTGGTACTACTTTAGATTCGAAGACCCAGTCCCTACTTATTGTTAATAACGCTACTAATGTTGT GAGAAGTCTAACATAATAAGAGGCTGGATTTTTGGTACTACTTTAGATTCGAAGACCCAGTCCCTACTTATTGTTAATAACGCTACTAATGTTGT GAGAAGTCTAACATAATAAGAGGCTGGATTTTTGGTACTACTTTAGATTCGAAGACCCAGTCCCTACTTATTGTTAATAACGCTACTAATGTTGT GAGAAGTCTAACATAATAAGAGGCTGGATTTTTGGTACTACTTTAGATTCGAAGACCCAGTCCCTACTTATTGTTAATAACGCTACTAATGTTGT GAGAAGTCTAACATAATAAGAGGCTGGATTTTTGGTACTACTTTAGATTCGAAGACCCAGTCCCTACTTATTGTTAATAACGCTACTAATGTTGT GAGAAGTCTAACATAATAAGAGGCTGGATTTTTGGTACTACTTTAGATTCGAAGACCCAGTCCCTACTTATTGTTAATAACGCTACTAATGTTGT           390         400         410         420         430         440         450         460         470
2	290         300         310         320         330         340         350         360         370         380           GAGAAGT CTAACATAATAAGAG 6 CT66ATTTTT 6 GTACTACTT TAGATTC 6 AAGACCCAG TCCCTACTTATT 6 TTAATAACGCTACTAATGTT 6 TTAATAACGCTACTAATGTT 6 TTAATAACGCTACTAATGTT 6 TTAATAACGCTACTAATGT 6 TTCCGAAGAACCCAG GTCCCTACTTATT 6 TTAATAACGCTACTAATGT 6 TTCCGAAGACCCAG TCCCTACTTATT 6 TTAATAACGCTACTAATGT 6 TGAAGACCCAG TCCCTACTTATT 6 TTAATAACGCTACTAATGT 6 TGAAGACCAACAACAACAACAACAACAACAACAACAACAAC
2 -	290         300         310         320         330         340         350         360         370         380           GAGAAGT CTAACATAATAAGAGG CTGGATTTTTG GTACTACTTTAGATTCGAAGACCCAG TCCCTACTTATTGTTAATAACGCTACTAATGTTGT CTCTTCAGATTGTATTATTCTCCGACCTAAAAACCATGATGAAAACCATGAGCTTCTGGGTCAGGGATGAATAACAATTATTGCGATGATTACAACA           GAGAAGT CTAACATAATAAGAGG CTGGACTTTTG GTACTACTTTAGATTCGAAGACCCAG TCCCTACTTATTGTTAATAACGCTACTAATGTTGT GAGAAGT CTAACATAATAAGAGG CTGGATTTTG GTACTACTTTAGATTCGAAGACCCAG TCCCTACTTATTGTTAATAACGCTACTAATGTTGT GAGAAGT CTAACATAATAAGAGGCTGGATTTTG GTACTACTTTAGATTCGAAGACCCAG TCCCTACTTATTGTTAATAACGCTACTAATGTTGT GAGAAGT CTAACATAATAAGAGGCTGGATTTTTG GTACTACTTTAGATTCGAAGACCCAG TCCCTACTTATTGTTAATAACGCTACTAATGTTGT GAGAAGT CTAACATAATAAGAGGCTGGATTTTTG GTACTACTTTAGATTCGAAGACCCAG TCCCTACTTATTGTTAATAACGCTACTAATGTTGT GAGAAGT CTAACATAATAAGAGGCTGGATTTTTG GTACTACTTTAGATTCGAAGACCCAG TCCCTACTTATTGTTAATAACGCTACTAATGTTGT GAGAAGT CTAACATAATAAGAGGCTGGATTTTTG GTACTACTTTAGATTCGAAGACCCAGTCCCTACTTATTGTTAATAACGCTACTAATGTTG TATTAAAGT CTGTGAATTTC AATTTTTG TAATGATCCATTTTTG GTACTACTTTTG GTACTACTTATTCGCCACAAAAGCTACAAAAGTTG GAATGGAAGTTGGAATGGAA
2	290       300       310       320       330       340       350       360       370       380         GAGAAGTCTAACATAATAAGAGGCTGGATTTTTGGTACTACTTTAGATTCGAAGACCCAGTCCCTACTTATTGTTAATAACGCTACTAATGTTGT CTCTTCAGATTGTATTATTCTCCGACCTAAAAACCATGATGAAACCATGAAGCTCTAAGCTTCTGGGTCAGGGATAACAATTATTGCGATGATTACAACA         GAGAAGTCTAACATAATAAGAGGCTGGATTTTTGGTACTACTTTAGATTCGAAGACCCAGTCCCTACTTATTGTTAATAACGCTACTAATGTTGT GAGAAGTCTAACATAATAAGAGGCTGGATTTTTGGTACTACTTTAGATTCGAAGACCCAGTCCCTACTTATTGTAATAACGCTACTAATGTTGT GAGAAGTCTAACATAATAAGAGGCTGGATTTTTGGTACTACTTTAGATTCGAAGACCCAGTCCCTACTTATTGTAATAACGCTACTAATGTTGT GAGAAGTCTAACATAATAAGAGGCTGGATTTTTGGTACTACTTTAGATTCGAAGACCCAGTCCCTACTTATTGTAATAACGCTACTAATGTTGT         390       400       410       420       430       440       450       460       470       100         390       400       410       420       430       440       450       460       470       100       100       100       100       100       100       100       100       100       100       100       100       100       100       100       100       100       100       100       100       100       100       100       100       100       100       100       100       100       100       100       100       100       100       100       100       100       100       100       100       100       1
2 <b>3</b>	290       300       310       320       330       340       350       360       370       380         GAGAAGT CTAACATAAATAAGAG 6C CT 66 ATTTTT 6 GTACTACTT TA GATTC GAAG ACCCAG TC CCT ACTTATT GTTAATAACGCTACTAATGTT 6T       GAGAAGT CTAACATAATAAGAG 6C CT 66 ATTTTT 6 GTACTACTT TA GATTC GAAG ACCCAG TC CCT ACTTATT GTTAATAACGCTACTAATGTT 6T         GAGAAGT CTAACATAATAAGAG 6C CT 66 ATTTTT 6 GTACTACTT TA GATTC GAAG ACCCAG TC CCT ACTTATT GTTAATAACGCTACTAATGTT 6T       GAGAAGT CTAACATAATAAGAG 6C CT 66 ATTTTT 6 GTACTACTT TA GATTC GAAG ACCCAG TC CCT ACTTATT GTTAATAACGCTACTAATGTT 6T         GAGAAGT CTAACATAATAAGAG 6C CT 66 ATTTTT 6 GTACTACTT TA GATTC GAAG ACCCAG TC CCT ACTTATT GTTAATAACGCTACTAATGTT 6T       GAGAAGT CTAACATAATAAGAG 6C CT 6 GATTTTT 6 GTACTACTT TA GATTC GAAG ACCCAG TC CCT ACTTATT GTTAATAACGCTACTAATGTT 6T         GAGAAGT CTAACATAATAAGAG 6C CT 6 GATTTTT 6 GTACTACTT TA GATTC GAAG ACCCAG TC CCT ACTTATT GTTAATAACGCTAC TAATGTT 6T       GAGAAGT CT AACATAATAAG AG GC CT GGATTTTT 6 GTACTACTT TA GATTC GAAG ACCCAG TC CCT ACTTATT GTTAATAACGCTAC TAATGTT 6T         GAGAAGT CT AACATAATAAG AG GC CT GGATTTTT 6 GTACTACTT TA GATTC GAAGAACCAACAACAACAACAACAACAACAACAACAACAA
2 → 3 →	290       300       310       320       330       340       350       360       370       380         GAGAAAGT CTAACATAATAAGAG GCTGGATTTTTG GGACTACTTTAGATTCGAAGACCCAGTCCCTACTTATTGTTAATAACGCTACTAATGTTGT CTCTTCAGGATTGTATTATTCTCCGACCTAAAAAACCATGATGAAATCTAAGCTTCGGGGCCGGGATGAATAACAATTATTGCGATGGATG
2 → 3 →	290       300       310       320       330       340       350       360       370       380         GAGAAGT CTAACATAATAAGAG GC CGGATTTTT GGTACTACTT TAGATT CGAAGACCCAGT CC CT ACTT ATT GTTAATAACGCT ACTAATGTT GT         CTCTTCAGATTATTCTCCGAACGACCTGGATTTTTGGTACTACTT TAGATTCGAAGACCCAGT CC CT ACTT ATT GTTAATAACGCT ACTAATGTT GT         GAGAAGT CTAACATAATAAGAG GC TGGATTTTTGGTACTACTT TAGATTCGAAGACCCAGT CC CT ACTT ATT GTTAATAACGCT ACTAATGTT GT         GAGAAGT CTAACATAATAAGAG GC TGGATTTTTGGTACTACTT TAGATTCGAAGACCCAGT CC CT ACTT ATT GTTAATAACGCT ACTAATGTT GT         GAGAAGT CTAACATAATAAGAG GC TGGATTTTTGGTACTACTT TAGATTCGAAGACCCAGT CC CT ACTT ATT GTTAATAACGCT ACTAATGT TGT         GAGAAGT CTAACATAATAAGAG GC TGGATTTTT GGTACTACTT TAGATTCGAAGACCCAGT CC CT ACTT ATT GTTAATAACGCT ACTAATGT TGT         GAGAAGT CTAACATAATAAGAG GC TGGATTTTT GGTACT ACTT TAGATT CGAAGACCCAGT CC CT ACTT ATT GTTAATAACGCT ACTAATGT TGT         GAGAAGT CTAACATAATAAGAG GC TGGATTTT TGGTACT ACT TT AGATT CGAAGACCCAGT CC CT ACTT ATT GTTAATAACGCT ACT AAT TT TGGTACT GTT TT TGGTACT GAAGACCCAGT CC T ACT TAT TG TAATAACGCT ACT AAT TT TGGTACT GAAAACCCAT TT TT GGT ACT ACT TT TT TT TGGT ACT CC ACT TT TT TG TAATAACGCT ACT TAATAACGT TACT ACGT ACCT TT TT TG TAATAACGT TACT ACGT ACCT TT ATT ACCACAAAAACAACAACAAACAACAAAGT TACT ACGGT ACT TT TT TT TG TAATAACGT TACT ACGGT AAAAACCCACAAAAAACCCACAAAAAACAACAAACAAA
2 → 3 →	290       300       310       320       330       340       350       360       370       380         GAGAAGECTAACATAATAAGAGGCTGGATTITTGGTACTACTATCACATACTATTGGATCCCAGTCCCTACTAATAACGATGATGATATAACGCTACTAATGTTGT         CTCTTCAGATTGTATTATTCCCGACCTAAAAACCATGATGAAAACCATGATGAAGACTCCAGGGCCCAGTCCCTACTTATTGTTAATAACGCTACTAATGTTGT         GAGAAGECTGAAATAACAATAATGAAGGCTGGAATTTTGGTACTACTTAGGATGGAAGCCCAGTCCCTACTTATTGTTAATAACGCTACTAATGTTGT         GAGAAGECTGAAATAACAATGATGTGT         GAGAAGECTGAAATAACAATGAAGGGCTGGAATTTTGGTACTTTAGGATGCAAAGAACCCAGTCCCTACTTATTGTTAATAACGCTACTAAAGATGTGTG         GAGAAGECTGAATTTTGGTACTACTTTAGGATCGAAGACCCAGTCCCTACTTATTGTTAATAACGCTACTAATGTTGT         GAGAAGECTGGATTTTTGGTACTACTTTAGGATCGAAGACCCAGTCCCTACTTATTGTTAATAACGCTACTAATGTTGT         GAGAAGECTGGATTTTTGGTACTACTTTAGGATCGAAGACCCAGTCCCTACTTATTGTTAATAACGCTACTAAAGETTGTGT         GAGAAGECTGGAATTTTGGTACTTTAGGATCGAAGACCCAGTCCCTACTTATTGTTAATAACGCTACTAATGTTGT         GAGAAGECTGGAATTTTGGTACTTTAGGATCGAAGACCCAGTCCCTACTTATTGTTAATAACGCTACTAAAGETTCGAAGECCAGTCCCAGTCCCTACTTATTGTAATAACGCTACTAAAGETTCGAAGECCAGTCCCAGTCCCTACTTATTGTAATAACGCTACTAAAGETTCAAGETTCAGAGETGAAGETGAAGETTCAAGETTAGATCCATTTTTGGGTGTTTATTGCGACAAAAAAGAACAACAAAAAGETTGGATGGAAGETGAAGETCAAGAGE         390       400       410       420       430       440       450       460       470       I         TTTAAAAGECTGCAATTTTGGAACACTACAACAAAAAACCCAACAAAAAAAA
2 → 3 →	290         300         310         320         330         340         350         360         370         380           6AGAAGTCTAACATAATAAGAGGCTGGATTTTTGGTACTACTTTAGATTCGAAGACCCAGTCCCTACTTATTGTTAATAACGCTACTAATGTTGT CTCTTCAGGATGTATTATTCTCCGGACCTAAAAACCATGATGAAAACCATGATGAAAACCACTATGTGT GAGAAGTCTAACATAATAAGAGGCTGGACTTTTGGTACTACTTTAGATCGAAGACCCAGTCCCTACTTATTGTTAATAACGCTACTAATGTTGT GAGAAGTCTAACATAATAAGAGGCTGGATTTTTGGTACTACTTTAGATTCGAAGACCCAGTCCCTACTTATTGTTAATAACGCTACTATGTTG GAGAAGTCTAACATAATAAGAGGCTGGATTTTTGGTACTACTTTAGATTCGAAGACCCAGTCCCTACTTATTGTTAATAACGCTACTATGTTG GAGAAGTCTAACATAATAAGAGGCTGGATTTTTGGTACTACTTTAGATTCGAAGACCCAGTCCCTACTTATTGTTAATAACGCTACTATGTTG GAGAAGTCTAACATAATAAGAGGCTGGATTTTTGGTACTACTTTAGATTCGAAGACCCAGTCCCTACTTATTGTTAATAACGCTACTATGTTG GAGAAGTCTAACATAACA
2 → 3 → 2 → 2 → 2 → 2 → 2 → 2 → 2 → 2 →	290         300         310         320         330         340         350         360         370         380           6AGAAGTCTAACATATAAGAGGCTGGATTTTTGGTACTACTTTAGATTCGAAGACCCAGTCCCTACTTATTGTAATAACGCTACTAATGTTGT CTCTTCAGGATGTATTATTCTCCCGACCTAAAAACCATGATGAAAACCATGAGGCTCAGTCCCTACTTATTGTAATAACGCTACTAATGTTGT GAGAAGTCTAACATAATAAGAGGCTGGATTTTTGGTACTACTTTAGATTCGAAGACCCAGTCCCTACTTATTGTAATAACGCTACTAATGTTGT GAGAAGTCTAACATAATAAGAGGCTGGATTTTTGGTACTACTTTAGATTCGAAGACCCAGTCCCTACTTATTGTAATAACGCTACTATGTTG GAGAAGTCTAACATAATAAGAGGCTGGATTTTTGGTACTACTTTAGATTCGAAGACCCAGTCCCTACTTATTGTAATAACGCTACTAATGTTGT GAGAAGTCTAACATAATAAGAGGCTGGATTTTTGGTACTACTTTAGATTCGAAGACCCAGTCCCTACTTATTGTAATAACGCTACTAATGTTGT GAGAAGTCTAACATAACA

	580 590 600 610 620 630 640 650 660
	GAATTT6T6TTTAA6AATATT6AT66TTATTTTAAAATATATTCTAA6CACAC6CCTATTAATTTA6T6C6T6ATCTCCCTCA666TTTTTC66C
	CTTAAACACAAATTCTTATAACTACCAATAAAATTTTATATAAGATTCGTGTGCGGATAATTAAATCACGCACTAGAGGGAGTCCCCAAAAAGCCG
	D215G
	GAATTTGTGTTTTAAGAATATTGATGGTTATTTTAAAATATATTCTAAGCACGCCTATTAATTTAGTGCGTGATCTCCCTCAGGGTTTTTCGGC
2 🔶	GAATTTGTGTTTTAAGAATATTGATGGTTATTTTAAAATATATTCTAAGCACACGCCTATTAATTTAGTGCGTGGTCTCCCTCAGGGTTTTTCGGC
3 🔶	GAATTTGTGTTTAAGAATATTGATGGTTATTTTAAAAATATATTCTAAGCACACGCCTATTAATTTAGTGCGTG <mark>0</mark> TCTCCCTCAGGGTTTTTCGGC
	670         680         690         700         710         720         730         740         750         760
	TTTAQAACCATTGGTAGATTTGCCAATAGGTATTAACATCACTAGGTTTCAAACTTTACATAGAAGTTATTTGACTCCTGGTGATTCTTCTTCAG
	AAATCTTGGTAACCATCTAAACGGTTATCCATAATTGTAGTGATCCAAAGTTTGAAATGTATCTTCAATAAACTGAGGACCACTAAGAAGAAGTC
	TTTAGAACCATTGGTAGATTTGCCAATAGGTATTAACATCACTAGGTTTCAAACTTTACATAGAAGTTATTTGACTCCTGGTGATTCTTCTTCAG
2 📥	TTTAGAACCATTGGTAGATTTGCCAATAGGTATTAACATCACTAGGTTTCAAACTTTACATAGAAGTTATTTGACTCCTGGTGATTCTTCTCA
з 🝝	TTTAGAACCATTGGTAGATTTGCCAATAGGTATTAACATCACTAGGTTTCAAACTTTACATAGAAGTTATTTGACTCCTGGTGATTCTTCTTCAG
	770 700 700 000 010 010 030 040 050
	· //0 · /00 · /20 · 000 · 010 · 010 · 020 · 020 · 040 · 020 ·
	GTTGGACAGCTGGTGCTGCAGCTTATTATGTGGGTTATCTTCAACCTAGGACTTTTCTATTAAAATATAATGGAAAATGGAACCATTACAGATGGA CAACCTGTCGACCACGACGTCGAATAATACACCCCAATAGAAGTTGGATCCTGAAAAGATAATTTAATTACTTTTACCTTTGGTAATGGTAATGCTACGA
	ST 55 ACT 55 ACT 55 ACT 55 ACT 54 ACT
2 📥	
	860 870 880 890 900 910 920 930 940 950
	GTAGACTGTGCACTTGACCCTCTCTCAGAAACAAAGTGTACGTTGAAAATCCTTCACTGTAGAAAAAGGAATCTATCAAACTTCTAACTTTAGAGT
2 🗕	GTAGACTGTGCACT
3 🔶	GTAGACTGTGCACCTGACCCTCTCTCAGAAACAAAGTGTACGTTGAAATCCTTCACTGTAGAAAAAGGAATCTATCAAACTTCTAACTTTAGAGT
8 🔶	ACTTCTAACTTTAGAGT
	· 300 · 310 · 380 · 330 · 1080 · 1010 · 1070 · 1070 · 1070 · 1040 ·
	CCAACCAACAGAATCTATTGTTAGATTTCCTAATATTACAAACTTGTGCCCTTTTGGTGAAGTTTTTAACGCCACCAGATTTGCATCTGTTTATG
	CCAACCAACAGAATCTATIGTTAGATTTCCTAATATTACAAACTTGTGCCCTTTTGGTGAAGTTTTTAACGCCACCAGATTTGCATCTGTTTAA
0 -	
	1050 1060 1070 1080 1090 1100 1110 1120 1130 1140
	CTT6GAACA6GAA6A6AATCA6CAACTGT6TT6CTGATTATTCT6TCCTATATAATTCC6CATCATTTTCCACTTTTAA6T6TTAT6GA6T6TCT
	GAACCTTGTCCTTCTCTTAGTCGTTGACACAACGACTAATAAGACAGGATATATTAAGGCGTAGTAAAAGGTGAAAATTCACAATACCTCACAGA
	CTTGGAACAGGAAGAGAATCAGCAACTGTGTTGCTGATTATTCTGTCCTATATAATTCCGCATCATTTTCCACTTTTAAGTGTTATGGAGTGTCT
3 🔶	CTTGGAACAGGAAGAGAATCAGCAACTGTGTTGCTGATTATTCTGTCCTATATAATTCCGCATCATTTTCCACTTTTAAGTGTTA
8 🗕	CTTGGAACAGGAAGAGAATCAGCAACTGTGTTGCTGATTATTCTGTCCTATATAATTCCGCATCATTTTCCACTTTTAAGTGTTATGGAGTGTCT
	1150 1160 1170 1180 1190 1200 1210 1220 1230
	CCTACTAAATTAAATGATCTCTGCTTTACTAATGTCTATGCAGATTCATTTGTAATTAGAGGTGATGAAGTCAGACAAATCGCTCCAGGGCAAAC
	GGATGATTTAATTTACTAGAGACGAAATGATTACAGATACGTCTAAGTAAACATTAATCTCCACTACTTCAGTCTGTTTAGCGAGGTCCCGTTTG
	CCTACTAAATTAAATGATCTCTGCTTTACTAATGTCTATGCAGATTCATTTGTAATTAGAGGTGATGAAGTCAGACAAATCGCTCCAGGGCAAAC
4 -	GGTGATGAAGTCAGACAAATCGCTCCAGGGCAAAC
8 🕳	CCTACTAAAATGAATGATCTCTGCTTTACTAATGTCTATGCAGATTCATTTGTAATTAGAGGTGATGAAGTCAGACAAATCGCTCCAGGGCAAAC

		1240 1250 1260 1270 1280 1290 1300 1310 1320 1330
		TGGAAAGATTGCTGATTATAAATTATAAATTACCAGATGATTTTACAGGCTGCGTTATAGCTTGGAATTCTAACAATCTTGATTCTAAGGTTGGTG
		K417N
		TGGAAAGATTGCTGATTATAAATTATAAATTACCAGATGATTTTACAGGCTGCGTTATAGCTTGGAATTCTAACAATCTTGATTCTAAGGTTGGTG
4	+	TGGAAA <mark>T</mark> ATT6CT6ATTATAAATTATAAATTACCAGATGATTTTACA66CT6C6TTATA6CTT66AATTCTAACAATCTT6ATTCTAA66TT66T6
8	+	TGGAAA <mark>T</mark> ATTGCTGATTATAAATTATAAATTACCAGATGATTTTACAGGCTGCGTTATAGCTTGGAATTCTAACAATCTTGATTCTAAGGTTGGTG
		1340 1350 1360 1370 1380 1390 1400 1410 1420
		GTAATTATAATTACCTGTATAGATTGTTTAGGAAGTCTAATCTCAAACCTTTTGAGAGAGA
		GTAATTATAATTACCTGTATAGATTGTTTAGGAAGTCTAATCTCAAACCTTTTGAGAGAGA
4	+	GTAATTATAATTACCTGTATAGATTGTTTAGGAAGTCTAATCTCAAACCTTTTGAGAGAGA
8	+	GTAATTATAATTACCTGTATAGATTGTTTAGGAAGTCTAATCTCAAACCTTTTGAGAGAGA
		1430 . 1440 . 1430 . 1400 . 1440 . 1400 . 1430 . 1300 . 1310 . 1370
		CCTTGTAATGGTGTTGAAGGTTTTAATTGTTACTTTCCTTTACAATCATATGGTTTCCAACCCACTAATGGTGTTGGTACCAACCA
		GGAACATTACCACAACTTCCAAAATTAACAATGAAAGGAAATGTTAGTATACCAAAGGTTGGGTGATTACCACAACCAATGGTTGGT
		(in frame with N501Y)
		E484K N501Y
		CCTTGTAATGGTGTTGAAGGTTTTAATTGTTACTTTCCTTTACAATCATATGGTTTCCAACCCACTAATGGTGTTGGTTACCAACCA
4	+	CCTTGTAATGGTGTTGAAGGTTTTAATTGTTACTTTCCTTTACAATCATATGGTTTCCAACCCACTAATGGTGTTGGTTACCAACCA
4	++	<mark>ссттетаатеетот ваасетт тааттеттаст тестт тасаатся татеетт тесаа сссастаатеет совтестае ссаассатасавает</mark> сстте таатеетот <mark>а</mark> аветт тааттеттаст тесст тасаатся татеет тесаа сссаст <mark>т</mark> атеет тееттассая ссаатасавает сстте таатеетот <mark>а</mark> аветт таатте таст тесст тасаатся татеет тесаа сссаст <mark>т</mark> атеет в стветтассая ссатасавает
4	+	ССТТЕТААТЕВТЕТЕВАВЕТТТТААТТЕТТАСТТТССТТТАСААТСАТАТЕВТТТССААСССАСТААТЕВТЕТЕВТТАССААССАТАСАВАВТ ССТТЕТААТЕВТЕТТААВЕТТТТААТТЕТТАСТТЕССТТТАСААТСАТАТЕВТТЕССААСССАСТ <mark>Т</mark> АТЕВТЕТЕВТТАССААССАТАСАВАВТ ССТТЕТААТЕВТЕТТ <mark>А</mark> АВЕТТТТААТТЕТТАСТТЕССТТТАСААТСАТАТЕВТТЕССААСССАСТ <mark>Т</mark> АТЕВТЕТЕВТТАССААССАТАСАВАВТ
4	++	CCTTGTAATGGTGTTGAAGGTTTTAATTGTTACTTTCCTTTACAATCATATGGTTTCCAACCCACTAATGGTGTTGGTTACCAACCA
4 8	++	CCTTGTAATGGTGTTGAAGGTTTTAATTGTTACTTTCCTTTACAATCATATGGTTTCCAACCCACTAATGGTGTTGGTTACCAACCA
8	+	ccttgtaatggtgttgaaggttttaattgttactttcctttacaatcatatggtttccaacccactaatggtgttggttaccaacca
4	+	ccttgtaatggtgttgaatggttttaattgttactttcctttacaatcatatggtttccaacccatatggtgttggtgttggttaccaacca
8	+	CCTTGTAATGGTGTTGAAGGTTTTAATTGTTACTTTCCTTTACAATCATATGGTTTCCAACCCACTAATGGTGTTGGTTACCAACCA
4	+	CCTTGTAATGGTGTTGAAGGTTTTAATTGTTACTTTCCTTTACAATCATATGGTTTCCAACCCACTAATGGTGTTGGTTACCAACCA
8	+ +	CCTTGTAATGGTGTTGAAGGTTTTAATTGTTACTTTCCTTTACAATCATATGGTTTCCAACCCACTAATGGTGTGGTTACCAACCA
8	+	CCTTGTAATGGTGTTGAAGGTTTTAATTGTTACTTTCCTTTACAATCATATGGTTTCCAACCCACCATAGGTGTTGGTTACCAACCA
4	+	CCTTGTAATGGTGTTGAAGGTTTTAATTGTTACTTTCCTTTACAATCATATGGTTTCCAACCCACCACCATGGTGGTTACCAACCA
4	++	CCTTGTAATGGTGTTGAAGGTTTTAATTGTTACTTTCCTTTACAATCATATGGTTTCCAACCCACTAATGGTGTTGGTTACCAACCA
4	++	CCTTGTAATGGTGTTGAAGGTTTTAATTGTTACTTTCCTTTACAATCATATGGTTTCCAACCCACTATGGTGTTGGTTACCAACCA
4	++	CCTTGTAATGGTGTTGAAGGTTTTAATTGTTACTTTCCTTTACAATCATATGGTTTCCAACCCACTAATGGTGTTGGTTACCAACCA
4 1	++	CCTTGTAATGGTGTTGAAGGTTTTAATTGTTACTTTCCTTTACAATCATATGGTTTCCAACCCACCACTAATGGTGTTGGTTACCAACCA
4 1	++	CCTTGTAATGGTGTTGAAGGTTTTAATTGTTACTTTCCTTTACAATCAAT
4 8	++	CCTTGTAATGGTGTT0AAGGGTTTTAATTGTTACTTTCCTTTACAATCATATGGTTTCCAACCCACTAATGGTGTTACCAACCA
4 8	**	CCTTGTAATGGTGTTGAAAGGTTTTAATTGTTACTTTCCTTTACAATCATATGGTTTCCAACCCACTAATGGTGTTACCAACCA
4 8	**	CCTTGTAATGGTGTTGAAGGTTTTAATTGTTACTTTCCTTTACAATCATAGGTTTCCAACCCACTAATGGTGTTGCTACCAACCA
4 1 8 1	++	CCTTGTAATGGTGTTGAAGGTTTTAATTGTTACTTTGCTTTACAATCATATGGTTTCCAACCCACTAATGGTGTTGGTTACCAACCA

	1720 1730 1740 1750 1760 1770 1780 1790 1800
	GATECTETCCETEATCCACAGACACTTGAGATTCTTGACATTACACCATETTCTTTTEETEETEATCACETETTATAACACCAGGAACAAATACTTC
	CTACGACAGGCACTAGGTGTCTGTGAACTCTAAGAACTGTAATGTGGTACAAGAAAACCACCACAGTCACAATATTGTGGGTCCTTGTTATGAAG
	DAVRDPQTLEILDITPCSFGGVSVITPGTNTS (Inframe with N501V)
	GATGCTGTCCGTGATCCACAGACACTTGAGATTCTTGACATTACACCATGTTCTTTGGTGGTGTCAGTGTTATAACACCCAGGAACAAATACTTC
11	
8 📥	GATECTERCCGTGATCCACAGACACTTGAGATTCTTGACATTACACCCATGTTCTTTTGGTGGTGTCAGTGTTATAACACCCAGGAACAAATACTTC
	1810         1820         1830         1840         1850         1860         1870         1880         1890         1900
	TAACCAGGTTGCTGTTCTTTATCAGGATGTTAACTGCCACAGAAGTCCCTGTTGCTATTCATGCAGATCAACTTACTCCTACTTGGCGTGTTTATT
	N Q V A V L Y Q D V N C T E V P V A I H A D Q L T P T W R V Y (In frame with N501Y)
	D614G
	TAACCAGGTTGCTGTTCTTTATCAGGATGTTAACTGCACAGAAGTCCCTGTTGCTATTCATGCAGATCAACTTACTCCTACTTGGCGTGTTTATT
1	
8 -	TAACCAGGTTGCTGTTCTTTATCAGGGTGTTAACTGCACAGAAGTCCCCTGTTGCTATTCATGCAGATCAACTTACTCCTACTTGGCGTGTTTATT
	1910 1920 1930 1940 1950 1960 1970 1980 1990
	CTACAGGTTCTAATGTTTTTCAAACACGTGCAGGCTGTTTAATAGGGGCTGAACATGTCAACAACTCATATGAGTGTGACATACCCATTGGTGCA
	STGSNVPQTRAGCLIGAEHVNNSYECDIPIGA (In frame with NS01Y)
	CTACAGETTCTAATETTTTTCAAACACGTECAEECTETTTAATAEEEECTEAACATETCAACAACTCATATEAETETEACACACAC
4 🔶	CTACAGGTTCTAATGTTTTTCAAACACGTGCAGGCTGTTTAATAGGGGGCTGAACATGTCAACAACTCATATGAGTGTGACATACCCATTGGTGCA
5 📥	CTACAGGTTCTAATGTTTTTCAAACACGTGCAGGCTGTTTAATAGGGGGCTGAACATGTCAACAACTCATATGAGTGTGACATACCCATTGGTGCA
0 -	
	2000 2010 2020 2030 2040 2050 2060 2070 2080 2090
	GGTATATGCGCTAGTTATCAGACTCAGACTAATTCTCCCTCGGCGGGCACGTAGTGTAGCTAGTCAATCCATCATTGCCTACACTAGTCAACTGCCTAGGTAGTCAGTGACCTAGGTAGTAGTGACGGATCAATACGGGATCAAATCCGATCAGTGAACGGGATCTGAGTCAGATCGGATCAGTGAACGGGATCGAATCGGATCAGTGAACGGGATCGAATCGGATCAGGTGGATCGGATCAGTGAACGGGATGTGAACGGGATGTGAACGGGATGGAACG
	GICASYQTQTNSPRRARSVASQSIIAYTMSLG
	GGTATATGCGCTAGTTATCAGACTCAGACTAATTCTCCCTCGGCGGGCACGTAGTGTAGCTAGTCAATCCATTGCCTACACTAGTCACTTGG
1	
8 🔸	GGTATATGCGCTAGTTATCAGACTCAGACTAATTCTCCCTCGGCGGGCACGTAGTGTAGCT
	2100 2110 2120 2130 2140 2150 2160 2160 2170 2180
	TGCAGAAAATTCAGTT6CTTACTCTAATAACTCTATT6CCATACCCACAAATTTTACTATTAGTGTTACCACAGAAATTCTACCAGGTGTCTATGA
	A E N S V A Y S N N S I A I P T N F T I S V T T E I L P V S M (In frame with N501Y)
	A7 01V
	TGCAGAAAATTCAGTTGCTTACTCTAATAACTCTATTGCCATACCCACAAATTTTACTATTAGTGTTACCACAGAAATTCTACCAGTGTCTATGA
4 🔶	TGTAGAAAATTCAGTTGCTTACTCTAATAACTCTATTGCCATACCCACAAATTTTACTATTAGTGTTACCACAGAAATT
5 🗲	TG <mark>T</mark> AGAAAATTCAGTTGCTTACTCTAATAACTCTATTGCCATACCCACAAATTTTACTATTAGTGTTACCACAGAAATTCTACCAGTGTCTATGA

	2190 2200 2210 2220 2230 2240 2250 2260 2270 2280
	CCAAGACATCAGTAGATTGTACAATGTACATTTGTGGGGGATTCAACTGAATGCAGCAATCTTTTGTTGCAATATGGCAGTTTTTGTACACAAAAAA
	ткт sv p c т м ү i c g p s т е c s n L L L Q Y g s F c т Q L (In frame with N501Y)
	CCAAGACATCAGTAGATTGTACAATGTACATTTGTGGTGATTCAACTGAATGCAGCAATCTTTTGTTGCAATATGGCAGTTTTTGTACACAATTA
5 🛶	CCAAGACATCAGTAGATTGTACAATGTACATTTGTGGTGATTCAACTGAATGCAGCAATCTTTTGTTGCAATATGGCAGTTTTTGTACACAATTA
	2290 2310 2320 2330 2340 2350 2360 2360 2370
	AACCGTGCTTTAACTGGAAAAGCTGTTGAACAAGACAAG
	N R A L T G I A V E Q D K N T Q E V F A Q V K Q I Y K T P P I K (in frame with NS01Y)
	AACCETECTTTAACTEEAATAECTETTEAACAAEAACAACACCCAAEAAETTTTECACAAETCAAAAAAATTTACAAAAACACCACCAATTAA
5 🔶	AACCGTGCTTTAACTGGAATAGCTGTTGAACAAGACAAG
7 🗭	AAACACCACCAATTAA
	2380 2390 2400 2410 2420 2430 2440 2450 2450 2450 2470
	AGATTTTGGTGGTTTTAATTTTTCACAAATATTACCAGATCCATCAAAACCAAGCAAG
	TCTAAAACCACCAAAATTAAAAAGTGTTTATAATGGTCTAGGTAGTTTTGGTTCGTTC
	DFGGFNFSQILPDPSKPSKRSFIEDLLFNKV (n (rame with NSOTY)
	AGATTTTGGTGGTTTTAATTTTTCACAAATATTACCAGATCCATCAAAACCAAGCAAG
7 -	AGATTTTGGTGGTTTTAATTTTCACAAAATATTACCAGATCCATCAAAAACCAAGAGGTCATTTATTGAA
	7480 7460 7500 7510 7520 7530 7530 7550 7550
	*****
	GTGAACGTCTACGACCGAAGTAGTTGTTATACCACTAAGGGAACCACGTATAACGACGATCTCTGGAGTAAACACGTGTTTTCAAATTGCCGGAA T L A D A G F I K O Y G D C L G D I A A R D L I C A O K F N G L
	(in frame with NSDIY)
	CACTT&CAGAT&CT&&CCATCATCAAACAATAT>&ATT&CCTT&>&ATATT&CT&CT&&GA&AACCTCATTT&T&CCAAAAA&CTTTAAC&&CCTT
6 🔶	ATTGCTGCTAGAGACCTCATTTGTGCACAAAAGTTTAACGGCCTT
7-	CACTTECAGATECTEGECTICATCAAACAATATEETEATTECTEGTEATATTECTECTAEAGACCTCATTTETECACAAAAGTTTAACEECCTT
	2570 2580 2590 2600 2610 2620 2630 2640 2650 2660
	ACTGTTTTGCCACCTTTGCTCACAGATGAAATGATTGCTCAATACACTTCTGCACTGTTAGCGGGTACAATCACTTCTGGTTGGACCTTTGGTGC
	TGACAAAACGGTGGAAACGAGTGTCTACTTACTAACGAGTTATGTGAAGACGTGACAATCGCCCATGTTAGTGAAGACCAACCTGGAAACCACG
	TVLPPLLTDEMIAQYTSALLAGTITSGWTFGA (in frame with NSOLY)
6 🔶	ACTGTTTTGCCACCTTTGCTCACAGATGAAATGATTGCTCAATACACTTCTGCACTGTTAGCGGGTACAATCACTTCTGGTTGGACCTTTGGTGC
7 🔶	ACTGTTTTGCCACCTTTGCTCACAGATGAAATGATTGCTCAATACACTTCTGCACTGTTAGCGGGTACAATCACTTCTGGTTGGACCTTTGGTGC
	2670 2680 2690 2700 2700 2710 2720 2730 2730 2730 2740 2750
	2670         2690         2700         2710         2720         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730         2730 <td< th=""></td<>
	AGGTGCTGCATTACAAATACCATTTGCTATGCAAATGGCTTATAGGTTTAAGGTATTGGAGTACACAGAATGTTCTCTATGAGAACCAAAAAT TCCACGACGTAATGTTTATGGTAAACGATACGTTTACCGAATACCATAACCTCAATGTGTCTACAAGAGAATACCCTTGGTTTTA G A A L Q I P F A N Q M A Y R F N G I G V T Q N V L Y E N Q K (In frame with N501Y)
	AGGTGCTGCATTACAAATACCATTTGCTATGCAAATGGCTTATAGGTTTAATGGTATTGGAGTTACACAGAATGTTCTCTATGAGAACCAAAAAT G A A L Q I P F A N Q M A Y R F N G I G V T Q N V L Y E N Q K (n frame with NSDIY)
1 🖛	2670       2680       2690       2700       2710       2720       2730       2740       2750         AGGTGCTGCATTACAAAATACCATTTGCTATGCAAATGGCTTATAGGTTTAAGGTATTGGAGTTACACAGGAATGTTCTCTATGGGAACCAAAAAT         TCCACGACGTAAGGTTACGGATACGATAGGCTTATGGAATTACCAAATGGCTCTACACAGGAATGTTCTCTATGGAGATACCCTCAAGGAAGATGTTCTCTAGGTAAACGATACCCTCAAGGAATGTTCTCTAGGTATGGAGATACCCTCAAGGAATGTTCTCTAGGTATGGAGGAACCAAAAAT         CCACGACGTAAGGTTTACGGAATGTCCCAAATGCCTCAAGGATGTCCCCAATGTGGCTTACACAGGAGATGTTCTCTAGGAAACCAAAAAT         CCACGACGTACGCTTACGGATACCGCTTATGGAGTTACACCAGGAATGTTCTCTATGGAGAACCAAAAAT         CCACGACGTGCCTGCATTGCCAAATGGCTTATGGAGTTACACCAGGAATGTTCTCTATGGAGAACCAAAAAT         CCACGAATGCCGCTGCATTGCCAAATGGCTTATGGAGTTACACCAGGAATGTTCTCTATGGAGAACCAAAAAT         CCAAAAT
1	AGGTGCTGCATTACAAATACCATTTGCTATGCAAATGGCTTATAGGTTTAATGGTATTGGAGTTACACAGAATGTTCTCTATGAGAACCAAAAAT AGGTGCTGCATTACAAATACCATTTGCTATGCAAATGGCTTATAGGTTTAATGGTATTGGAGTTACACAGAATGTTCTCTATGAGAACCAAAAAT CCACAGACGTAATGTTTATGGTAAACGATACGTTACGAAATGGCTTATAGGTTTAATGGTATTGGAGTTACACAGAATGTTCTCTATGAGAACCAAAAAT CCACAGACGTACAAATACCATTTGCTATGCAAATGGCTTATAGGTTTAATGGTATTGGAGTTACACAGAATGTTCTCTATGAGAACCAAAAAT CCACAGACTGCATTACAAATACCATTTGCTATGCAAATGGCTTATAGGTTTAATGGTATTGGAGTTACACAGAATGTTCTCTATGAGAACCAAAAAT CCACAGACTGCTGCATTACAAAATACCATTTGCTATGCAAATGGCTTATAGGTTTAATGGTATTGGAGTTACACAGAATGTTCTCTATGAGAACCAAAAAT CCACAGACTGCTGCATTACAAATACCATTTGCTATGCAAATGGCTTATAGGTTTAATGGTATTGGAGTTACACAGAATGTTCTCTATGAGAACCAAAAAT

	2760 2770 2780 2790 2800 2810 2820 2830 2840 2850
	TGATTGCCAACCAATTTAATAGTGCTATTGGCAAAATTCAAGACTCACTTTCTTCCACAGCAAGTGCACTTGGAAAACTTCAAGATGTGGGTCAAC ++++++++++++++++++++++++++++++++++
	L I A N Q F N S A I G K I Q D S L S S T A S A L G K L Q D V V N (In frame with N501Y)
	TGATTGCCAACCAATTTAATAGTGCTATTGGCAAAATTCAAGACTCACTTTCTTCCACAGCAAGTGCACTTGGAAAACTTCAAGATGTGGTCAAC
1 📥	TGATTGCCAACCAATTTAATAGTGCTATTGGCAAAATTCAAGACTCACTTTCTTCCACAGCAAGTGCACTTGGAAAACTTCAAGATGTGGTCAAC
6 🔶	TGATTGCCAACCAATTTAATAGTGCTATTGGCAAAATTCAAGACTCACTTTCTTCCACAGCAAGTGCACTTGGAAAACTTCAAGATGTGGTCAAC
7 📥	TGATTGCCAACCAATTTAATAGTGCTATTGGCAAAATTCAAGACTCACTTTCTTCCACAGCAAGTGCACTTGGAAAACTTCAAGATGTGGTCAAC
	2860 2870 2880 2890 2900 2910 2920 2930 2940
	CAAAATGCACAAGCTTTTAAACAACCTTGTTAAACAACTTAGCTCCCAATTTTGGTGCAATTTCAAGTGTTTTAAATGATATCCTTTCACGTCTTGA GTTTTACGTGTTCGAAATTTGTGCGAACAATTTGTGCGAACAATTTGTGAACGAGGTTAAAACCACGTTAAAGGTTCACAAAATTTACTATAGGAAAGTGCAGAACT
	Q N A Q A L N T L V K Q L S S N F G A I S S V L N D I L S R L D (In frame with N501Y)
	CAAAATGCACAAGCTTTAAACACGCTTGTTAAACAACTTAGCTCCAATTTTGGTGCAATTTCAAGTGTTTTAAATGATATCCTTTCACGTCTTGA
1 🖛	CAAAATGCACAAGCTTTAAACACGCTTGTTAAACAACTTAGCTCCAATTTTGGTGCAATTTCAAGTGTTTTAAATGATATCCTTTCACGTCTTGA
6 🔶	CAAAATGCACAAGCTTTAAACACGCTTGTTAAACAACTTAGCTCCCAATTTTGGTGCAATTTCAAGTGTTTTAAATGATATCCTTTCACGTCTTGA
7 📥	CAAAATGCACAAGCTTTAAACACGCTTGTTAAACAACTTAGCTCCAATTTTGGTGCAATTTCAAGTGTTTTAAATGATATCCTTTCACGTCTTGA
	2950 2960 2970 2980 2990 3000 3010 3020 3030 3040
	CAAAGTTGAGGCTGAAGTGCAAATTGATAGGTTGATCACAGGCAGACTTCAAAGTTTGCAGACATATGTGACTCCAACAATTAATT
	K V E A E V Q I D R L I T G R L Q S L Q T Y V T Q Q L I R A A (in frame with N501Y)
	CAAAGTTGAGGCTGAAGTGCAAATTGATAGGTTGATCACAGGCAGACTTCAAAGTTTGCAGACATATGTGACTCAAAAATTAATT
1 🔶	CAAAGTTGAGGCTGAAGTGCAAATTGATAGGTTGATCACAGGCAGACTTCAAAGTTTGCAGACATATGTGACTCAACAATTAATT
1 <b>+</b> 6 <b>+</b>	CAAAGTTGAGGCTGAAGTGCAAATTGATAGGTTGATCACAGGCAGACTTCAAAGTTTGCAGACATATGTGACTCAACAATTAATT
1 <b>+</b> 6 <b>+</b> 7 <b>+</b>	CAAAGTTGAGGCTGAAGTGCAAATTGATAGGTTGATCACAGGCAGACTTCAAAGTTTGCAGACATATGTGACTCAACAATTAATT
1 <b>•</b> 6 <b>•</b> 7 <b>•</b>	CAAAGTTGAGGCTGAAGTGCAAATTGATAGGTTGATCACAGGCAGACTTCAAAGTTTGCAGACATATGTGACTCAACAATTAATT
1 <b>•</b> 6 <b>•</b> 7 <b>•</b>	CAAAGTT GAGGCT GAAGT GCAAATT GATAGGTT GAT CACAGGCAGACTT CAAAGTTT GCAGACATAT GT GACT CAACAATT AATT
1 <b>•</b> 6 <b>•</b> 7 <b>•</b>	CAAAGTT GAGGCT GAAGT GCAAATT GATAGGTT GAT CACAGGCAGACTT CAAAGTT T GCAGACATAT GT GAC T CAACAATT AATT
1 <b>•</b> 6 <b>•</b> 7 <b>•</b>	CAAAGTT GAGGCT GAAGT GCAAATT GAT AGGTT GAT CACAGGCAGACTT CAAAGTT T GCAGACAT AT GT GAC T CAACAATT AATT
1 <b>•</b> 6 <b>•</b> 7 <b>•</b> 7	CAAAGTT GAGGCT GAAGT GCAAATT GAT AGGTT GAT CACAGGCAGACTT CAAAGTT TGCAGACAT AT GTGACT CAACAATT AATT
1 <b>←</b> 6 <b>→</b> 7 <b>→</b>	CAAAGTT GAGGCT GAAGT GCAAATT GAT AGGTT GAT CACAGGCAGACT T CAAAGT T GCAGACAT AT GT GAC T CAACAATT AATT
1 <b>• • • • • • • • • •</b>	CAAAGTT GAAGGT GAAGT GCAAATT GAT AGGTT GAT CACAGGCAGACTT CAAAGTT T GCAGACAT AT GT GAC T CAACAATT AATT
1 <b>• • • • • • • • • •</b>	CAAAGTT GAGGCT GAAGT GC AAATT GATAGGT T GAT CACAGGC CAGACTT CAAAGT T GC AGACAT AT GT GAC T CAACAATT AATT
1 <b>•</b> 6 <b>•</b> 7 <b>•</b> 7	CAAAGTT GAGGCT GAAGT & CAAATT & GATAGGT T GAT CACAGGC CAGACTT CAAAGT T & GAGCAT AT & GT & GACAATT AATT A & GAGCT & GACAAGT T & GAAGT T & GAGGCT & GAAAGT T & GAAGT T &
$1 \leftarrow 6 \rightarrow 7 \rightarrow 1 \leftarrow 7 \rightarrow 1 \rightarrow 1 \leftarrow 7 \rightarrow 1 \rightarrow$	CAAAGTT GAGGCT GAAGT GC AAATT GA TAGGT T GAT CACAGGC CAGACTT CAAAGT T GC AGACAT AT GT GAC T CAACAATT AATT
1 <b>4</b> 6 <b>→</b> 7 <b>→</b> 1 <b>4</b> 6 <b>→</b> 7 <b>→</b>	CAAAGTT GAGGCT GAAGT GCAAATT GAT AGGTT GAT CACAGGCAGACTT CAAAGTT T GCAGACAT AT GT GACT CAACAATT AATT
1 <b>• • • • • • • • • •</b>	CAAAGTT GAAGT GAAATT GATAGGTT GAT CACAGGCAGACT T CAAAGTT T GCAGACATAT GT GACT CAACAATTAATTAGGCT GCAG         CAAAGTT GAGGCT GAAGT GCAAATT GAT AGGT T GAT CACAGGCAGACT T CAAAGTT T GCAGACATAT GT GACT CAACAATTAATTAGGCT GCAG         CAAAGTT GAGGCT GAAGT GCAAATT GAT AGGT T GAT CACAGGCAGACT T CAAAGTT T GCAGACATAT GT GACT CAACAATTAATTAGGCT GCAG         CAAAGTT GAGGCT GAAGT GCAAATT GAT AGGT T GAT CACAGGCAGACT T CAAAGTT T GCAGACATAT GT GACT CAACAATTAATTAGGCT GCAG         CAAAGTT GAGGCT GAAGT GCAAATT GAT AGGT T GAT CACAGGCAGACT T CAAAGTT T GCAGACATAT GT GACT CAACAATTAATTAGAGCT GCAG         CAAAGTT GAGGCT GAAGT GCAAATT GAT AGGT T GAT CACAGGCAGACT T CAAAGTT T GCAGACATAT GT GACT CAACAATTAATTAGAGCT GCAG         CAAAGTT GAGGCT GAAATT GAT AGGT T GAT CACAGGCAGACT T CAAAGTT T GCAGACATAT GT GACT CAACAATT T AT T A
1 <b>4</b> 6 <b>→</b> 7 <b>→</b> 1 <b>4</b> 6 <b>→</b> 7 <b>→</b>	CAAAGTT GAAGT GC AAATT GA TAG GTT GAT CACAGG CAGACT T CAAAGTT T GC AGACAT AT GT GA CT CAAAATT AATT
1 <b>4</b> 6 <b>4</b> 7 <b>4</b> 6 <b>4</b> 7 <b>4</b>	CAAAGTT GAAGGGCT GAAGTGCAAATT GATAGGTT GATCACAGGCAGGCT TCAAAGTT TGCAGACCATAT GTGACTCCAACAATTAATTAGAGCTCCAG         CAAAGTT GAAGGGCT GAAATT GAAAGGT T GATCACAGGCAGGCT TCAAAGTT TGCAGGCATAT GTGACT CAACAATTAATTAGAGCT GCAG         CAAAGTT GAAGGC CGAAATT GGAAGT GCAAAATT GATCAGGC GAGACT TCAAAGT TTGCAGGCATAT GTGACT CAACAATTAATTAGAGCT GCAG         CAAAGTT GAAGGC CGAAATT GGAAGT GCAAAATT GATCAGGC GAGACT TCAAAGGT TTGCAGGCATAT GTGACT CAACAATTAATTAGAGCT GCAG         CAAAGTT GAAGGC CGAAATT GGAAGT GGACAAATT GATCACAGGCAGGC TTCAAAGT TTGCAGGCATAT GTGACT CAACAATTAATTAGAGCT GCAG         CAAAGTT GAAGGC CGAAATT GGAAATT GATCACAGGCAGGC GGAGCT TCAAAGT TTGCAGGACAATT GTGGACAAATT GTGAGCACAATT GAACAAGTT GAACAAGT TGAATT TAGGGC CGAGGCT TCAACAATT GAAGGC CGAT GAAAATT GCAGGC CGAGCAGC GTGAT CAAAAGGAGT TGAT TTTGCAGGAGCAGT CAAAAAGAAGT TGAT TTTGCAGGAGCAGT CAAAAAGAAGCT TCAACAAAGAAGC TTGCATT TTGCT GGAAAAGGAGCT TCATAAATT GCAGGC GAT GATT TTTGCT GGAAAAGGAGCT TCAAAAAAGAAGCT TCACAAAAAGAAGCT TCACAAAAGAAGCT TCACAAAAGGAGCT TCAAAAAGAAGCT TCGCT AAAAGT TGCAGGGC TAT CATAAAAGGAGT TGAT TTTG TGGAAAAGGAGCT ACCAT         AAATC AGGAGCCT TCGCT AAT CTT GCT GCT ACT AAAAT GT CAGAGGT GGT GT ACT TG GGACAAT CAAAAAGAGT TGAT TTTT GT GGAAAGGGC TAT CAT         AAATC AGGAGCT TCG GCT ACT AAAAT GT CAGAGT GGT GT ACT TG GGACAAT CAAAAAGAGT TGAT TTTT GT GGAAAGGGC TAT CAT         AAATC AGGAGCT TCG CT AAT CT TG CT ACT AAAAT GT CAGGGT GT GT ACT TG GGACAAT CAAAAAGAGT TGAT TTTG TG GGAAAGGGC TAT CAT         AAATC AGGAGCT TCG CT AAT CT TAAAT GT CAGGGT GT GT ACT TG GGACAAT CAAAAAGAGT TGAT TTTG TG GGAAAGGGCT AT CAT         AAATC AGGAGCT TCG CT AAT CT TAAAAT GT CAGGGT GT GT ACT TG GGACAAT CAAAAAGAGT TG AT TTTG TG GGAAAGGGCT AT CAT         AAATC AGGAGCT TCG CT AAT CT TAAAAT GT CAGGGT GT
	CAAABTT GAAGT GCAAATT GCT AGAT TGAT AG GTT GAT CACAGGCAGACT TT CAAAG TT TT CCAGACATT AT TT GAGCT CCAACAATT AATT
	CAAAGTT GAGGCT GAAGT GCAAATT GATAGGTT GAT CACAGGC AGGCT T CAAAGTT T GCAGGCACAT T GTGAC CAACAT T AATT AGGCT GCAACATT AATT A
$1 \leftarrow 6 \rightarrow 7 \rightarrow 1 \leftarrow 6 \rightarrow 1 \leftarrow 7 \rightarrow 1 \leftarrow 6 \rightarrow 1 \leftarrow 7 \rightarrow 1 \rightarrow 1 \leftarrow 7 \rightarrow 1 \rightarrow$	CAAAGTTGAGGCTGAAGTGCAAATTGATAGGTTGATCACAGGCAGACTTCAAAGTTTGCAGGCAATGTGAGCCAACAATTAATT

	3240 3250 3260 3270 3280 3290 3300 3310 3320
	ТТТ6ТСАТ6АТ66АААА6САСАСТТТССТС6Т6АА66Т6ТСТТ16ТТТСАААТ66САСАССАСТ66ТТТ6ТААСАСААА66ААТТТТТАТ6ААС 
617	I C H D G K A H P P R E G V S N G T H W P V T Q R N P Y E
	for manife mich readers
CAT	ITTOTCATGATGGAAAAGCACACTTTCCTCGTGAAGGTGTCTTTGTTTCAAATGGCACACACTGGTTTGTAACACAAAGGAATTTTTATGAAC
1 🔶 CAT	ITTETCATEGAAAAAGCACACTTTCCTCGTGAAGGTGTCTTTGTTTCAAATGGCACACTGGTTTGTAACACAAAGGAATTTTTATGAAC
6 🔶 CA	
7 🔶 CA	
-	
33.	30 3340 3350 3360 3370 3380 3390 3400 3410 3420
CAC TT GT C	CAAATCATTACTACAGACAACACATTT6T6TCT66TAACT6T6AT6T6TATAG6AATT6TCAACAACAACAACATTAT6ATCCTT76CAACCT 
P	Q I I T T D N T F V S G N C D V V I G I V N N T V Y D P L Q P (in frame with NSDIY)
CAC	CAAATCATTACTACAGACAACACATTTGTGTCTGGTAACTGTGATGTTGTAATAGGAATTGTCAACAACACAGTTTATGATCCTTTGCAACCT
1 🔶 CAC	CAAATCATTACTACAGACAACACATTTGTGTCTGGTAACTGTGATGTTGTAATAGGAATTGTCAACAACACAGTTTATGATCCTTTGCAACCT
2000	
-	1 3430 1 3440 1 3450 1 3460 1 3470 1 3480 1 3490 1 3500 1 3510 1
644 111 CT1	ATTAGACTCATTCAAGGAGGAGTTAGATAAATATTTTTAAGAATCATCACCACAGATGTTGATTTAGGTGACATCTCTGGCATTAATGCTTC HILTITI HILTITI HILTITI HAATCTGAGTAAGTTCCTCCTCAATCTATTTATAAAAITCTTAGTAATGTAGTGATCTACAACTAAATCCACTGAAGAGCGTGACTAATTACGAAG
E	L D S F K E E L D K Y F K N H T S P D V D L G D I S G I N A S
	(in trame with MSOLY)
GAA	ATTAGACTCATTCAAGGABGAGTTAGATAAATATTTTTAAGAATCATACATCACCAGATGTTGATTTAGGTGACATCTCTGGCATTAATGCTTC
1 🖛 GAA	XTTAGACTCATTCAAGGAGGAGTTAGATAAATATTTTTAAGAATCATCACCAGATGTTGATTTAGGTGACATCTCTGGCATTAATGCTTC
100	
35	20 3530 3540 3550 3560 3570 3580 3590 3600 3610
AG1 +++	TTGTAAACATTCAAAAAGAAATTGACCGCCTCAATGAGGTTGGCAAGAATTTAAATGAATCTCTCATCGATCTCCCAAGAACTTGGAAAGTATG HILLINIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII
	V V N I Q K E J D R L N E V A K N L N E S L I D L Q E L G K Y
AGT	ITGTAAACATTCAAAAAGAAATTGACCGCCTCAATGAGGTTGCCAAGAATTTAAATGAATCTCTCATCGATCTCCAAGAACTTGGAAAGTATG
1 🔶 A 6 1	ITGTAAACATTCAAAAAGAAATTGACCGCCTCAATGAGGTTGCCAAGAATTTAAATGAATCTCTCATCGATCTCCAAGAACTTGGAAAGTATG
1000	3620 3630 3640 3650 3650 3660 3670 3680 3690 3700
AGO	AGTATATAAAATGGCCATGGTACATTTGGCTAGGTTTTATAGCTGGCTTGATTGCCATAGTAATGGTGACAATTATGCTTTGCTGTATGACC
+++ TCG	GTCATATATTTTACC66TACCAT6TAAACC6ATCCAAAATATC6ACC6AACTAAC6GTATCATTACCACT6TTAATAC6AAAC6ACATAC766
E	QY1KWPWY1WLGFIAGL1AIVNVTIMLCCMT (In frame with NSDIY)
AGO	CAGTATATAAAAATGGCCATGGTACATTTGGCTAGGTTTTATAGCTGGCTTGATTGCCATAGTAATGGTGACAATTATGCTTTGCTGTATGACC
1 🖛 AGO	AGTATATAAAATGECCATGGTACATTTGGCTAGGTTTTATAGCTGGCTTGATTGCCATAGTAATGGTGACAATTATGCTTTGCTGTATGACC
	WESTERN CAPE
37	10 3720 3730 3740 3750 3760 3770 3780
AGT	TTECTETAETTETCTCAAGGECTETTETTETGEGATCCTECTECGATTACAAGGATGACGACGATAAGTAA
TCA	AACBACATCAACAGAGTTCCCGGACAACAACAACAACACCTAGGACGACGACGACGCTCCTACTGCTGCTGCTGCTATTCATT 5/
s	
	Stop Codon
140	
1 - AG	TTGCT6TAGTTGTCTCAA666CT6TT6TT6TTGTGGATCCT6CT6C6ATTACAA66ATGAC6AC6AC6ATAA6TAA

#### References

(2023). NEBuilder HiFi DNA Assembly Cloning Kit. <u>New England Biolabs</u>. Ipswich, Massachusetts, New England Biolabs**:** 3.

Abebe, E. C. and T. A. Dejenie (2023). "Protective roles and protective mechanisms of neutralizing antibodies against SARS-CoV-2 infection and their potential clinical implications." <u>Frontiers in Immunology</u> **14**: 1055457.

Andersen, K. G., et al. (2020). "The proximal origin of SARS-CoV-2." <u>Nature medicine</u> **26**(4): 450-452.

Arya, R., et al. (2021). "Structural insights into SARS-CoV-2 proteins." Journal of molecular biology **433**(2): 166725.

Biolabs, N. E. (2022). "NEBuilder HiFi DNA assembly reaction (E2621)."

Burger, C., et al. (2022). "The health impact of free access to antiretroviral therapy in South Africa." <u>Social Science & Medicine</u> **299**: 114832.

Burnett, L. C., et al. (2009). "Biosafety: guidelines for working with pathogenic and infectious microorganisms." <u>Current protocols in microbiology</u> **13**(1): 1A. 1.1-1A. 1.14.

Cao, Y., et al. (2023). "Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution." <u>Nature</u> **614**(7948): 521-529.

Cao, Y., et al. (2021). "Characterization of the SARS-CoV-2 E protein: sequence, structure, viroporin, and inhibitors." <u>Protein Science</u> **30**(6): 1114-1130.

Chakraborty, S. (2022). "E484K and N501Y SARS-CoV 2 spike mutants Increase ACE2 recognition but reduce affinity for neutralizing antibody." <u>International immunopharmacology</u> **102**: 108424.

Chen, H.-Y., et al. (2021). "Cytoplasmic tail truncation of SARS-CoV-2 spike protein enhances titer of pseudotyped vectors but masks the effect of the D614G mutation." Journal of Virology **95**(22): 10.1128/jvi. 00966-00921.

Chen, K.-W. K., et al. (2022). "SARS-CoV-2 variants-evolution, spike protein, and vaccines." <u>biomedical journal</u> **45**(4): 573-579.

Cheng, M. H., et al. (2022). "Impact of new variants on SARS-CoV-2 infectivity and neutralization: A molecular assessment of the alterations in the spike-host protein interactions." <u>Iscience</u> **25**(3).

Chmielewska, A. M., et al. (2021). "Immune response against SARS-CoV-2 variants: the role of neutralization assays." <u>Npj Vaccines</u> 6(1): 142.

Chvatal-Medina, M., et al. (2021). "Antibody responses in COVID-19: a review." <u>Frontiers in</u> <u>Immunology</u> **12**.

Condor Capcha, J. M., et al. (2021). "Generation of SARS-CoV-2 spike pseudotyped virus for viral entry and neutralization assays: a 1-week protocol." <u>Frontiers in cardiovascular</u> <u>medicine</u> 7: 618651.

Cui, X., et al. (2023). "Future trajectory of SARS-CoV-2: Constant spillover back and forth between humans and animals." <u>Virus research</u> **328**: 199075.

De La Torre-Tarazona, E., et al. (2023). "Treatment with integrase inhibitors alters SARS-CoV-2 neutralization levels measured with HIV-based pseudotypes in people living with HIV." Journal of Medical Virology **95**(2): e28543.

Dispinseri, S., et al. (2021). "Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival." <u>Nature communications</u> 12(1): 1-12.

Dougan, M., et al. (2022). "Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19." <u>medrxiv</u>: 2022.2003. 2010.22272100.

Duffy, S. (2018). "Why are RNA virus mutation rates so damn high?" <u>PLoS biology</u> **16**(8): e3000003.

Elena, S. F. and R. Sanjuán (2005). "Adaptive value of high mutation rates of RNA viruses: separating causes from consequences." Journal of Virology **79**(18): 11555-11558.

Fani, M., et al. (2020). "Comparison of the COVID-2019 (SARS-CoV-2) pathogenesis with SARS-CoV and MERS-CoV infections." <u>Future Virology</u> 15(5): 317-323.

Fukushi, S., et al. (2005). "Vesicular stomatitis virus pseudotyped with severe acute respiratory syndrome coronavirus spike protein." Journal of general virology **86**(8): 2269-2274.

Fukushi, S., et al. (2008). "Pseudotyped vesicular stomatitis virus for analysis of virus entry mediated by SARS coronavirus spike proteins." <u>SARS-and Other Coronaviruses: Laboratory</u> <u>Protocols</u>: 331-338.

Galipeau, Y., et al. (2020). "Humoral responses and serological assays in SARS-CoV-2 infections." <u>Frontiers in Immunology</u> 11: 610688.

Garcia-Beltran, W. F., et al. (2021). "COVID-19-neutralizing antibodies predict disease severity and survival." <u>Cell</u> **184**(2): 476-488. e411.

Gattinger, P., et al. (2022). "Vaccine based on folded receptor binding domain-PreS fusion protein with potential to induce sterilizing immunity to SARS-CoV-2 variants." <u>Allergy</u> 77(8): 2431-2445.

Gottlieb, R. L., et al. (2021). "Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial." Jama **325**(7): 632-644.

Greaney, A. J., et al. (2021). "Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies." <u>Cell host & microbe</u> **29**(3): 463-476. e466.

Gupta, S. L. and R. K. Jaiswal (2022). "Neutralizing antibody: a savior in the Covid-19 disease." <u>Molecular Biology Reports</u>: 1-10.

Harvey, W. T., et al. (2021). "SARS-CoV-2 variants, spike mutations and immune escape." Nature Reviews Microbiology **19**(7): 409-424.

Hossain, M. G., et al. (2021). "SARS-CoV-2 host diversity: An update of natural infections and experimental evidence." Journal of Microbiology, Immunology and Infection **54**(2): 175-181.

Huang, D., et al. (2021). "A rapid assay for SARS-CoV-2 neutralizing antibodies that is insensitive to antiretroviral drugs." <u>The Journal of Immunology</u> **207**(1): 344-351.

Huang, Y., et al. (2020). "Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19." <u>Acta Pharmacologica Sinica</u> **41**(9): 1141-1149.

Hui, K. P., et al. (2020). "Tropism, replication competence, and innate immune responses of the coronavirus SARS-CoV-2 in human respiratory tract and conjunctiva: an analysis in exvivo and in-vitro cultures." The Lancet Respiratory Medicine 8(7): 687-695.

Jackson, C. B., et al. (2022). "Mechanisms of SARS-CoV-2 entry into cells." <u>Nature reviews</u> <u>Molecular cell biology</u> **23**(1): 3-20.

Jassat, W., et al. (2022). "Clinical severity of COVID-19 in patients admitted to hospital during the omicron wave in South Africa: a retrospective observational study." <u>The Lancet Global Health</u> **10**(7): e961-e969.

Jassat, W., et al. (2021). "Difference in mortality among individuals admitted to hospital with COVID-19 during the first and second waves in South Africa: a cohort study." <u>The Lancet Global Health</u> **9**(9): e1216-e1225.

Jayakar, H. R., et al. (2004). "Rhabdovirus assembly and budding." <u>Virus research</u> **106**(2): 117-132.

Johnson, M. C., et al. (2020). "Optimized pseudotyping conditions for the SARS-COV-2 spike glycoprotein." Journal of Virology **94**(21): 10.1128/jvi. 01062-01020.

Kendall, E., et al. (1962). "Virus isolations from common colds occurring in a residential school." <u>British medical journal</u> **2**(5297): 82.

Khan, K., et al. (2022). "Omicron infection of vaccinated individuals enhances neutralizing immunity against the Delta variant." <u>medrxiv</u>.

Khoury, D. S., et al. (2021). "Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection." <u>Nature medicine</u>: 1-7.

Klasse, P. and Q. Sattentau (2002). "Occupancy and mechanism in antibody-mediated neutralization of animal viruses." Journal of general virology **83**(9): 2091-2108.

Lam, T. T.-Y., et al. (2020). "Identifying SARS-CoV-2-related coronaviruses in Malayan pangolins." <u>Nature</u> **583**(7815): 282-285.

Lan, J., et al. (2020). "Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor." <u>Nature</u> **581**(7807): 215-220.

Lau, E. H., et al. (2021). "Neutralizing antibody titres in SARS-CoV-2 infections." <u>Nature</u> <u>communications</u> **12**(1): 1-7.

Letchworth, G., et al. (1999). "Vesicular stomatitis." The Veterinary Journal 157(3): 239-260.

Li, C., et al. (2021). "Overview of the pathogenesis of COVID-19." <u>Experimental and</u> <u>Therapeutic Medicine</u> **22**(3): 1-10.

Li, C., et al. (2020). "Genetic evolution analysis of 2019 novel coronavirus and coronavirus from other species." <u>Infection, Genetics and Evolution</u> 82: 104285.

Li, D., et al. (2021). "In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies." <u>Cell</u> **184**(16): 4203-4219. e4232.

Li, Q., et al. (2018). "Current status on the development of pseudoviruses for enveloped viruses." <u>Reviews in medical virology</u> 28(1): e1963.

Liu, G., et al. (2021). "Vesicular stomatitis virus: from agricultural pathogen to vaccine vector." <u>Pathogens</u> **10**(9): 1092.

Liu, P., et al. (2020). "Are pangolins the intermediate host of the 2019 novel coronavirus (SARS-CoV-2)?" <u>PLoS Pathogens</u> 16(5): e1008421.

Lu, Y., et al. (2021). "Advances in neutralization assays for SARS-CoV-2." <u>Scandinavian</u> Journal of Immunology **94**(3): e13088.

Ma, K. C. (2023). "Genomic Surveillance for SARS-CoV-2 Variants: Circulation of Omicron Lineages—United States, January 2022–May 2023." <u>MMWR. Morbidity and Mortality</u> <u>Weekly Report</u> 72.

Magazine, N., et al. (2022). "Mutations and evolution of the SARS-CoV-2 spike protein." <u>Viruses</u> **14**(3): 640.

Malone, B., et al. (2022). "Structures and functions of coronavirus replication-transcription complexes and their relevance for SARS-CoV-2 drug design." <u>Nature reviews Molecular cell</u> <u>biology</u> **23**(1): 21-39.

Martinez, D. R., et al. (2021). "Prevention and therapy of SARS-CoV-2 and the B. 1.351 variant in mice." <u>Cell reports</u> **36**(4).

Matusali, G., et al. (2021). "SARS-CoV-2 serum neutralization assay: a traditional tool for a brand-new virus." <u>Viruses</u> **13**(4): 655.

Millet, J. K. and G. R. Whittaker (2015). "Host cell proteases: critical determinants of coronavirus tropism and pathogenesis." <u>Virus research</u> **202**: 120-134.

Min, L. and Q. Sun (2021). "Antibodies and Vaccines Target RBD of SARS-CoV-2." <u>Frontiers in Molecular Biosciences</u> **8**: 247.

Mishra, N., et al. (2021). "Cross-neutralization of SARS-CoV-2 by HIV-1 specific broadly neutralizing antibodies and polyclonal plasma." <u>PLoS Pathogens</u> **17**(9): e1009958.

Morales-Núñez, J. J., et al. (2021). "Overview of neutralizing antibodies and their potential in COVID-19." <u>Vaccines</u> **9**(12): 1376.

Morens, D. M. and A. S. Fauci (2020). "Emerging pandemic diseases: how we got to COVID-19." <u>Cell</u> **182**(5): 1077-1092.

Motozono, C., et al. (2021). "SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity." <u>Cell host & microbe</u> **29**(7): 1124-1136. e1111.

Moyo-Gwete, T., et al. (2022). "Shared N417-dependent epitope on the SARS-CoV-2 omicron, beta, and delta plus variants." Journal of Virology **96**(15): e00558-00522.

Naqvi, A. A. T., et al. (2020). "Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach." <u>Biochimica et Biophysica Acta</u> (BBA)-Molecular Basis of Disease **1866**(10): 165878.

Neuman, B. W., et al. (2011). "A structural analysis of M protein in coronavirus assembly and morphology." Journal of structural biology 174(1): 11-22.

Nova, N. (2021). "Cross-species transmission of coronaviruses in humans and domestic mammals, what are the ecological mechanisms driving transmission, spillover, and disease emergence?" <u>Frontiers in Public Health</u> **9**: 717941.

Noy-Porat, T., et al. (2020). "A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes." <u>Nature communications</u> **11**(1): 1-7.

Palmer, E. and T. Freeman (2004). "Investigation into the use of C-and N-terminal GFP fusion proteins for subcellular localization studies using reverse transfection microarrays." <u>Comparative and functional genomics</u> **5**(4): 342-353.

Pang, N. Y.-L., et al. (2021). "Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice." <u>Military Medical Research</u> **8**(1): 1-17.

Papageorgiou, A. C. and I. Mohsin (2020). "The SARS-CoV-2 spike glycoprotein as a drug and vaccine target: structural insights into its complexes with ACE2 and antibodies." <u>Cells</u> **9**(11): 2343.

Peck, D. E., et al. (2020). "Management strategies for reducing the risk of equines contracting vesicular stomatitis virus (VSV) in the western United States." Journal of equine veterinary science **90**: 103026.

Pedenko, B., et al. (2023). "SARS-CoV-2 S Glycoprotein Stabilization Strategies." <u>Viruses</u> **15**(2): 558.

Perkmann, T., et al. (2021). "Spike protein antibodies mediate the apparent correlation between SARS-CoV-2 nucleocapsid antibodies and neutralization test results." <u>Microbiology</u> <u>Spectrum</u> **9**(1): 10.1128/spectrum. 00218-00221.

Petrovszki, D., et al. (2022). "Penetration of the SARS-CoV-2 spike protein across the bloodbrain barrier, as revealed by a combination of a human cell culture model system and optical biosensing." <u>Biomedicines</u> **10**(1): 188.

Pinto, D., et al. (2020). "Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody." <u>Nature</u> **583**(7815): 290-295.

Polatoğlu, I., et al. (2023). "COVID-19 in early 2023: Structure, replication mechanism, variants of SARS-CoV-2, diagnostic tests, and vaccine & drug development studies." <u>MedComm</u> **4**(2): e228.

Redondo, N., et al. (2021). "SARS-CoV-2 accessory proteins in viral pathogenesis: knowns and unknowns." <u>Frontiers in Immunology</u>: 2698.

Richardson, S. I., et al. (2022). "SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated, individuals." <u>Cell host & microbe</u> **30**(6): 880-886. e884.

Robba, C., et al. (2020). "Multiple organ dysfunction in SARS-CoV-2: MODS-CoV-2." <u>Expert review of respiratory medicine</u> 14(9): 865-868.

Rozo-Lopez, P., et al. (2018). "Vesicular stomatitis virus transmission: A comparison of incriminated vectors." Insects **9**(4): 190.

Sanyaolu, A., et al. (2021). "The emerging SARS-CoV-2 variants of concern." <u>Therapeutic</u> <u>Advances in Infectious Disease</u> **8**: 20499361211024372.

Sarzotti-Kelsoe, M., et al. (2014). "Optimization and validation of a neutralizing antibody assay for HIV-1 in A3R5 cells." Journal of immunological methods **409**: 147-160.

Schmidt, F., et al. (2020). "Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses." Journal of Experimental Medicine **217**(11): e20201181.

Scialo, F., et al. (2020). "ACE2: the major cell entry receptor for SARS-CoV-2." Lung 198: 867-877.

Seydoux, E., et al. (2020). "Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual." <u>BioRxiv</u>.

Shang, J., et al. (2020). "Structural basis of receptor recognition by SARS-CoV-2." <u>Nature</u> **581**(7807): 221-224.

Shereen, M. A., et al. (2020). "COVID-19 infection: Emergence, transmission, and characteristics of human coronaviruses." Journal of advanced research 24: 91-98.

Shi, J., et al. (2020). "Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS–coronavirus 2." <u>Science</u> **368**(6494): 1016-1020.

Shi, R., et al. (2020). "A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2." <u>Nature</u> **584**(7819): 120-124.

Steeds, K., et al. (2020). "Pseudotyping of VSV with Ebola virus glycoprotein is superior to HIV-1 for the assessment of neutralising antibodies." <u>Scientific Reports</u> **10**(1): 14289.

Stephens, D. S. and M. J. McElrath (2020). "COVID-19 and the Path to Immunity." Jama **324**(13): 1279-1281.

Strasfeld, L. and S. Chou (2010). "Antiviral drug resistance: mechanisms and clinical implications." <u>Infectious Disease Clinics</u> **24**(2): 413-437.

Stremlau, M., et al. (2004). "The cytoplasmic body component TRIM5α restricts HIV-1 infection in Old World monkeys." <u>Nature</u> **427**(6977): **84**8-853.

Syed, A. M., et al. (2022). "Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles." <u>Proceedings of the National Academy of Sciences</u> **119**(31): e2200592119.

Tang, Y., et al. (2020). "Laboratory diagnosis of COVID-19: current issues and challenges. McAdam AJ, ed." <u>J Clin Microbiol</u> **58**(6): e00512-200520.

Tegally, H., et al. (2020). "Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa." <u>medrxiv</u>: 2020.2012. 2021.20248640.

Tiwari, R., et al. (2020). "COVID-19: animals, veterinary and zoonotic links." <u>Veterinary</u> <u>Quarterly</u> **40**(1): 169-182.

Tolossa, T., et al. (2021). "Survival from a triple co-infection of COVID-19, HIV, and tuberculosis: a case report." <u>International Medical Case Reports Journal</u>: 611-615.

Travieso, T., et al. (2022). "The use of viral vectors in vaccine development." <u>Npj Vaccines</u> 7(1): 75.

Tulimilli, S. V., et al. (2022). "Variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and vaccine effectiveness." <u>Vaccines</u> **10**(10): 1751.

V'kovski, P., et al. (2021). "Coronavirus biology and replication: implications for SARS-CoV-2." <u>Nature Reviews Microbiology</u> **19**(3): 155-170.

Van Der Hoek, L., et al. (2006). "Human coronavirus NL63, a new respiratory virus." <u>FEMS</u> microbiology reviews **30**(5): 760-773.

Velusamy, P., et al. (2021). "SARS-CoV-2 spike protein: Site-specific breakpoints for the development of COVID-19 vaccines." Journal of King Saud University-Science **33**(8): 101648.

Vogt, I. (2008). Analysis of Biological Screening Data and Molecular Selectivity Profiles Using Fingerprints and Mapping Algorithms, Universitäts-und Landesbibliothek Bonn.

von der Thüsen, J. and M. van der Eerden (2020). "Histopathology and genetic susceptibility in COVID-19 pneumonia." <u>European journal of clinical investigation</u> **50**(7): e13259.

Wang, J., et al. (2021). "Specific cytokines in the inflammatory cytokine storm of patients with COVID-19-associated acute respiratory distress syndrome and extrapulmonary multiple-organ dysfunction." <u>Virology Journal</u> **18**(1): 1-12.

Wang, Q., et al. (2023). "Key mutations in the spike protein of SARS-CoV-2 affecting neutralization resistance and viral internalization." Journal of Medical Virology **95**(1): e28407.

Wang, Q., et al. (2020). "Structural and functional basis of SARS-CoV-2 entry by using human ACE2." <u>Cell</u> **181**(4): 894-904. e899.

Wang, X., et al. (2021). "Deletion of ER-retention motif on SARS-CoV-2 spike protein reduces cell hybrid during cell-cell fusion." <u>Cell & Bioscience</u> 11(1): 1-12.

Wang, Y., et al. (2022). "Structural basis for SARS-CoV-2 Delta variant recognition of ACE2 receptor and broadly neutralizing antibodies." <u>Nature communications</u> **13**(1): 871.

Weissenhorn, W., et al. (2007). "Virus membrane fusion." FEBS letters 581(11): 2150-2155.

Westendorf, K., et al. (2022). "LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants." <u>Cell reports</u> **39**(7).

Whitt, M. A. (2010). "Generation of VSV pseudotypes using recombinant  $\Delta$ G-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines." Journal of virological methods **169**(2): 365-374.

Wibmer, C. K., et al. (2021). "SARS-CoV-2 501Y. V2 escapes neutralization by South African COVID-19 donor plasma." <u>Nature medicine</u> **27**(4): 622-625.

Wolfe, M., et al. (2022). "Detection of SARS-CoV-2 variants Mu, Beta, Gamma, Lambda, Delta, Alpha, and Omicron in wastewater settled solids using mutation-specific assays is associated with regional detection of variants in clinical samples." <u>Applied and Environmental Microbiology</u> **88**(8): e00045-00022.

Wong, N. A. and M. H. Saier Jr (2021). "The SARS-coronavirus infection cycle: a survey of viral membrane proteins, their functional interactions and pathogenesis." <u>International journal of molecular sciences</u> **22**(3): 1308.

Wrapp, D., et al. (2020). "Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation." <u>Science</u> **367**(6483): 1260-1263.

Yadav, R., et al. (2021). "Role of structural and non-structural proteins and therapeutic targets of SARS-CoV-2 for COVID-19." <u>Cells</u> **10**(4): 821.

Yang, W. and J. L. Shaman (2022). "COVID-19 pandemic dynamics in South Africa and epidemiological characteristics of three variants of concern (Beta, Delta, and Omicron)." <u>Elife</u> 11.

Ye, Z.-W., et al. (2020). "Zoonotic origins of human coronaviruses." <u>International journal of biological sciences</u> **16**(10): 1686.

Yoon, E., et al. (2022). "Severe acute respiratory syndrome coronavirus 2 variants–Possibility of universal vaccine design: A review." <u>Computational and Structural Biotechnology Journal</u> **20**: 3533-3544.

Young, M., et al. (2022). "Covid-19: virology, variants, and vaccines." BMJ medicine 1(1).

Yuan, S., et al. (2020). "Analysis of possible intermediate hosts of the new coronavirus SARS-CoV-2." <u>Frontiers in Veterinary Science</u>: 379.

Yurkovetskiy, L., et al. (2020). "Structural and functional analysis of the D614G SARS-CoV-2 spike protein variant." <u>Cell</u> **183**(3): 739-751. e738.

Zandi, M., et al. (2022). "The role of SARS-CoV-2 accessory proteins in immune evasion." Biomedicine & Pharmacotherapy: 113889.

Zárate, S. and I. S. Novella (2004). "Vesicular stomatitis virus evolution during alternation between persistent infection in insect cells and acute infection in mammalian cells is dominated by the persistence phase." Journal of Virology **78**(22): 12236-12242.

Zhang, L., et al. (2023). "Cytoplasmic Tail Truncation Stabilizes S1-S2 Association and Enhances S Protein Incorporation into SARS-CoV-2 Pseudovirions." Journal of Virology **97**(3): e01650-01622.

Zhang, Y.-Z. and E. C. Holmes (2020). "A genomic perspective on the origin and emergence of SARS-CoV-2." <u>Cell</u> **181**(2): 223-227.

Zhang, Z., et al. (2022). "Structure of SARS-CoV-2 membrane protein essential for virus assembly." <u>Nature communications</u> **13**(1): 4399.

Zhao, J., et al. (2020). "The potential intermediate hosts for SARS-CoV-2." <u>Frontiers in</u> <u>microbiology</u> **11**: 2400.

Zhou, H., et al. (2020). "A novel bat coronavirus closely related to SARS-CoV-2 contains natural insertions at the S1/S2 cleavage site of the spike protein." <u>Current biology</u> **30**(11): 2196-2203. e2193.

Zhou, T., et al. (2022). "Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B. 1.1. 529." <u>Science</u> **376**(6591): eabn8897.



## UNIVERSITY of the WESTERN CAPE